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Acute myeloid leukemia (AML) is a hematopoietic malignancy characterized by great 
heterogeneity and clonal nature. In recent years, rapidly evolving next-generation sequencing 
methods provided a deep insight into the mutational background of AML. It was shown that 
~ 44 % of AML patients harbor mutations in genes that regulate DNA methylation. So far, 
many researchers have tried to evaluate the prognostic significance of DNA methylation 
changes in AML, however, due to a great inconsistency in these studies, none of the reported 
markers were implemented into clinical practice. 
 The aim of this work was to further investigate the DNA methylation changes in AML 
patients with specific mutations and their prognostic effect. Next, we wanted to develop a new 
approach for a complex evaluation of prognostically significant DNA methylation aberrations. 
 In our first project, we assessed the overall DNA methylation, hydroxymethylation, 
and gene expression in AML patients with mutations in either DNMT3A or IDH1/2 or their 
combinations. We discovered that each genetic aberration is connected with a distinct pattern 
of DNA hydroxy-/methylation changes that are not entirely reflected in altered gene 
expression. Patients with mutations in both genes exhibited a mixed DNA methylation profile 
most similar to healthy controls. Furthermore, we found a prognostically significant 
hypermethylation in an upstream enhancer of GZMB gene (p = 0.035). Prior to validation 
of the DNA hydroxy-/methylation levels measured with arrays in the first project, 
we compared four most common methods for DNA methylation validation: analysis with 
methylation specific restriction enzymes, pyrosequencing, methylation-specific high-
resolution melting, and methylation-specific PCR. Pyrosequencing proved to be the most 
convenient method due to its single base resolution and easy implementation. Next, 
we focused on a comprehensive evaluation of prognostically significant DNA methylation 
changes using a custom sequencing panel. To assess a summarizing influence of various 
aberrations in DNA methylation on patients’ prognosis we developed MethScore, a simply 
computed value that reliably stratified the patients with better and worse survival (p < 0.001). 
MethScore significance was verified in multivariate analyses and validated on an independent 
cohort of AML patients. We further showed that MethScore may be primarily helpful 
for stratifying the patients with intermediate risk. 
 Our research contributed to the knowledge of AML epigenetic background and 
the prognostic significance of DNA methylation. MethScore may serve as a new surrogate 





Akutní myeloidní leukémie (AML) je maligní hematopoetické onemocnění, které je vysoce 
heterogenní zejména díky své klonální podstatě. Rozvoj sekvenování nové generace umožnil 
důkladně prozkoumat mutační pozadí AML. Bylo zjištěno, že asi 44 % pacientů má mutaci 
v některém z genů ovlivňujících metylaci DNA. Od té doby již mnoho autorů publikovalo 
prognostický význam určitých změn v metylaci DNA u AML. Žádný z těchto poznatků však 
nebyl převeden do klinické praxe, především kvůli značné rozdílnosti jednotlivých studií. 
 Cílem této práce bylo jednak hlouběji prozkoumat změny v metylaci DNA u pacientů 
se specifickým genetickým pozadím a pokusit se nalézt jejich prognostický význam. Dále 
jsme chtěli vyvinout nový způsob pro komplexní zhodnocení změn v metylaci DNA, 
u kterých byl již význam pro prognózu AML pacientů prokázán. 
  V našem prvním projektu jsme zkoumali celkové DNA metylační, hydroxymetylační 
a expresní profily AML pacientů s mutacemi v DNMT3A nebo IDH1/2 nebo v obou těchto 
genech. Zjistili jsme, že každá mutace je spojena s charakteristickými změnami v hydroxy-
/metylaci DNA, které ovšem nejsou zcela reflektovány změnami v genové expresi. Pacienti 
s mutacemi v obou genech se vyznačovali směsným DNA hydroxy-/metylačním profilem, 
který byl nejpodobnější vzorkům zdravých dárců. Dále jsme nalezli prognosticky významnou 
hypermetylaci v enhanceru genu GZMB (p = 0.035). Dříve, než jsme provedli validaci dat 
naměřených pomocí čipů v prvním projektu, porovnali jsme čtyři nejběžněji používané 
metody pro tyto účely: analýzu s použitím metylačně specifických restrikčních endonukleas, 
pyrosekvenaci, metylačně specifickou analýzu křivek tání s vysokým rozlišením a metylačně 
specifickou PCR. Pyrosekvenace byla zvolena jako nejvhodnější metoda především díky 
svému rozlišení na úrovni jednotlivých basí a snadnému provedení. V posledním projektu 
jsme se soustředili na nalezení komplexního přístupu pro hodnocení prognosticky 
významných změn v metylaci DNA. Navrhli jsme vlastní DNA metylační sekvenační panel 
a pro jeho vyhodnocení vyvinuli snadno spočítatelné MethScore, které spolehlivě rozdělilo 
pacienty dle jejich přežití (p < 0.001). Význam MethScore pro hodnocení prognosy pacientů 
byl dále ověřen v multivariantní analýze a validován na nezávislé kohortě AML pacientů. 
Ukázali jsme, že MethScore jako stratifikátor prognosy velmi dobře funguje i u pacientů 
se středním rizikem. 
 Naše práce přispívá k rozšíření vědomostí o epigenetické podstatě AML a prognostickém 
významu metylace DNA. Námi zavedené MethScore má nesporný potenciál pro zpřesnění 





1.1 Acute myeloid leukemia 
Acute myeloid leukemia (AML) is a highly heterogenous hematological malignancy. 
This aggressive clonal disease is characterized by poorly or abnormally differentiated cells 
of the myeloid hematopoietic system, called blasts, that infiltrate blood, bone marrow, 
and other tissues. Blast cells develop from hematopoietic progenitor cells that acquire genetic 
mutations as well as other aberrations (such as epigenetic). Thus, they are capable of fast 
proliferation and self-renewal. Their accumulation leads to impaired hematopoiesis 
and eventually to bone marrow failure (Döhner et al., 2015; Papaemmanuil et al., 2016). 
In adults, AML is the most common acute leukemia, but still it is a sporadic disease 
(e.g. representing only 1.1 % of newly diagnosed cancers in the United States). Median age 
at diagnosis is 68 years. The incidence is approximately 4.3 new cases per 100,000 men 
and women per year. However, the incidence rises with age and is 17 per 100,000 per year 
for patients older than 65 years. Five-year relative survival for AML  
is ~ 28 % (for US population) (Doubek & Mayer, 2013; Ley et al., 2013;  
National Cancer Institute, 2020). 
Clinical symptoms of AML are usually unspecific manifestations of cytopenia such 
as fatigue, headache, dyspnea, hematomas, and recurrent infections. AML is diagnosed when 
more than 20 % of myeloid blasts are detected in bone marrow (BM). In the presence 
of characteristic cytogenetic abnormalities such as t(15;17), t(8;21), inv(16), and t(16;16), 
AML is diagnosed despite the number of blasts in BM. Myelocytic or monocytic origin of the 
blast cells is verified using flow cytometry and cytochemistry. Further AML classification 
requires thorough morphological, immunophenotyping, cytogenetic, and genetic 
characterization of the disease (Šálek, 2013; Arber et al., 2016; Döhner et al., 2017). 
 
1.1.1 Classification 
There are two major classification systems for AML (Table 1). The French-American-British 
(FAB) was established in the mid-70s and divides AML into seven subtypes according to the 
blast cell maturation level and the type of ancestral hematopoietic cell that the leukemia 
developed from (Bennet et al., 1976). The WHO classification, last updated in 2016, is more 
thorough and takes into account also immunophenotyping criteria and the latest findings 





Table 1 FAB and WHO classifications of AML (The American Cancer Society, 2018)  
FAB subtype WHO classification of AML and related neoplasms  
 AML with recurrent genetic abnormalities 
         AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1  
   AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11  
M3   APL with PML-RARA  
   AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A  
   AML with t(6;9)(p23;q34.1);DEK-NUP214  
   AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM  
   AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1  
   AML with mutated NPM1  
   AML with biallelic mutations of CEBPA  
   Provisional entity: AML with BCR-ABL1, AML with mutated RUNX1  
 AML with myelodysplasia-related changes  
 Therapy-related myeloid neoplasms  
 AML not otherwise specified (NOS)  
M0   AML with minimal differentiation  
M1   AML without maturation  
M2   AML with maturation  
M4   Acute myelomonocytic leukemia  
M5   Acute monoblastic/monocytic leukemia  
M6   Pure erythroid leukemia  
M7   Acute megakaryoblastic leukemia  
   Acute basophilic leukemia  
   Acute panmyelosis with myelofibrosis  
 Myeloid sarcoma  
 Myeloid proliferations related to Down syndrome  
 
1.1.2 Prognostic factors 
A significant independent prognostic factor for AML is age. In older patients, there is a higher 
probability of adverse cytogenetic features and cumulation of genetic mutations  
(Tsai et al., 2016). The effect of age is further modulated by general patient’s health 
condition, performance status and other comorbidities. These factors have also a major impact 
to the tolerance of chemotherapy. AML type is another important prognostic factor, especially 
the cytogenetic and genetic characteristic of the disease. Patients with previous oncological 
treatment or prior myelodysplasia may develop secondary AML which has an unfavorable 
prognosis (Šálek, 2013; Döhner et al., 2017; Leisch et al., 2019). 
 Besides the pretreatment prognostic factors, it is also essential to monitor AML throughout 
the course of the disease. In particular the presence of minimal residual disease (MRD) should 
be assessed after treatment to evaluate the patient’s response, adjust the therapy, and follow 





The standard treatment of younger (< 55 years) and older patients who are physically fit 
is “3+7” induction chemotherapy consisting of 3 days of bolus administration of anthracycline 
(e.g. daunorubicin) and 7 days of continuous infusion of cytarabine. Complete remission (CR) 
is reached when patients attain hematologic recovery, have less than 5 % of blasts in bone 
marrow, and no circulating blasts. CR is achieved in 60 - 85 % of patients less than 60 years 
old and in 40 - 60 % of patients more than 60 years old. Achievement of CR after primary 
intensive treatment indicates long-term survival  (Walter et al., 2010). In case of failure of the 
intensive therapy, so called salvage protocols are employed, e.g. Fla-Ida (fludarabine, 
idarubicin, cytarabine) (Šálek, 2013; Döhner et al., 2017). 
After a patient reaches CR, consolidation therapy is used to eradicate residual leukemia. 
Consolidation protocols include several cycles of high-dose cytarabine (HiDAC), for patients 
with good risk AML, or allogeneic stem cell transplantation in case of a donor (Šálek, 2013; 
Doubek & Mayer, 2013). 
 Older patients or those with other comorbidities are unfit for intensive chemotherapy and 
thus receive palliative treatment with hydroxyurea, hypomethylating drugs (HMAs, 
e.g. azacytidine), or low dose cytarabine (Doubek & Mayer, 2013; Döhner et al., 2015; 
Döhner et al., 2017). 
Recently, a number of new drugs were developed targeting specific molecules with a role 
in AML progression. Midostaurin, an inhibitor of FLT3 tyrosine kinase activity, was 
approved by FDA in combination with standard chemotherapy in 2017 for newly diagnosed 
FLT3 mutation-positive AML patients. In 2018, another tyrosine kinase inhibitor, gliterinib, 
was approved by FDA for relapsed/refractory FLT3 mutation-positive AML patients. 
And other FLT3 tyrosine kinase inhibitor, quizartinib, is currently a subject of clinical trials. 
Ivosidenib and enasidenib are inhibitors of isocitrate dehydrogenase 1 and 2, respectively. 
These drugs were approved by FDA in 2017 and 2018 as a monotherapy for patients with 
mutated IDH1/2. Venetoclax is an inhibitor of anti-apoptotic protein BCL-2 and was 
approved in 2018 by FDA for newly diagnosed AML patients unfit for intensive 
chemotherapy in combination with hypomethylating agents, decitabine and azacitidine, 
or low-dose cytarabine. Gentuzumab ozogamicin is an anti-CD33 antibody conjugated with 
cytotoxic calicheamicin which inhibits DNA synthesis. This drug was approved in 2017 
by FDA for newly diagnosed CD33-positive AML in combination with standard induction 
therapy or as a monotherapy for relapsed/refractory CD33-positive AML  




1.2 Genetic aberrations in AML 
AML is a complex and molecularly heterogenous disease. Patients that develop this malignity 
suffer from various somatically acquired genetic lesions (Figure 1). In 2013, with the rapid 
development of next-generation sequencing (NGS) technology and high-throughput methods, 
the first summarizing analysis of 200 patients was carried out examining genomic and 
epigenomic landscape of AML. Out of 237 mutated genes that were detected in two or more 
patients, 23 genes were repeatedly mutated in AML. The average number of mutations per 
sample was 13, quite low number in comparison with other cancers, and of these an average 
of 5 mutations were in genes recurrently mutated in AML (Ley et al., 2013). Further 
investigations of AML genetic profiles revealed that patients can be divided into 11 classes 
with distinct phenotype and outcome according to their patterns of co-mutations 
(Papaemmanuil et al., 2016). All the recent findings about AML genetic landscape 
and its prognostic significance were summarized in the 2017 recommendations of Europen 
LeukemiaNet (ELN), see Table 2. Based on these suggestions, the common clinical practice 
examining cytogenetic aberrations, gene-fusions, and some of the mutations (FLT3, NPM1, 
CEBPA) should be extended, at least to asses also mutations in TP53, RUNX1, and ASXL1 
(Döhner et al., 2015; Döhner et al., 2017). Furthermore, the integration of NGS into routine 
clinical examination of newly diagnosed AML patients is highly recommended 
(Levine & Valk, 2019). 
 
 
Figure 1 Genes recurrently mutated in myeloid malignancies (Tremblay et al., 2018). Genes relevant 
to AML pathogenesis can be divided into nine groups according to their function and almost all 
patients have at least one mutation in a gene belonging to one of these categories: activated signaling 
genes (detected in 59 % of AML), DNA-methylation related genes (44 %), chromatin-modifying 
genes (30 %), NPM1 mutations (27 %), myeloid transcription factor genes (22 %), transcription factor 
fusions (18 %), tumor suppressor genes (16 %), spliceosome-complex genes (14 %), cohesin-complex 




Table 2 Risk stratification of AML patients based on their genetic lesions (Grimwade et al., 2016; 
Döhner et al., 2017) 
Risk category Cytogenetic characteristic Molecular-genetic characteristic 
Favorable 
t(8;21)(q22;q22.1) RUNX1-RUNX1T1 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22) CBFB-MYH11 
Typically associated with normal karyotype 
Mutated NPM1 without FLT3-ITDhigh* 
or with FLT3-ITDlow* 
Typically associated with normal karyotype Biallelic mutated CEBPA 
Intermediate 
Typically associated with normal karyotype Mutated NPM1 and FLT3-ITDhigh* 
Typically associated with normal karyotype 
Wild-type NPM1 without FLT3-ITD or 
with FLT3-ITDlow* (without adverse-risk 
gene mutations) 
t(9;11)(p21.3;q23.3) MLLT3-KMT2A 
Abnormalities not classified as favorable or adverse  
Adverse 
t(6;9)(p23;q34.1) DEK-NUP214 
t(v;11q23.3) KMT2A rearranged 
t(9;22)(q34.1;q11.2) BCR-ABL1 
inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) GATA2, MECOM(EVI1) 
−5 or del(5q); −7; −17/abn(17p)   
Complex karyotype (≥3 abnormalities)   
Monosomal karyotype    
 Wild-type NPM1 and FLT3-ITDhigh* 






*low allelic ratio (< 0.5)/high allelic ratio (> 0.5) 
†Should not be used as an adverse prognostic marker if detected in favorable-risk AML subtypes  
 
Another characteristic feature of AML genetics is clonal heterogeneity. Studies have 
shown that at diagnosis, there is always at least one subclone detected among the founding 
leukemic clone (the initial transformed cell). However, majority of mutations detected 
in AML are present in nearly all the cells. It is because the hematopoietic stem cells acquire 
these mutations before the initiating event causes the development of AML  
(Welch et al., 2012; Ley et al., 2013; Shlush et al., 2014). These early mutations, called 
“passenger lesions”, are typically detected at high variant allele frequency (VAF) in AML 
blasts. In most cases, these genes are involved in histone modifications, DNA methylation, 
and chromatin rearrangements (e.g. DNMT3A, TET2, ASXL1, PPM1D, SF3B1) and alone are 
not sufficient to cause AML. Mutations in these landscaping genes can also be found at low 
VAF in 10 – 20 % of blood samples from healthy older individuals who have thus higher risk 




potential“ (Jaiswal et al., 2014; Steensma et al., 2015). Also, ancestral preleukemic cells with 
these mutations can survive chemotherapy and eventually cause relapse after expansion 
during remission. Nevertheless, the myeloid neoplasm develops only after acquisition 
of further mutations. These late, so called “driver mutations” affect usually genes from 
activated signaling pathways (e.g. FLT3, JAK, NRAS) (Corces-Zimmerman et al., 2014; 
Döhner et al., 2015; Leisch et al., 2019). 
 
1.2.1 Cytogenetics  
Cytogenetic assessment of metaphase cells is an essential part of AML diagnostics since 
aberrant cytogenetic features have major prognostic impact and directly affect the selection 
of post remission therapy (Šálek, 2013; Döhner et al., 2017). Abnormal karyotype is detected 
in about 60 % of newly diagnosed AML patients. In MRC (Medical Research Council, 
London) trials, Grimwade et al. studied the predictive value of cytogenetic changes in older 
patients (median age 66 years) and then revised his findings in a large meta-analysis 
of 5,876 younger patients (age range 16 - 59 years) (Grimwade et al., 2001;  
Grimwade et al., 2010). By these criteria, patients were divided into three major groups 
(Table 3). Acute promyelocytic leukemia (APL) and AML with translocations including core 
binding factor belong to the group with favorable prognosis. These patients respond well 
to conventional chemotherapy. On the contrary, patients within the adverse risk category, 
for example those with complex or monosomal karyotype, do not respond well and are 
preferentially indicated for allogenic transplantation or experimental treatment. Nevertheless, 
the majority of AML are classified as intermediate risk (IR) patients (most commonly with 
normal karyotype). For those, other molecular biomarkers, especially various gene mutations, 
are crucial for establishing the prognosis (Ley et al., 2013; Šálek, 2013;  
















Table 3 Prognostic stratification based on cytogenetic changes (Grimwade et al., 2010)  
Cytogenetic abnormality  
Favorable  






Intermediate  Entities not classified as favorable or adverse  
 
Adverse  






add(5q), del(5q), −5,  
−7, add(7q)/del(7q),  
t(6;11)(q27;q23),  
t(10;11)(p11∼13;q23),  
t(11q23) [excluding t(9;11)(p21∼22;q23) and t(11;19)(q23;p13)]  
t(9;22)(q34;q11),  
−17/abn(17p),  
Complex (≥ 4 unrelated abnormalities)  
 
1.2.1.1 Fusion genes 
Balanced rearrangements are detected in a significant proportion of younger AML patients  
(30 - 50 % in younger adults and children) and on the contrary are rare in secondary AML 
(Grimwade, David & Mrózek, 2011). A number of fusion genes are recognized as recurrent 
genetic abnormalities in AML and some of them are considered sufficient to diagnose AML 
irrespective of blast count in BM (Grimwade et al., 2016; Arber et al., 2016). The occurrence 
of inversion or translocation events is considered to be an initiating step in the AML 
development causing disruption in cells’ differentiation, however, not sufficient on its own 
for the leukemic transformation (Miyamoto et al., 2000). Fusions involving hematopoietic 
transcription factors (mainly RUNX1-RUNX1T1, CBFB-MYH11, PML-RARA) are frequently 
accompanied by mutations in signaling genes (e.g. KIT, N/KRAS, FLT3, NF1) as a “second 
hit” mutations that enhance proliferation activity of the undifferentiated cells 
(Jourdan et al., 2013; Duployez et al., 2016; Grimwade et al., 2016).  
 
PML-RARA 
Acute promyelocytic leukemia (APL), a unique subtype of AML, is associated with t(15;17) 
leading to a formation of fusion gene PML-RARA. APL patients feature favorable prognosis 
and respond well to ATRA (all-trans retinoic acid) and ATO (arsenic trioxide) therapy 





RUNX1-RUNX1T1 and CBFB-MYH11 
AML with inv(16) and t(8;21), leading to CBFB-MYH11 and RUNX1-RUNX1T1 fusion 
genes, are collectively called core-binding factor (CBF) AML. Patients with CBF AML 
(approximately 15 % of de novo AML in adult patients) are categorized as low risk and profit 
from high-dose chemotherapy. Nevertheless, the relapse incidence is up to 40 % and thus 
the spectrum of co-mutations further defines the patients’ prognosis (Šálek, 2013; 
Duployez et al., 2016). 
As mentioned previously, CBF AML rearrangements are usually associated with mutations 
in tyrosine kinase signaling genes. However, further investigations revealed a different 
spectrum of co-mutations for each subtype. RUNX-RUNX1T1 fusions are significantly 
associated with mutations in cohesion complex genes (18 %) and chromatin modifiers (42 %) 
including ASXL1 and ASXL2 (35 %) (Micol et al., 2014; Döhner et al., 2017).  
On the contrary, these mutations are nearly absent in inv(16) AML. It was also shown that 
mutations in KIT and FLT3 were associated with higher probability of relapse for CBF AML. 
Also, high KIT mutant allelic ratio has significant negative impact on t(8;21) AML prognosis  
and, on the contrary, high N/KRAS mutant allele ratios were associated with favorable 
outcome and a lack of KIT or FLT3 mutations (Duployez et al., 2016). 
 
Other recurrent cytogenetic abnormalities 
From the rest of the balanced rearrangements detected in AML patients, only KMT2A (MLL) 
is more common with incidence about 4 % of de novo AML. These translocations  
are in general associated with poor prognosis and rather aggressive disease. The only 
exception is t(9;11)/MLLT3-KMT2A, most common KMT2A rearrangement, classified 
as intermediate risk (Behdad & Betz, 2016).  
Other cytogenetic abnormalities (DEK-NUP214, GATA2, MECOM, and BCR-ABL1) are 
less common, each type accounts only for ~ 1 – 2 % of newly diagnosed AML  
(Papaemmanuil et al., 2016; Döhner et al., 2017). 
 
1.2.2 Recurrently mutated genes in AML with prognostic significance 
NPM1 
Nucleophosmin (NPM1) is a multifunctional phosphoprotein normally detected in cell 
nucleolus. NPM1 is involved in DNA repair, chromatin remodeling, ribosome biogenesis, 
replication and transcription, and have both tumor suppressive and growth promoting 




discovered in AML (Falini et al., 2005). Since then, more than forty different mutations were 
described with the most common mutations, detected in ~ 90 % of cases, being  
type A, B, and D. In the majority of cases, these mutations are four-base insertions causing 
disruption of nucleolar localization signal and relocation of nucleophosmin to cytoplasm. 
 NPM1 mutations (NPM1mut) are the most common mutations in AML. NPM1mut is detected 
in 30 % of AML and more than 50 % of cytogenetically normal AML (CN-AML)  
and is generally considered a founder event in AML onset. Most frequent co-mutations  
are detected in DNMT3A (50 %) and FLT3 (40 %) genes (Falini et al., 2005;  
Grimwade et al., 2016). 
 NPM1mut AML patients generally respond well to induction chemotherapy and have higher 
CR rate. NPM1mut is thus considered as a marker of favorable prognosis. However, the overall 
survival (OS) and relapse ratio is markedly dependent on the co-occurrence of FLT3-ITD 
and its mutant allelic ratio (Grimwade et al., 2016; Döhner et al., 2017).  
 
FLT3 
FLT3 (FMS-like tyrosine kinase 3) gene encodes a hematopoiesis regulating tyrosine kinase 
receptor that activates downstream differentiation, proliferation and apoptosis pathways 
in hematopoietic stem cells via activation of RAS/RAF/MEK and PI3K/AKT cascades 
(Grafone et al., 2012). FLT3 is mutated in one third of all AML patients and two types 
of mutations can be found: internal tandem duplications (FLT3-ITD, detected  
in 27 % of AML) and point mutations in the kinase domain (FLT3-TKD, detected  
in 7 % of AML). In both cases, the gene aberration leads to constitutive activation  
of the receptor. However, only FLT3-ITD has been proved as an independent prognostic 
factor predicting poorer OS and higher relapse rate especially in case of higher mutant allelic 
burden (Grimwade et al., 2016). Moreover, if FLT3-ITD is concurrently detected in both 
alleles (FLT3-ITD/FLT3 wild-type ratio is higher than 0.5), the adverse effect is so strong that 
even in case of concurrent NPM1mut the patients have worse prognosis and are classified 
as intermediate risk, see Table 2 (Döhner et al., 2017; Levine & Valk, 2019). The prognostic 
significance of FLT3-TKD mutations is less clear and is rather associated with better survival 
(Grimwade et al., 2016). 
 Mutated FLT3 kinase represents an attractive therapeutic target. Therefore, many new 
drugs in form of small molecule tyrosine kinase inhibitors were developed and recently 






Mutations in CEBPA (CCAAT/enhancer-binding protein alpha) gene, that encodes a myeloid 
transcription factor, are found approximately in 11 % of AML (Fasan et al., 2014). The gene 
consists of a single exon where the mutations occur mostly in two distinct regions. Frameshift 
mutations are found prevalently in the N-terminal transactivation domain, whereas insertions 
and deletions in C-terminal domain disrupt the dimerization and DNA-binding site  
of the resulting protein. Interestingly, in more than half of the CEBPA mutated cases, both 
alleles are affected, each in one, either N-terminal or C-terminal, region. It was also shown, 
that only patients with this biallelic mutation in CEBPA, sometimes referred to as CEBPA 
double mutant (CEBPAdm) AML, have favorable prognosis. Single mutations in CEBPA have 
no significant impact on patients’ prognosis (Wouters et al., 2009; Taskesen et al., 2011).  
CEBPA mutations are mutually exclusive of balanced rearrangements, usually lack  
FLT3-ITD, but are associated with GATA2 and NRAS mutations (Grimwade et al., 2016). 
 
RUNX1  
Gene encoding the hematopoietic transcription factor RUNX1 (runt-related transcription 
factor 1) is mutated in about 10 % of AML patients. Besides mutations, RUNX1 is also 
frequently involved in chromosomal rearrangements in AML (e.g. RUNX1-RUNX1T1, 
MECOM(EVI1)-RUNX1) (Gaidzik et al., 2016).  
RUNX1 mutations (RUNX1mut) are mostly mutually exclusive of FLT3, NPM1, and 
CEBPA mutations and balanced rearrangements. To the co-occurring genetic lesions belong 
mutations in ASXL1, SRSF2, IDH2, and KMT2A gene (Ley et al., 2013; Grimwade et al., 
2016). 
Many studies confirmed that mutations in RUNX1 indicate poor prognosis and define 
a group of patients with unfavorable clinicopathological features such as older age, immature 
morphology, or secondary AML evolved from myelodysplastic syndrome. Thus, RUNX1mut 
AML was proposed as a provisional entity in 2016 WHO classification and was established 
as an individual category of patients with inferior outcome by the 2017 ELN 
recommendations (Gaidzik et al., 2016; Arber et al., 2016; Döhner et al., 2017). 
  
TP53 
TP53 is a tumor suppressor with a key role in DNA repair, regulation of apoptosis, 
and cellular senescence. Mutations in TP53 gene (TP53mut) occur in ~ 10 % of AML patients 




complex and monosomal karyotype and specific aneuploidies (e.g. deletions of chromosomes 
5 or 7) (Haferlach et al., 2008). TP53mut patients have low response rate to chemotherapy 
and high relapse rates after stem cell transplantation. Thus, TP53 mutations are a marker 
of particularly poor outcome (Rücker et al., 2012; Kadia et al., 2016). 
 
1.2.2.1 Epiregulatory genes 
Mutations in genes encoding epigenetic regulators, including DNA methylation and histone 
modifications, has been repeatedly reported by a number of groups that investigated 
the overall mutational landscape of AML with NGS technology (Ley et al., 2013; 
Papaemmanuil et al., 2016; Metzeler et al., 2016). It is also apparent from several studies, that 
these mutations are not exactly AML specific, however, they define a preleukemic state that 
can lead to AML development through acquisition of cooperating mutations  
(Jaiswal et al., 2014; Shlush et al., 2014; Grimwade et al., 2016). 
 
DNMT3A 
DNMT3A gene encodes de novo DNA methyltransferase. This enzyme catalyzes the addition 
of methyl group to the 5´-carbon of cytosine residue in a CG dinucleotide (called CpG) 
and thus generates a newly methylated site in the genome (Ley et al., 2010). 
DNMT3A mutations (DNMT3Amut) are detected in up to 36 % of AML patients 
and therefore belong to the triad of most frequently mutated genes in AML together with 
FLT3 and NPM1 mutations (Wouters & Delwel, 2016). Quite commonly, these three 
mutations co-occur, which suggest their mutual cooperation in AML pathogenesis.  
It is presumed that DNMT3Amut appear first as a founding mutation in the preleukemic clone 
that later acquires NPM1 and FLT3 mutations, see Figure 2 (Shlush et al., 2014;  
Corces-Zimmerman et al., 2014).  
Most frequent DNMT3Amut is R882H located in the region encoding the enzyme’s catalytic 
site. The resulting protein has a dominant-negative activity and inhibits the formation 
of tetramers of wild-type DNMT3A resulting in focal hypomethylation of specific CpGs 
throughout the genome (Russler-Germain et al., 2014). Interestingly, it appears that DNMT3A 
wild-type AML possess abnormal hypermethylation in specific CpGs. The authors of the 
study propose that this “break” is an adaptive response of the cells that try to stop the rapid 
proliferation or leukemic transformation. Thus, the DNMT3Amut patients lose this protective 




 DNMT3Amut is usually seen as an adverse prognostic factor and it was demonstrated that 
DNMT3Amut promotes chemoresistance (Guryanova et al., 2016). However, the outcome 
of DNMT3Amut AML patients depends strongly on other co-mutations, especially in case 
of NPM1mut which is detected in majority (80 %) of DNMT3Amut AML (Gale et al., 2015). 
 
 
Figure 2 Hypothetical clonal evolution of AML in a patient who carries cooperating DNMT3Amut, 
NPM1mut, and FLT3-ITD. Mutation in DNMT3A appears first, prior to overt disease, and facilitates 
the clonal expansion. Subsequently, NPM1mut occurs in the founding clone as a disease-defining 
mutation. Further acquisition of FLT3-ITD results in a hyperproliferative clone and leukemia 
expansion. This dominant clone is then detected at diagnosis. The proportion of cells carrying 
a specific somatic mutation in a sample can be estimated based on its allele frequency, as shown 
on the right (Grimwade et al., 2016).  
 
IDH1/2 
IDH1 and IDH2 are cytosolic and mitochondrial isoenzymes of isocitrate dehydrogenase that 
catalyze one of the reactions in Krebs cycle, the oxidative decarboxylation of isocitrate  
to α-ketoglutarate. Mutated enzymes IDH1/2 produce an oncometabolite 2-hydroxyglutarate 
which inhibits the function of dioxygenase enzymes, including TET2. This leads to a global 
hypermethylation of the genome similar to patients with TET2 mutations (Ward et al., 2010; 
Montalban-Bravo & DiNardo, 2018). 
IDH1/2 mutations (IDH1/2mut) are detected in about 20 % of AML, with slightly more 
prevalent mutations in IDH2 (~ 12 % of newly diagnosed patients). IDH1mut and IDH2 mut are 
mostly mutually exclusive and associated with normal karyotype. The prognostic effect 
of IDH1/2 mutations presumably depends on the position of the mutation (most commonly 
IDH1 R132H/C, IDH2 R140Q and R172K), co-occurring mutations, and other genetic lesions 
(Papaemmanuil et al., 2016; Liu & Gong, 2019). The IDH1R140 mutation is associated with 
NPM1mut and indicates better prognosis. On the other hand, IDH2R172 is not detected 
in NPM1mut patients and predicts a poor clinical outcome (Grimwade et al., 2016). However, 




mutations (Montalban-Bravo & DiNardo, 2018). Nevertheless, new drugs with good clinical 
response for relapsed/refractory AML patients with mutations in IDH1 or IDH2 were recently 
approved by FDA (see chapter 1.1.3). 
 
TET2 
TET2 (ten-eleven translocation oncogene family member 2) encodes a methylcytosine 
dioxygenase. This enzyme catalyzes the conversion of 5´-methylcytosine (5-mC)  
to 5´-hydroxymethylcytosine (5-hmC), the initial step of DNA demethylation  
(Grimwade et al., 2016). 
 Mutations in TET2 are detected in ~ 8 % of patients with AML but can be detected in older 
healthy individuals as well, which supports the concept of pre-leukemic clonal hematopoiesis 
(chapter 1.2) (Jaiswal et al., 2014). TET2 mutations (TET2mut) are mutually exclusive 
of IDH1/2mut and mutations in WT1 gene that encodes a tumor suppressor transcription factor. 
It was found that besides IDH1/2, mutations in WT1 (found approximately in 9 % of AML) 
can also impair the function of TET2, in both cases leading to site-specific changes in DNA 
hydroxymethylation and overall genome hypermethylation (Rampal et al., 2014;  
Wang et al., 2015). These findings suggest the existence of TET2-IDH1/2-WT1 mutated 
AML subtype characterized by particular epigenetic changes (Grimwade et al., 2016;  
Wouters & Delwel, 2016). Nevertheless, no clear prognostic impact of TET2mut on the clinical 
outcome of AML patients was found (Gaidzik et al., 2016). 
 
ASXL1 
ASXL1 (additional sex comb-like 1) belongs to the enhancers of polycomb and trithorax 
genes, which regulate various genes’ expression via chromatin remodeling  
(Fisher et al., 2006). Somatic mutations in ASXL1 gene have been described in various types 
of myeloid malignancies including AML where it is detected in ~ 10 % of patients with 
higher prevalence in older patients and secondary AML (Metzeler et al., 2016).   
ASXL1 mutations (ASXL1mut) are inversely associated with FLT3-ITD, mutually exclusive 
with NPM1mut, and co-occur with RUNX1mut and IDH2mut  (Pratcorona et al., 2012;  
Paschka et al., 2015). 
Mutations in ASXL1 have been consistently reported as an independent prognostic marker 
of a poor survival. Therefore, ASXL1mut AML patients were established as a new individual 





1.2.2.2 Other genes recurrently mutated in AML 
As mentioned before, with the high-throughput NGS technologies many other genes were 
discovered to be mutated in AML. These include signaling pathways genes, e.g. cKIT, RAS, 
NF1, CBL, and PTPN11 (Grimwade et al., 2016). Also, the histone modifying genes 
are frequently mutated in AML, especially the lysine methyltransferases (mainly KMT2A, also 
called MLL) and components of the polycomb repressor complexes, for example EZH2 
encoding H3K27 methyltransferase (Wouters & Delwel, 2016). Splicing factor genes 
are prevalently mutated in myelodysplastic syndromes and thus detected in secondary AML, 
however, mutations in these genes (e.g. SRSF2, SF3B1, and U2AF1) were also found  
in de novo AML cases (Lindsley et al., 2015). In the TCGA 2013 study, the category 
of cohesion complex genes was identified as recurrently mutated in AML, including RAD21, 
SMC1A, and STAG1 or STAG2 genes (Ley et al., 2013; Thol et al., 2014). 
 
1.3 Epigenetic changes in AML 
It is not surprising that the epigenetic landscape of AML was found to be markedly disturbed, 
since 44 % of AML patients harbor mutations in genes encoding the regulators of DNA 
methylation and 43 % of AML in genes functioning as chromatin modifiers or genes 
of cohesion complex (Ley et al., 2013). Many recent studies show that the knowledge 
of epigenetic background should not be neglected when establishing the AML prognosis 
because epigenetic changes are inseparably connected to genetic lesions and they function 
together as a driver mechanism in leukemogenesis (Fong et al., 2014).  
Furthermore, targeting the epigenome offers new therapeutic strategies, especially because 
epigenetic changes are mostly reversible. A variety of small molecule inhibitors are being 
developed affecting the epiregulatory genes. Currently approved drugs are for example 
the inhibitors of IDH1/2, inhibitors of histone deacetylases or DNA methyltransferases  
(e.g. azacytidine) (Cai & Levine, 2019).  
 
1.3.1 DNA methylation  
DNA methylation is an essential process for genome stability maintenance, proper embryonic 
development, gene expression regulation and cellular differentiation. In mammals, DNA 
methylation occurs almost exclusively on cytosines in CG dinucleotides, so called CpGs. 
There are over 28 milion CpGs in the human genome and most of them (~ 80 %) 
are methylated (Schubeler, 2015). About 10 % of CpGs are accumulated in so-called CpG 




in nearly a half of mammalian gene promoters (Smith & Meissner, 2013). These CGIs 
are mostly unmethylated regardless of expression and many studies have found an association 
between the methylation status of a CGI and transcription of the associated gene. Moreover, 
aberrant hypermethylation of CGIs in promoters of tumor suppressors connected to reduced 
transcription of the gene and hypomethylation of non-CpG-rich regions is a well-known 
phenomenon in cancer (Jones, 2012). However, further studies of the epigenome revealed that 
changes in DNA methylation outside the CGIs, in CGI shores (regions adjacent to CpG 
islands up to 2 kbp away) and shelves (regions subsequent to CGI shores), and even in gene 
bodies may have the same or even more important role in initiation and maintenance  
of a malignancy (Akalin et al., 2012; Schoofs et al., 2014). In CGIs, the methylation usually 
functions as a direct obstruction for transcription factors or attracts methyl-CpG binding 
proteins (MBP) that recruit corepressor complexes. Mechanisms behind the gene expression 
regulation by differentially methylated regions (DMR) in intragenic areas are still poorly 
understood but probably involve regulation of elongation during transcription, determination 
of alternative poly-A sites and regulation of pre-mRNA splicing (Fong et al., 2014). 
 DNA methyltransferases (DNMT) are enzymes able to add the methyl group to the fifth 
carbon of cytosine in CpG dinucleotide. DNMT1 maintains the methylation pattern  
of the genome via recognition and methylation of hemi-methylated sites, thus restoring 
the methylation symmetry during DNA replication. DNMT3 can methylate both  
hemi-methylated and unmethylated sites in the genome, helping to maintain the DNA 
methylation equilibrium and also being able to create newly methylated loci which 
is particularly important during embryogenesis and stem cell differentiation  
(Fong et al., 2014). There are two homologs of DNMT3, DNMT3A and DNMT3B, and each 
preferably methylate specific sites in the genome. DNMT3B is highly expressed during early 
embryogenesis and then silenced in somatic cells. However, DNMT3B aberrant 
overexpression is tumorigenic and has been detected also in AML and connected to poor 
prognosis (Norvil et al., 2020). Mutations in DNMTs, especially DNMT3A in AML  
(see chapter 1.2.2.1), are connected with overall hypomethylation of the genome  
(Norvil et al., 2020). 
Other genes affecting directly the DNA methylation are IDH1/2 and TET2, described 
in chapter 1.2.2.1. Mutations in these genes are associated with prevailing DNA 
hypermethylation. Interestingly, although these mutations are mutually exclusive, 
the resulting hypermethylation patterns in DNA of IDH1/2mut and TET2mut patients 




Moreover, specific DNA methylation changes are detected in nearly all subtypes of AML 
with various genetic lesions. This could be partially explained by the epigenetic drift  
as an independent phenomenon that occurs in the course of repetitive cell cycling in aging 
cells or transformed cancer cells. But specific DNA methylation profiles are also connected 
with for example mutations in genes regulating the histone modifications, especially 
the histone methyltransferases like MLL or EZH2, or cohesines, that regulate 
the chromosomal interactions (Akalin et al., 2012; Schoofs et al., 2014). It was also reported 
that some oncogenic transcription factors (e.g. RUNX1-RUNX1T1 protein) may recruit 
DNMTs to their target sites and cause an abnormal methylation. On the contrary, other 
transcription factors are able to protect their binding sites from methylation  
(Gebhard et al., 2010; Schoofs et al., 2014). Thus, specific methylation losses were detected 
in patients with NPM1mut and cooccurring mutations in NPM1, DNMT3A, and FLT3. Distinct 
methylation patterns were also found in AMLs with CEBPA or RUNX1 mutations, and with 
gene fusions of transcription factors like CBF AML and APL (Figueroa et al., 2010;  
Ley et al., 2013; Gebhard et al., 2019). 
 
1.3.1.1 Prognostically significant changes in DNA methylation 
Because of the great heterogeneity of AML, there is a constant search for novel biomarkers 
that would help to stratify the patients. DNA methylation is an attractive target mainly 
because it is a stable marker that is relatively easy to measure. Many studies use simple  
PCR-based methods and focus primarily on methylation levels in small regions, sometimes 
only one or a few loci, particularly in gene promoters (for example: Guo et al., 2017;  
Hájková et al., 2012; Liu et al., 2017; Zhou et al., 2017). With the advancement in high-
throughput and NGS technologies, increasing number of researchers try to evaluate 
the methylation changes in a more complex way broadening the investigation to a large 
number of regions throughout the whole genome (Deneberg et al., 2011; Luskin et al., 2016; 
Kelly et al., 2017; Li et al., 2017).  
Recently published studies evaluating the prognostic significance of DNA methylation 
aberrations in AML patients are summarized in Table 4. It is apparent that the outcome  
of a specific methylation change is highly dependent on its position in the genome. About half 
of the studies found out that higher methylation at a certain region is associated with better 
survival of patients (e.g. Deneberg et al., 2011; Marcucci et al., 2014; Qu et al., 2017), 
however, other studies got to exactly opposite results when reporting that lower  




Treppendahl et al., 2012; Jost et al., 2014; Guo et al., 2017). Not always there was 
a connection between DNA methylation and expression of the associated gene, so the biology 
behind some of these presumably prognostic significant changes is unclear. A few studies 
referred to the association with HOX genes because their expression is regulated 
epigenetically by polycomb and trithorax proteins and they play a central role in embryonic 
development and hematopoiesis (Deneberg et al., 2011; Hájková et al., 2012;  
Jost et al., 2014). Some of the studies provided connection between genetic aberrations 
and DNA methylation changes (Marcucci et al., 2014; Jost et al., 2014; Kelly et al., 2017;  
Liu et al., 2017). Nevertheless, Li et al. (2016) highlighted in their work that genetic 
and epigenetic changes follow distinct patterns with different kinetics during the disease 
progression and thus should be evaluated separately as independent prognostic markers.  
Unfortunately, none of these findings were implemented into clinical practice. The main 
reason is that there are no validation studies that would confirm or reject the clinical 
significance of reported DNA methylation changes with presumable prognostic impact. 
Another drawback is that these studies usually used different methods and so the results may 
also vary. For example, when comparing the broader studies that focused on promoter 
methylation, Figueroa et al. (2010) presented a methylation classifier based on 15 genes, 
Deneberg et al. (2011) discovered 62 CpGs associated with patients’ survival,  
and Marcucci et al. (2014) identified 82 genes, methylation of which was associated with OS, 
and proposed a 7-gene panel for prognostic evaluation of AML patients. Surprisingly, there 
was no overlap between the identified prognostically significant DNA methylation changes 
among these three papers. On the other hand, when Qu et al. (2017) were searching 
for survival-associated methylation regions, they re-discovered some of the sites published 





Table 4 Summary of potential prognostically relevant changes in DNA methylation of AML patients published in recent studies 
Author Studied region/gene Clinical significance Notes 
Figueroa et al. (2010) 
Fifteen genes including transcription 
factors, protein-metabolism 
regulators, genes related to 
telomeres regulation, and signaling 
Unique methylation classifier computed using 
supervised principal components (SuperPC) method 
predictive of OS (p < 0.001). 
Aberrant methylation associated with 
downregulated expression. 
Deneberg et al. 
(2011) 
PcG (polycomb group proteins) 
target genes 
Higher methylation associated with better disease-free 
survival (p = 0.01) and OS (p = 0.001) in CN-AML. 
  
Lin et al. (2011) CEBPA distal promoter 
Higher methylation was associated with longer  
OS (p = 0.03) in patients with normal karyotype and 
without CEBPA mut and NPM1mut. 
 
Hájková et al. (2012) 
Promoters of tumor suppressor 
genes (CDKN2B, ESR1, MYOD1, 
CALCA, SOCS1, CDH1) and HOX 
genes 
Hypermethylation of SOCS1 promoter associated with 
better outcome (p = 0.04). Patients with smaller 
number of hypermethylated genes (p = 0.012) or with 
lower levels of cumulative DNA methylation value 
computed from methylation levels of all studied 
regions have worse OS (p = 0.027). 
Studied negative impact of HOX genes and 
tumor suppressors’ promoters hypomethylation 
caused by DNMT3Amut. 
Treppendahl et al. 
(2012) 
VTRNA2-1 promoter 
Patients with hypermethylation had poorer survival 
(p = 0.001). 
Methylation was inversely correlated with 
expression. 
Marcucci et al. 
(2014) 
DMRs in promoters of seven genes 
(CD34, RHOC, SCRN1, F2RL1, 
FAM92A1, MIR155HG, and VWA8) 
High DMRs methylation associated with lower 
expression linked to higher CR rate, longer disease-free 
survival and OS (p < 0.001) in CN-AML. 
FLT3-ITD and DNMT3A mutations associated 
with low methylation at DMRs, NPM1 and IDH 
mutations associated with higher methylation 
at DMRs (p < 0.001). 
Hájková et al. (2014) PBX3 (TAF1 binding site) 
Lower methylation correlated with higher expression 
of PBX3 that was associated with higher incidence 
of relapse (p = 0.004). 
Newly discovered hypomethylation pattern 
specific to CBFB-MYH11 fusion with 
corresponding gene overexpression. 
Jost et al. (2014) Promoter region of DNMT3A 
Aberrant hypermethylation (> 10 %) detected in ~40 % 
of studied patients with shorter EFS and OS and poor 
or intermediate cytogenetic risk. 
Higher methylation in the region were mostly 
observed in patients without DNMT3Amut and 
was associated with moderate downregulation 
of DNMT3A transcription. 
Božić et al. (2015) 1 CpG in C1R gene 
Higher methylation (> 27 %) associated with longer  
OS (p < 0.0001). 
Only moderate association of DNA methylation 







Author Studied region/gene Clinical significance Notes 
Wertheim et al. 
(2015); Luskin et al. 
(2016) 
Seventeen loci identified as having 
a prognostic significance for AML 
Higher M-score (methylation statistic computed with 
the random forest method) associated with death  
(p = 0.01) and failure to achieve CR (p = 0.03). 
 
Li et al. (2016) 
Promoter associated loci, each 
including four consecutive CpGs, 
with epigenetic allelic variance 
Higher epigenetic allele burden (magnitude of epiallele 
shifting, gain or loss, across the genome) disrupts 
transcriptional regulation and is associated with 
shorter time to relapse (p = 0.008). 
During disease progression, genetic and 
epigenetic allelic variations follow different 
kinetics and patterns. 
Zhou et al. (2016) DLX4 
Patients with methylated DLX4 presented lower  
CR rate (p = 0.001) and shorter OS (p = 0.003). 
DLX4 hypermethylation is negatively associated 
with expression. 
Kelly et al. (2017) 
Many CpG islands with aberrant 
methylation (CIMP), particularly 
SCGB3A1, NPM2, CDKN2B, and 
OSCP1 
Patients with long survival (> 1-year, median  
OS = 90 months) had more aberrant methylation  
at studied CGIs (p = 0.02). 
Patients with CIMP hypermethylation 
associated with IDH1/2mut showed poorer OS, 
than patients with IDH1/2mut-independent CIMP 
hypermethylation (p = 0.08). 
Qu et al. (2017) CGI shores of LZTS2 and NR6A1 
Hypomethylation in either of the two regions 
associated with worse OS (p < 0.001). 
Studied on AML patients with normal 
karyotype. 
Li et al. (2017) NKD2 promoter 
Higher methylation correlated with lower expression  
of NKD2 which was associated with shorter  
OS (p = 0.03) in CN-AML. 
  
Zhou et al. (2017) GPX3 promoter 
MDS patients with GPX3 methylation showed shorter 
OS (p = 0.01). 
GPX3 methylation increased during progression 
to AML. 
Guo et al. (2017) SFRP1 and SFRP2 promoter regions 
Higher methylation associated with shorter  
OS (p = 0.03). 
  
Liu et al. (2017) RASSF1A promoter 
Hypermethylation connected with decreased  
relapse-free survival (p = 0.04). 
Hypermethylation of RASSF1A associated with 
ASXL1 mutations and decreased mRNA levels. 
Šestáková et al. 
(2019) 
GZMB enhancer 
Hypermethylation associated with inferior  
OS (p = 0.03). 
Concurrent presence of both DNMT3Amut and 
IDH1/2mut partially cancel out the opposite 
influence of these aberrations on DNA 
methylation resulting in a mixed methylation 
and hydroxymethylation profiles. 
CGI – CpG island, CIMP – CGI methylator phenotype, CR – complete remission, DMR – differentially methylated region, EFS – event-free survival,  




1.3.2 DNA hydroxymethylation in AML 
There are more DNA modifications resulting from DNA methylation. TET enzymes catalyze 
oxidation of the methyl group subsequently resulting in 5´-hydroxymethylcytosine,  
5´-formycytosine, and 5´-carboxylcytosine. All of these forms of oxidized 5´-methylcytosine 
are stable epigenetic marks that inhibit DNMT1 causing a passive demethylation of the locus. 
5´-formycytosine, and 5´-carboxylcytosine also trigger the active DNA demethylation 
pathway mediated by base excision repair (Ko et al., 2015).  
 The biological function of these 5-mC derivatives is yet to be established but a role  
in the gene expression modulation has already been proposed. It was shown that these DNA 
modifications can regulate the recruitment and binding of polycomb repressive complexes and 
can reverse the transcriptional silencing (Fong et al., 2014; Wouters & Delwel, 2016). 
Furthermore, it was suggested, that DNA hydroxymethylation can play an important role 
in shaping the epigenetic landscape of cancer genomes and that TET enzymes can act as both 
tumor suppressors and promoters of a malignancy (Jeschke et al., 2016). A study evaluating 
DNA hydroxymethylation in AML patients found that 5-hmC levels were related to increased 
expression of associated genes. Moreover, this correlation was even more significant than 
between DNA methylation and downregulation of the gene (Rampal et al., 2014). Another 
research found an association between overall 5-hmC levels and AML prognosis, showing 
that higher levels of 5-hmC correlate with inferior survival of patients (Kroeze et al., 2014). 
 
1.3.3 Other epigenetic changes in AML 
In previous chapters, a role of histone modifications in AML epigenetic landscape was 
already mentioned. Histones (H1, H2A, H2B, H3, and H4) are basic globular proteins that 
form nucleosomes, key components in DNA organization. Loose N-terminal trails of histones 
can be subjected to a variety of modifications like methylation, acetylation, phosphorylation, 
ubiquitylation, etc. These alterations regulate the associated DNA region. Open chromatin 
structure allows gene expression and is marked by histone acetylation and methylation 
of certain histone lysine residues (H3K4me3, H3K36me3 or H3K79me2). Methylation 
of histone arginine residues also promotes transcriptional activation. In contrast, 
trimethylation of other H3 lysine residues (H3K9me3, H3K27me3) is a marker of gene 
repression which is also promoted by histone deacetylases (Hájková, 2015).  
The DNA and histone methylation mechanisms are tightly linked by various enzyme 
interactions. For example, it was found that EZH2 mediated methylation of H3K27, 




in cancer cells (Schlesinger et al., 2006). Also, the oncometabolite produced by mutated 
IDH1/2 enzymes, 2-hydroxyglutarate, inhibits a group of lysine demethylases containing 
Jumonji domain, leading to altered gene expression and impaired cell differentiation  
(Fong et al., 2014). Furthermore, lysine methyltransferases (mainly KMT2A and EZH2) were 
found to be recurrently mutated in AML and these patients exhibit specific DNA methylation 
changes (Schoofs et al., 2014; Wouters & Delwel, 2016).  
The histone modifications themselves have an impact on AML pathogenesis. Chromatin-
binding protein ASXL1 (described in chapter 1.2.2.1) should be mentioned because 
its interaction with EZH2, which is particularly important in AML development, leads  
to a global decrease of methylation at H3K27 residues and impaired upregulation of genes, 
including HOX genes (Fong et al., 2014). A recent study also showed that arginine 
methyltransferase PRM1 promotes the expansion of FLT3-ITD leukemic cells and thus 
PRMT inhibitors were proposed to enhance the AML therapy (He et al., 2019). Histone 
deacetylases were not found to be mutated in AML. Nevertheless, it was shown that these 
enzymes can be recruited by some oncoproteins, for instance the PML-RARA fusion protein, 
resulting in aberrant gene silencing (Abdel-Wahab & Levine, 2013; Fong et al., 2014). 
RNA-based mechanisms of gene silencing are also commonly classified as epigenetic 
regulations. RNA interference is a mechanism where short non-coding RNAs (miRNA, 
siRNA) cause degradation of target mRNA. Investigations of miRNAs in AML found 
for instance that certain miRNAs expression is associated with cytogenetics and FLT3 
mutations and that higher expression of miR-191 and miR-199a are linked to a worse outcome 
in AML patients (Garzon et al., 2008). Later studies discovered a tumor suppressing miR-29b 
(Garzon et al., 2009), and miR-29a and miR-142-3p decreased expression of which 
is involved in the development of AML (Wang et al., 2012). Long non-coding RNAs 
(lncRNA), involved in many biological processes such as imprinting, epigenetic regulation 
and apoptosis, were also found to have a role in AML pathogenesis. Various genetic lesions 
of AML were characterized by distinct profiles of lncRNAs and a subset of lncRNAs that 
strongly correlated with patients’ survival was also discovered (Garzon et al., 2014). It was 
further found that upregulated lncRNAs in AML are associated with lower DNA methylation 
levels, and that lncRNA LOC285758 enhances the expression of histone deacetylase 2 and 





1.4 Methods for genetic and DNA methylation studies 
1.4.1 Next Generation sequencing in AML 
Next generation sequencing (NGS) is a high-throughput method of massive parallel 
sequencing that allows for rapid and precise evaluation of multiple samples. Thanks to these 
advances in sequencing technologies in the last decade, an immense amount of new 
knowledge about the mutational landscape of AML was acquired that influenced AML 
classification, prognostic stratification, and even treatment choices and response assessment 
(Ley et al., 2013; Papaemmanuil et al., 2016; Folta et al., 2019). 
 There are various types of NGS technology. Thermo Fisher Scientific (USA) Ion proton 
system is based on semiconductors that measure the slight pH change that occurs when 
hydrogen ion is released during the attachment of a new base to the newly synthesized DNA 
strand. PacBio System developed by Pacific Bioscience (USA) is able to measure 
the fluorescent signal of each base attached to a single DNA molecule in real-time. Real-time 
sequencing of a single molecule is also used in Oxford Nanopore Technology (UK) that 
measures the electrical current of each base on a DNA strand passing through a nanopore 
placed on a synthetic membrane. However, the most commonly used technology 
is sequencing by synthesis utilizing fluorescently labeled reversible terminators developed 
by the Illumina company (USA) (Leisch et al., 2019). 
 The price of NGS depends mainly on the amount of genome that is sequenced. Whole 
genome sequencing (WGS) or whole exome sequencing (WES) are much more expensive 
than targeted sequencing that focuses only on certain chosen regions of DNA. Targeted 
sequencing is currently the most popular method and begins to be utilized in common clinical 
practice. There is still no consensus about the number and composition of genes that should 
be included in a myeloid sequencing panel. Nevertheless, there are several commercially 
available panels targeting genes most relevant for AML pathogenesis, e.g. AmpliSeq® 
Myeloid Sequencing Panel (Illumina), see Table 5, SureSeq myPanel™ NGS Custom AML 
(Oxford Gene Technology), and Human Myeloid Neoplasms Panel (Qiagen). It is also 
foreseen that once the costs and turnaround times of NGS technology are further reduced, 
whole-exome or even whole-genome sequencing will become the standard for AML 





Table 5 AmpliSeq™ for Illumina Myeloid Panel gene list 
Hotspot genes (n=23) 
ABL1 BRAF CBL CSF3R DNMT3A FLT3 GATA2 HRAS IDH1 IDH2 
JAK2 KIT KRAS MPL MYD88 NPM1 NRAS PTPN11 SETBP1 SF3B1 
SRSF2 U2AF1 WT1               
Full genes (n = 17) 
ASXL1 BCOR CALR CEBPA ETV6 EZH2 IKZF1 NF1 PHF6 PRPF8 
RB1 RUNX1 SH2B3 STAG2 TET2 TP53 ZRSR2       
Fusion driver genes (n = 29) 
ABL1 ALK BCL2 BRAF CCND1 CREBBP EGFR ETV6 FGFR1 FGFR2 
FUS HMGA2 JAK2 KMT2A (MLL) MECOM MET MLLT10 MLLT3 MYBL1 MYH11 
NTRK3 NUP214 PDGFRA PDGFRB RARA RBM15 RUNX1 TCF3 TFE3   
Expression genes (n = 5) Expression control genes (n = 5) 
BAALC MECOM MYC SMC1A WT1 EIF2B1 FBXW2 PSMB2 PUM1 TRIM27 
 
1.4.2 Methods for DNA methylation analysis 
Methods for epigenetic studies are also rapidly evolving. A few approaches have been 
developed to enrich the analyzed DNA regions of CpG sites that could possess a differential 
methylation: immunoprecipitation method based on antibody against 5-mC, a pull down 
of methylated regions using 5-mC binding protein (MBD), or the use of restriction enzymes 
that can be both methylation sensitive or insensitive and cleave a CpG site (for example 
HpaII, a methylation-sensitive enzyme that cuts CCGG sequence, and MspI, that cuts 
the same site but regardless of its methylation status) (Kurdyukov & Bullock, 2016; 
Šestáková et al., 2019). With these preparatory steps, a pool of CpG rich regions, mostly from 
CGIs, is obtained. Nevertheless, the majority of studies utilize bisulfite (BS) conversion 
of DNA as an initial step of DNA methylation assessment. Sodium bisulfite is used to mediate 
the deamination of cytosines into uraciles while methylated cytosines remain intact  
(Hayatsu et al., 1970). Usually, PCR amplification follows the conversion and thus converted 
residues are changed to thymines while methylcytosines remain cytosines. This method 
originally required great amount of DNA and was very damaging for the sample. Nowadays, 
there are commercial kits that able to convert as little as 100 pg of DNA in less than 2 hours 
and guarantee 99 % conversion efficiency (Šestáková et al., 2019). The main benefit of this 
approach is that any region of DNA or even a whole genome can be converted and examined.  
 
1.4.2.1 High-throughput methods 
Before NGS became generally available, other methods allowing DNA methylation analysis 




PCR) assay consists of MspI and HpaII digestion of genomic DNA and subsequent ligation 
and PCR amplification of resulting fragments (Khulan, 2006). Fluorescently labeled 
amplicons are then hybridized to custom-made oligonucleotide microarrays and signals from 
MspI and HpaII digestions are compared. This method was further optimized into MELP 
(Microsphere HpaII tiny fragment enrichment by ligation-mediated PCR) where the labeled 
amplicons are hybridized to microspheres with distinct fluorescent properties and then 
subjected to flow cytometry. The microsphere fluorescence identifies the locus and signal 
intensity of the PCR products reflects the methylation level (Wertheim et al., 2014). 
The authors further reduced the time for this assay by altering the linker oligonucleotides and 
called the improved assay xMELP (Expedited microsphere HpaII small fragment enrichment 
by ligation-mediated PCR) (Wertheim et al., 2015).  
A variety of microarrays was also developed for DNA methylation studies. Originally, 
the arrays were designed for hybridization of samples after the immunoprecipitation step, 
e.g. Human CpG Island Microarray Kit (Agilent). However, these kinds of chips were 
replaced with microarrays investigating the methylation status of BS converted samples, 
developed mostly by Illumina company. For example, Infinium HumanMethylation450 Bead 
Chip was used in The Cancer Genome Atlas 2013 study of large cohort of AML patients  
(Ley et al., 2013). Illumina further extended this microarray and presented Infinium 
MethylationEPIC Bead Chip that covers over 850,000 CpGs targeting CGIs, UTR regions 
and even CpGs inside gene bodies. The chip uses two types of probes, type I uses two probes 
for one locus, one for methylated and one for unmethylated allele. Type II probes use single 
probe for both methylated and unmethylated allele which are distinguished by a color mark 
that is attached to analyzed DNA fragments during sample preparation (Pidsley et al., 2016). 
Still, the use of microarrays is quite expensive because of the limited capacity of the chip  
(12 samples) (Kurdyukov & Bullock, 2016). Therefore, these techniques were shaded 
by rapidly evolving NGS approaches. 
 Early NGS studies of epigenetic landscape in AML preferentially used the enrichment 
methods (restriction enzymes, immunoprecipitation) as the first step to focus on aberrant 
methylation at CGIs. Reduced representation bisulfite sequencing (RRBS) uses MspI 
restriction fragments that are linked to adapters, treated with bisulfite, amplified, 
and sequenced (Meissner, 2005). This method was further adjusted to enhanced RRBS 
(ERRBS) by selecting longer MspI fragments to capture more regions, mainly beyond CGIs 
(Akalin et al., 2012). Nowadays, with the focus aimed preferentially at CpGs outside CGIs, 




examination of the genome. There, the DNA is only bisulfite converted, amplified with 
random primers and sequenced. However, BS sequencing of the whole genome is not only 
expensive, but also extremely challenging for bioinformatic analysis, mainly the mapping 
of acquired data, because bisulfite conversion markedly decreases the complexity of reads. 
Targeted bisulfite sequencing is thus more common for instance with SureSelect Human 
Methyl-Seq (Agilent) or SeqCap Epi Enrichment Kit (Roche) technologies. It is also possible 
to design and purchase custom made probes for the capture of specific sequences.  
In the future, single molecule sequencing approaches may further simplify the methylation 
assessment. For example, the nanopore technology (mentioned in chapter 1.4.1) could readily 
distinguish cytosine and methylated cytosine in a sequence without any previous DNA 
treatment (Kurdyukov & Bullock, 2016; Simpson et al., 2017).  
 
1.4.2.2 DNA methylation analysis of specific regions  
Beside the high-throughput technologies, there is a number of methods for measuring 
the DNA methylation level at certain loci or short region. These techniques are indispensable 
for validation of the data from NGS or microarrays and are usually quick, cost effective, 
sensitive, and suitable for measurement of large number of samples (Šestáková et al., 2019).  
 One of the fastest methods employs the methylation specific and unspecific restriction 
endonucleases (MSRE). After cleavage, the number of resulting fragments is measured 
by quantitative PCR. This approach enables the assessment of methylation level only at CpGs 
inside specific restriction sites which is the main drawback (Itoi et al., 2007). There are 
commercially available kits for this method, e.g. OneStep qMethyl kit (Zymo Research) 
(Kurdyukov & Bullock, 2016). 
 Other methods require bisulfite conversion. The golden standard of DNA methylation 
measurements is bisulfite sequencing, where selected bisulfite converted DNA region 
is cloned into a vector and transformed into bacteria. At least ten bacterial colonies are then 
harvested and their vectors are sequenced for the DNA methylation assessment  
(Frommer et al., 1992). Another approach with base-resolution is pyrosequencing, where 
a specific region of BS converted DNA is amplified via PCR and then sequenced. 
Pyrosequencing uses a mix of enzymes that produce light in every sequencing cycle when 
the specific base is attached to immobilized template strand. The methylation percentage 
is counted from the signal ratio of attached cytosines and thymines at certain CpG loci  
(Tost & Gut, 2007). The rest of the methods lack the base resolution and are able to measure 




high-resolution melting analysis (MS-HRM) is based on different melting temperatures (Tm) 
of methylated and unmethylated DNA. The studied region is amplified with PCR and then 
a melting analysis is performed with small ramping (0.1°C). Melting curves can 
be distinguished because of the different Tm between CG base pair of methylated cytosine and 
AT base pair resulting from converted unmethylated cytosine (Wojdacz & Dobrovic, 2007). 
Very common method is methylation-specific PCR (MS-PCR) which requires two sets 
of primers that span the region of interest, one for methylated allele and the other 
for unmethylated allele (Herman et al., 1996). More quantitative modification of MS-PCR 
is called MethylLight and uses methylation specific probes in quantitative PCR. The probes 
are designed for any combination of the methylated state inside the selected region 
(methylated/unmethylated allele of each CpG) which increases the accuracy of the DNA 
methylation assessment (Eads et al., 2000). 
 
1.4.3 Methods for DNA hydroxymethylation detection 
As described in chapter 1.3.2, DNA hydroxymethylation may too play a role in AML 
pathogenesis and thus methods for the detection and measurement of 5-hmC should 
be mentioned. Global DNA hydroxymethylation levels can be measured by liquid 
chromatography of DNA digested to single nucleotides and linked to electrospray ionization 
tandem mass spectrometry (LC-MS/MS). LC-MS/MS can distinguish all bases and their 
modifications and measure their amount in the sample (Le et al., 2011). A few methods were 
developed for the investigation of 5-hmC in specific regions. Digestion-based techniques use 
a glycosyltransferase in the first step. Only hydroxymethyl cytosines are glycosylated 
and thus resistant to subsequent MspI cleavage. The resulting DNA fragments can 
be analyzed via PCR or NGS. 5-hmC antibodies are also available for the enrichment 
of hydroxymethylated sites prior to sequencing (Kurdyukov & Bullock, 2016). Furthermore, 
an adjusted BS-based method called oxidative bisulfite conversion (oxBS) was developed, 
where an additional oxidation step is performed prior to the BS conversion itself. 
The hydroxymethylated cytosines are oxidized to formylcytosines which are subsequently 
converted by BS to thymines together with the unmethylated cytosines. The location  
of 5-hmC is extracted from a comparison of BS and oxBS converted samples analyzed either 





2 AIMS OF THE THESIS 
With the advancements in high-throughput sequencing, there was a great progress in mapping 
of the genetic landscape of AML that contributed to a more accurate risk classification 
(Döhner et al., 2017). However, AML is a highly heterogenous malignancy and patients with 
this disease would still benefit from a better prognostic stratification. It is well known that 
nearly half of AML patients harbor mutations in genes that regulate epigenetic mechanisms, 
especially DNA methylation (Ley et al., 2013). It is therefore understandable to assume that 
DNA methylation by itself may affect the prognosis of AML patients. Indeed, many studies 
addressed and confirmed the prognostic potential of various DNA methylation changes. 
However, none of the reported prognostically significant DNA methylation aberrations were 
implemented into clinical practice. The reason is a prevailing inconsistency of these studies, 
mainly in used methods and studied regions, and also a lack of robust validation studies.  
The aims of this thesis were to deeper investigate the DNA methylation changes in AML 
patients with defined genetic background, to assess the suitability of particular DNA 
methylation validation techniques, and to evaluate potentially predictive DNA methylation 
changes using a comprehensive approach. 
Firstly, we focused on the overall methylation profiles of patients with mutations in either 
DNMT3A or IDH1/2 genes and their combinations. These mutations have an opposing effect 
on DNA methylation and we were therefore curious how the methylation profiles would 
differ. Secondly, we aimed for the evaluation of DNA methylation validation techniques since 
choosing the appropriate methodology is a critical aspect of validation studies. Finally, 
we wanted to develop a new complex NGS-based approach for the overall evaluation of DNA 
methylation changes that were previously described as having a prognostic significance. 
We hoped that the results from a custom DNA methylation sequencing panel would both 
validate the results previously published by other authors and help to better stratify the AML 
patients, mostly those within intermediate risk group whose outcome and therapeutic strategy 





3 MATERIAL AND METHODS 
3.1 DNA methylation and hydroxymethylation changes in AML patients with 
mutations in DNMT3A, IDH1/2 or their combinations 
3.1.1 Patients 
De novo CN-AML patients (n = 24) were chosen from a collaborative mutational study 
of 58 non-APL intensively treated AML patients examined for their mutational status 
by ClearSeq AML kit (Agilent Technologies, Santa Clara, CA, USA) (Folta et al., 2019). 
Selected samples were divided according to their mutations into 5 groups: IDH1mut (n = 4), 
IDH2mut (n = 4), DNMT3Amut (n = 8), DNMT3A&IDH1mut (n = 4), and DNMT3A&IDH2mut  
(n = 4). Summary of patients’ mutational background is shown in Table 6. We preferentially 
picked samples with the same type of mutation in the three genes and with higher VAF. 
In these patients, overall hydroxy-/methylation and expression profiles were measured with 
arrays. Gene expression and DNA methylation of specific genes was further measured  
in a large cohort of diagnostic AML samples (n = 104, patients’ clinical characteristics are 
provided in supplementary Table 1 in section 9). 
This study was approved by the Institutional Ethics Committee and all patients gave their 

































DNMT3Amut_1 F 58 A 37.2% +30bp negative negative negative R882H 46.4% negative negative negative negative negative 
DNMT3Amut_2 F 53 negative +51bp negative negative negative R882H 43.7% negative negative negative negative negative 
DNMT3Amut_3 F 58 A 38.8% +21bp negative negative negative R882H 46.8% negative negative negative negative negative 
DNMT3Amut_4 F 71 A 40.5% +57bp negative negative negative R882C 46.6% negative negative negative negative negative 




DNMT3Amut_6 M 54 A 39.0% +81bp negative negative negative R882H 43.0% negative negative negative negative negative 
DNMT3Amut_7 M 65 negative negative negative negative negative R882H 44.7% negative negative negative negative negative 




IDH1mut_1 F 84 A 39.0% negative negative G12V 21.2% 
Y368D 
2.3% 
negative R132C 42.0% negative negative negative negative 
IDH1mut_2 M 89 D 43.4% negative 
D835V 29.5% 
D835Y 7.2% 
G12D 2.3% negative negative R132H 39.4% negative negative negative negative 
IDH1mut_3 F 65 A 10.8% +57bp negative Q61K 36.8% negative negative R132H 37.8% negative negative negative negative 
IDH1mut_4 M 65 negative negative negative negative negative negative R132C 33.4% negative negative negative negative 
IDH2mut_1 F 90 A 42.3% +18bp negative negative negative negative negative R140Q 44.5% negative negative negative 
IDH2mut_2 M 64 A 43.5% negative negative negative negative negative negative R140Q 42.8% negative negative 
P95delinsRP 
35.3% 
IDH2mut_3 M 84 A 41.5% negative negative negative negative negative negative R140Q 46.1% negative negative negative 
IDH2mut_4 M 75 A 37.3% negative negative negative negative negative negative R140Q 48.1% negative negative negative 




DNMT3A&IDH1mut_2 F 78 A 44.5% negative negative 
G13D 2.0% 
Q61K 2.9% 
negative R882C 45.3% R132S 47.5% negative negative negative negative 
DNMT3A&IDH1mut_3 F 86 negative negative negative negative negative R882H 32.4% R132C 29.9% negative negative negative negative 
DNMT3A&IDH1mut_4 F 62 A 37.3% negative negative G13D 38.0% negative R882H 44.7% R132H 35.0% negative negative negative negative 
DNMT3A&IDH2mut_1 M 86 negative +36bp negative negative negative R882H 42.7% negative R140Q 46.4% negative negative negative 
DNMT3A&IDH2mut_2 M 50 B 18.9% negative negative negative 
C416S 4.9% 
R420Q 67.6% 
R882C 40.5% negative R140Q 36.6% negative negative negative 
DNMT3A&IDH2mut_3 M 57 negative negative negative negative negative R882C 45.3% negative R140Q 43.4% negative negative negative 




3.1.2 Samples’ preparation 
In case of AML samples investigated with arrays, RNA and DNA were extracted with 
AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany) from peripheral blood leukocytes 
lysed in RLT buffer.  
In the larger AML cohort where methylation and expression of specific genes were 
assessed, DNA was extracted either from peripheral blood with MagCore system 
(RBCBioscience, New Taipei City, Tchaj-wan) or with AllPrep DNA/RNA Mini Kit from 
RLT lysates. RNA was isolated with TRIzol reagent (Thermo Fisher Scientific, Waltham, 
MA, USA) from peripheral blood leukocytes. Reverse transcription was performed with  
M-MLV Reverse Transcriptase (Promega, Madison, WI, USA). 
Ficoll gradient centrifugation (Histopaque, Sigma-Aldrich, St. Louis, MO, USA) was used 
for isolation of mononuclear cells (MNC) of selected AML patients (from diagnostic whole 
blood samples) or healthy blood donors (from buffy coats). CD34+/CD117+ cells were 
isolated from MNC using magnetic separation with MicroBeads kit (Miltenyi Biotec, Bergish 
Gladbach, Germany). DNA was subsequently extracted with MagCore instrument 
(RBCBioscience). 
 
3.1.3 Methylation and hydroxymethylation assessment with arrays 
TrueMethyl-Seq kit (CEGX, Cambridge, UK) was used for both BS and oxBS conversion 
of 1.2 μg of DNA from each sample (AML: n = 24, listed in Table 6; healthy donors: n = 4). 
BS and oxBS-converted DNA (140-250 ng) was subsequently investigated using Infinium 
MethylationEPIC BeadChip (Illumina, San Diego, CA, USA). Raw IDAT files were analyzed 
with R package ChAMP and β-values that correspond to methylation percentage (range 0-1), 
were acquired for each investigated locus. The batch effect between individual arrays was 
corrected using ComBat function (Johnson et al., 2007) and β-values were normalized via 
Functional normalization (Fortin et al., 2014).  
OxBS β-values were used for DNA methylation assessment. DNA hydroxymethylation 
levels were computed from the difference between BS and oxBS β-values (ΔβBS-oxBS). 
A threshold was set based on the 95th percentile of negative ΔβBS-oxBS values across all 
examined samples, as recommended in previous publication (Lunnon et al., 2016) and lower 
ΔβBS-oxBS values were considered as not hydroxymethylated. R package pvclust  





3.1.4 Bisulfite conversion 
EZ DNA Methylation-Lightning Kit (Zymo Research, Irvine, CA, USA) was used for DNA 
(~ 500 ng) treatment. Concentration of converted DNA was measured with NanoDrop™ 
One/OneC Microvolume UV-Vis Spectrophotometer (Thermo Fisher Scientific). 
 
3.1.5 Pyrosequencing 
PyroMark PCR kit (Qiagen) was used for the initial PCR amplification of oxBS and BS 
converted DNA (10-20 ng). The PCR reaction and conditions were kept according  
to the manufacturer’s protocol with 25 μl final volume and 0.2 μM final concentration  
of forward and reverse biotinylated primers. When the universal biotinylated primer was used, 
the final concentration of primers was 0.2 μM of forward and universal biotinylated primer 
and 0.04 μM of reverse tailed primer. Primers’ sequences and used annealing temperatures 
(Tann) are shown in Table 7. Quality of acquired amplicons (1 μl of PCR reaction) was 
checked using 2% agarose gel electrophoresis. Pyrosequencing was performed on PyroMark 
Q24 instrument (Qiagen). Two steps of the original manufacturer’s protocol (User Manual 
01/2016) were optimized: 2 μl of sepharose-coated streptavidin beads were added in step 
5.3.3.2 and the agitation was prolonged to 20 min (step 5.3.3.6). 
 
Table 7 Primers used for DNA hydroxymethylation and methylation validation by pyrosequencing 
Gene Primer Sequence Tann [°C] 
GZMB 
Forward 5'- TATAAATAGAGTTGTTTTGGTG -3' 
56 
Reverse biotinylated 5' biotin-AAACCATCATCTTCTCTAATAT -3' 
Sequencing 5'- ATTGAGGTTTGGATGTTTTA -3'  
MYB 
Forward 5'- GAGGTAGTTTATTAGATTTTG -3' 
50 
Reverse biotinylated 5' biotin- TAATATATACCATCATCACC -3' 
Sequencing 5'- TGTTTATTTTGAAGTTGTTG -3'   
 Universal biotinylated 5' biotin-ATCTGTGCCGAGGCTCAGGC -3'  
CHFR 
Forward 5'- TAAGAATYGGTGGGTAGAATAT -3' 
54 
Reverse - tailed 5'- GTGCCGAGGCTCAGGCATCTCCRCAAATATAAATCC -3' 
Sequencing 5'- TTTATTTTAYGGAAAAATTTGGAG -3'   
RNF216 
Forward 5'- AGTTAATTTAGTTGAAATGTTAGGTTT -3' 
54 
Reverse - tailed 5'- GTGCCGAGGCTCAGGCTCTTTTCTTCTCACAAATTAAAA -3' 
Sequencing 5'- AGTTAATTTAGTTGAAATGTTAGGTTT -3'   
 
3.1.6 Gene expression analyses  
HumanHT-12 v4 Expression BeadChip (Illumina) was used to investigate the overall gene 
expression of samples (AML: n = 24, listed in Table 6; healthy donors: n = 6). Data analysis 




by NormExp and quantile normalization were applied on raw IDAT files. ComBat function 
was used for batch effect correction (Johnson et al., 2007).  
TaqMan Gene Expression Assays (Life Technologies, Carlsbad, MA, USA) were used 
to measure the expression levels of GZMB (Hs188051_m1), CHFR (Hs00943495_m1), 
and reference gene GAPDH (Hs02758991_g1) in the large cohort of AML samples (n = 104) 
and healthy donors (n = 10). The amplification was performed with TaqMan Universal 
MasterMix II (Life Technologies) with 10 µl final volume. The expression was measured 
on StepOnePlus Real-Time PCR System (Life Technologies) with conditions according  
to the manufacturer’s protocol. 
 
3.1.7 Statistics 
The overall and event-free survivals were estimated by Kaplan-Meier curves with two-sided 
logrank test in GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA). SPSS software 
(IBM, Armonk, NY, USA) was used for Cox regression analysis. The correlation of DNA 
hydroxy-/methylation and expression data, and hydroxy-/methylation validation were 
performed in Microsoft Excel, F-test of overall significance and Pearson correlation 
coefficient were used. 
 
3.1.8 Gene ontology analysis 
Bed files with positions of differentially methylated sites were submitted to online tools 
GREAT (http://great.stanford.edu/public/html/) (McLean et al., 2010) and Enrich 
(https://amp.pharm.mssm.edu/Enrichr/) (Kuleshov et al., 2016). 
 
3.1.9 DNA hydroxymethylation assessment via mass spectrometry 
DNA (1 µg) of AML samples at diagnosis (n = 40) and two healthy donors’ samples were 
first cleaved by DNA Degradase Plus (Zymo Research) according to manufacturer’s protocol. 
The reaction was stopped with 0.1% formic acid added to 150 µl final volume of the mix. 
The mix was then filtered with centrifugal filters Microcon-10kDa with Ultracel-10 
membrane (Sigma-Aldrich) and evaporated to ~ 3 µl volume in vacuum concentrator 
Speedvac SPD111V (Thermo Fisher Scientific). Samples were analyzed using LC-MS/MS 
with Shimadzu Prominence chromatograph (Shimadzu, Kyoto, Japan) and mass spectrometer 
QTRAP 4000 (Sciex, Framingham, MA, USA) using selected reaction monitoring mode. 




3.2 DNA methylation validation methods 
3.2.1 Samples and DNA standards 
Mononuclear cells of healthy donors (n = 10) were harvested from buffy coats using Ficoll 
gradient centrifugation (Histopaque, Sigma-Aldrich). DNA was isolated with MagCore 
instrument (RBCBioscience). The blood donors provided their full consent and the study was 
approved by the Institutional Ethics Committee.  
Human Non-methylated & Methylated DNA Set (Zymo Research) was utilized 
as unmethylated and methylated DNA standards. 
 
3.2.2 Characterization of analyzed CpGs 
Three CpGs with different levels of DNA methylation were chosen based on data acquired 
in a previous project (chapter 4.1) from healthy donors’ samples analyzed on Infinium 
MethylationEPIC BeadChip (Illumina). Basic characteristic of selected loci is summarized 
in Table 8. Furthermore, these CpGs are placed within CCGG sequence and thus can 
be cleaved by MSRE. 
 
Table 8 Characteristics of selected CpG sites with distinct methylation levels 
Locus name BeadChip probe ID 
Cytosine location (hg 19) Average beta value for samples 
measured with BeadChip Chromosome Position 
M cg24337108 10 11797422 > 0.99 
IM cg25722983 1 36840028 from 0.45 to 0.55 
U cg09655782 4 57333859 < 0.1 
M – methylated, IM – intermediately methylated, U – unmethylated, BeadChip -Infinium 
MethylationEPIC BeadChip (Illumina), Beta value – a number corresponding to methylation 
percentage 
 
3.2.3 MSRE analysis 
For MSRE analysis, OneStep qMethyl Kit (Zymo Research) was utilized. Following 
the manufacturer’s protocol, DNA (20 ng) of each sample was processed through Reference 
and Test reactions. Annealing temperature was set to 60 °C in the PCR step, and the time 
of annealing was shortened to 45 s. We used Rotor-Gene Q 2plex HRM Platform (Qiagen) 
for the measurements. 
 
3.2.4 Bisulfite conversion 
EZ DNA Methylation-Lightning Kit (Zymo Research) was used for the BS conversion. About 




NanoDrop™ One/OneC Microvolume UV-Vis Spectrophotometer (Thermo Fisher 
Scientific). For the MS-HRM and quantitative MS-PCR (qMSP) experiments, 
the concentration of treated DNA was adjusted to 10 ng·μl−1. 
 
3.2.5 Primer design 
Online software Primer3Plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/ 
primer3plus.cgi) was used to design primers for MSRE analysis. Methyl Primer Express 
Software v1.0 (Thermo Fisher Scientific) was employed when designing primers for methods 
examining BS converted DNA. Sequences and characteristics of all used primers 
are summarized in Table 9. Figure 3 shows the three studied regions together with 
















GGTAGGAGGATGGTTTGAATT/   
GGTGGAAATGAAGTAGGTGTGTTTG 




GTTAAGGGGGTGTATTTTAGAGA/   
GGTAGAGAGAAGTTTTTTTTGTAGG 




GGGGGGGTGTTAGTATTTG/          
TTAGTATTTGYGTTGTGGAGTG 
GTGCCGAGGCTCAGGCCCAAACTAACCTAATAAAACC 58 300/290 
 
 
Universal biotinylated primer 5’biotin-TCTGTGCCGAGGCTCAGGC        
M MSRE TTTTCTGTGACCTCCTTTGG CAGTGTGACTGCTGGTGAAG 60 243  
N MSRE GCAATAGGCGTTAATGTCGT AGGAGTGGCAAAAGAGGACT 60 199  
U MSRE CGCTTAGCAATCATCGACTT GAAACAGGCCGCATCCTC 60 265  
M MSP Met GTATATTCGGAATTATTTCGTTTTC AATTAACAACCGACAACCG 56 72  
M MSP Unm GATGTATATTTGGAATTATTTTGTTTTT AATTAACAACCAACAACCA 56 75  
IM MSP Met CGGTTTTTATAGTTTTGAATTAGATC TTATTTATTATCACATCAACTACTTCCG 58 166  
IM MSP Unm ATTGGTTTTTATAGTTTTGAATTAGATT TTATTTATTATCACATCAACTACTTCCA 58 168  
U MSP Met CGTTGTGGAGTGAAGTGAATC ACCGAACGAACAATAAACGAA 54 210  
U MSP Unm TGTGTTGTGGAGTGAAGTGAATT ACCAAACAAACAATAAACAAAAAA 54 212  
M HRM TTGGGTGGAAATGAAGTAGGTGTG CCAAACCATTAACCATAACAATA 54-581 94  
IM HRM TTTGGGGAAAAAATATATGGAGTT CTACTAATAAAACCCTTTACTCCCA 54-581 90  
U HRM TTAGTATTTGYGTTGTGGAGTG CCRACACTTACTCTTATTAACRATC 54-581 93  
M HRM Wojdacz CGGGGGGGTGTTAGTATTTG CCCGACACTTACTCTTATTAACRATC 55 110  
U HRM Wojdacz TCGTGTTTTTTTTTGGGTGGAAATG GCGACCAAACCATTAACCATAACA 55 104  
1For HRM experiments Tann was 55°C, in MSP experiments Tann of MSP primers was used 
M – methylated locus, IM – intermediately methylated locus, U – unmethylated locus, MSP – methylation specific PCR, Met – primers for methylated DNA 






Figure 3 Positions of primer pairs, CpGs and restriction sites within studied regions. CpGs are shown as red and yellow bars on a line that represents the DNA 
sequence. Red CpG is the one chosen from Infinium MethylationEPIC BeadChip. Scissors indicate sites cleaved by MSRE. The patterned light green HRM 
primers were designed to include a CpG site on its 5’-end (M/U Wojdacz primers in Table 9). Lighter blue primers were used for initial pyrosequencing PCR, 





First, BS converted DNA (10–20 ng) was amplified using HotStar HiFidelity Polymerase Kit 
(Qiagen) with final MgCl2 concentration adjusted to 2.5 mM. CoralLoad Concentrate 
(from PyroMark PCR kit, Qiagen) was added to final concentration of 1x for easy gel loading 
and to increase the specificity of primers. Final concentration of universal biotinylated 
and forward primers was 0.2 μM. Final concentration of reverse tailed primer was 0.04 μM. 
Recommended PCR reaction conditions for PyroMark PCR were used with 48 PCR cycles 
and Tann according to Table 9. The quality of amplified PCR products was checked  
and the pyrosequencing was performed as described in chapter 3.1.5.  
 
3.2.7 MS-HRM analysis 
By mixing BS converted DNA of unmethylated and methylated standards, 100, 75, 50, 25, 10 
and 0 % methylated standards were prepared. BS converted samples (15 ng) and standards 
(15 ng) were processed with EpiTect HRM PCR Kit (Qiagen). Final reaction volume 
was 20 μ with 0.375 μM final concentration of each primer. Reaction conditions were set 
according to the manufacturer’s protocol. The experiment was performed using Rotor-Gene 
Q 2plex HRM Platform (Qiagen) with ramping for the HRM set from 67.1 to 82.2 °C, rising 
by 0.1 °C/2 s. Raw data were analyzed in web-based tool uAnalyze (Dwight et al., 2012). 
First, a baseline normalization was performed and then difference curves for all standards 
and samples were computed with the 0 % methylated standard used as a reference curve. 
Next, we plotted the calibration curves in Microsoft Excel according to Tse et al. (2011) using 
either area under the curve (AUC) of the standards’ processed data or their peak heights  
(Tse et al., 2011). The methylation percentage of samples was calculated from these 
calibration curves. 
 
3.2.8 Quantitative MS-PCR 
BS converted DNA (10-15 ng) was measured via quantitative PCR with subsequent melting 
curve analysis. QuantiTect SYBR® Green PCR Kit (Qiagen) was used to prepare the reaction 
mix with 20 μl final volume and 0.5 μM final concentration of primers. Recommended 
cycling conditions (40 cycles) were kept with Tann according to Table 9. All samples together 
with unmethylated and methylated DNA standards were amplified in three runs: with 
unmethylated methylation-specific primers (MSP Unm), methylated methylation-specific 




computed for each primer set according to Pfaffl (2007). Quantitative PCR was performed 
with four 4-time dilutions of BS converted DNA for each sample and decadic logarithm  
of the dilutions was plotted against acquired threshold cycles (Cts). The efficiency was 






− 1] ∙ 100. All measurements were performed on StepOnePlus instrument 
(Thermo Fisher Scientific). Methylation levels were subsequently calculated with all three 
methods reviewed in Husseiny et al. (2012). 
 
3.3 DNA methylation sequencing panel 
3.3.1 Patients 
Together we analyzed 178 adult AML patients divided into a test cohort (n = 128, patients 
from Institute of Hematology and Blood Transfusion, characteristics are provided 
in supplementary Table 2 in section 9) and a validation cohort (n = 50, patients from partner 
institution University Hospital Brno, characteristics are provided in supplementary Table 3 
in section 9). Patients were diagnosed between years 2013 - 2016 and treated with curative 
intent initiated with 3+7 induction regimen. Institutional Ethics Committees approved this 
study and all patients gave their full consent. The research conforms with The Code of Ethics 
of the World Medical Association. 
 
3.3.2 DNA methylation sequencing panel 
We designed a novel DNA methylation panel for targeted bisulfite sequencing. The panel 
comprised of 239 loci assigned to 186 genes. The custom probes were made by Roche 
company (Basel, Switzerland). The range of selected regions was 121–35,606 bp with average 
of 2,910 bp and median 1,473 bp. The total size of the panel was 573,406 bp. The investigated 
regions are listed in supplementary Table 4 in section 9. 
 
3.3.3 Samples’ preparation and targeted bisulfite sequencing 
Diagnostic DNA of AML patients was either isolated from whole peripheral blood with 
MagCore system (RBSBioscience) or from peripheral blood leukocytes lysed in RLT buffer 
using AllPrep DNA/RNA Mini Kit (Qiagen). We also analyzed 11 samples from healthy 
donors together with samples from the test cohort. Healthy donors’ DNA was isolated from 
CD34+ cells harvested from buffy coats using MicroBeads kit (Miltenyi Biotec), 




Each sequencing library consisted of 16-18 samples and libraries were prepared according 
to SeqCap Epi protocol (Roche) with KAPA HyperPrep Kit (Roche). First, Bisulfite-
conversion Control (unmethylated DNA from Enterobacteria phage lambda, a component 
of SeqCap Epi Accessory kit (Roche)) was added to 800–1,200 ng of patients/donors’ DNA. 
This DNA mixture was subsequently fragmented either via Bioruptor Pico instrument 
(Diagenode, Liège, Belgium) or E220 Focused ultrasonicator (Covaris, Woburn, MA, USA) 
to get ~ 200 bp DNA fragments. The size of fragments was checked in two random samples 
from each library on 4200 TapeStation System (Agilent Technologies, Santa Clara, CA, 
USA) using Agilent D1000 ScreenTape (Agilent Technologies). EZ DNA Methylation 
Lightning Kit (Zymo Research) was used for the bisulfite conversion, as recommended in the 
SeqCap Epi workflow. Each library was hybridized for ~ 68 hours with probes from our DNA 
methylation sequencing panel (chapter 3.3.2). KAPA Library Quantification Kit (Roche) was 
utilized to assess the final concentration of sequencing libraries. Average size of the libraries’ 
fragments was measured on 4200 TapeStation System with Agilent D1000 ScreenTape 
(Agilent Technologies). Sequencing was performed using MiSeq Reagent Kit v2 (300-cycles) 
(Illumina) on MiSeq instrument (Illumina). 
 
3.3.4 Sequencing data analysis 
Raw sequencing data were acquired as fastq files. First, the quality of reads was checked 
using MultiQC (Ewels et al., 2016) and FastQC (Andrews, 2010) software. Reads were 
subsequently trimmed and filtered with Cutadapt 2.4 (Martin, 2011) and the reads’ quality 
was checked once more. Next, mapping tool Segemehl (Otto et al., 2012) was used 
for mapping of the pre-processed data to human genome (version GRCh37/hg19) with added 
phage lambda sequence (NC_001416.1). The mapping statistic was computed and Samtools 
software was utilized for sorting and indexing of bam files that contained the mapped reads. 
Haarz tool (Otto et al., 2012), with enabled "callmethyl" option, was subsequently used 
for the subtraction of methylated positions, creating vcf files. These files, containing all 
methylated positions, were further processed in R software. Positions that corresponded  
to the lambda phage sequence were separated and used for the bisulfite conversion ratio 
assessment for each sample. The other positions were filtered and only CpG positions were 
left in the data. Finally, data for all samples from each cohort (test and validation) were put 
together and only CpGs that were measured in more than 75 % of the samples were left 





3.3.5 MethScore computation 
Initially, only the test cohort was analyzed. Cox univariate regression analysis for OS was 
performed for each detected CpG and only CpGs acquiring significant p-value (< 0.05) in this 
analysis were selected. Subsequently, using these CpGs, their methylation level and Cox 
regression coefficient beta, we computed a weighted summary score called MethScore. 
We adapted the procedure from Marcucci et al. (2014). MethScore (MS) for patient i was 
counted via linear combination as follows: 𝑀𝑆𝑖 =  ∑ 𝑤𝑗 ∙ 𝑥𝑖𝑗, where xij is a dichotomized 
methylation value (0 if methylation is < median methylation for the CpG in the whole cohort 
or 1 if methylation is ≥ median) for CpG j in patient i and wj is the Cox regression coefficient 
for CpG j. The computation was performed in statistical software R. The same set of CpGs, 
with methylation significantly affecting the OS of patients from the test cohort, was used 
to assess the MethScore for the validation cohort.  
 
3.3.6 Definitions and statistical analyses 
Overall survival was set as time from diagnosis until death of any cause, event-free survival 
was set as time from the first complete remission until hematological relapse or death. 
Surviving patients were censored to the 6th April 2020. To evaluate the significance for OS 
and EFS, we used Kaplan-Meier curves with two-sided logrank test. Uni- and multivariate 
analyses were performed via Cox regression analysis. Data were corrected to the time 
of transplantation for the multivariate regression and the assumption of proportionality was 
checked for each regression model. We used Mann-Whitney test (Wilcoxon test) when 
comparing continuous variables and Fishers’ exact test when comparing categorical variables 
in patients’ groups. All statistical analyses were performed in R. 
 
3.3.7 Gene ontology analysis 
Free online tools were used. Bed files with positions of detected CpGs were submitted 
to GREAT (http://great.stanford.edu/public/html/) (McLean et al., 2010) and Enrich 
(https://amp.pharm.mssm.edu/Enrichr/) (Kuleshov et al., 2016). Enrich program generated 
gene lists from the submitted bed files, which we further submitted to GOrilla  







4.1 DNA methylation and hydroxymethylation changes in AML patients with 
mutations in DNMT3A, IDH1/2 or their combinations 
4.1.1 DNA methylation profiles 
Using the methylation arrays, we acquired data from 716,847 probes for each investigated 
sample (n = 28). With those, we performed hierarchical clustering analysis, the resulting 
dendrogram is shown in Figure 4. The analysis revealed three main clusters: cluster 
of DNMT3Amut patients, IDH1/2mut patients, and cluster with healthy donors’ samples 
(controls). Majority of patients (63 %) with mutations in both DNMT3A and IDH1/2 genes 
were included in the controls’ cluster.  
 
Figure 4 Hierarchical clustering of methylation profiles of AML samples (n = 24) and healthy 
controls’ samples (n = 4) represented by oxBS β-values of 716,847 probes from Infinium 
MethylationEPIC BeadChip (Illumina).  
 
 Next, we were searching for differentially methylated positions (DMPs) between 
the groups of AML samples and controls. We considered the methylation difference (∆β) 
as biologically significant for -0.25 ≤ ∆β ≥ 0.25 with adjusted p-value < 0.05 as computed 
by the champ.DMP function in R software. The results are summarized in Table 10. 




and a hypermethylation tendency was found in samples with IDH1/2mut samples. Noticeably 
fewer DMPs were detected in DNMT3A&IDH1/2mut groups. Also, the ratio of hyper- 
and hypo-methylated sites was more balanced for DNMT3A&IDH2mut samples, with 
a prevalent hypomethylation in DNMT3A&IDH1mut group. A significantly more DMPs were 
found in the IDH2mut group than in the IDH1mut patients.  
 
Table 10 Numbers of differentially methylated positions detected between AML sample groups and 
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 (47 %) 
DMPs – differentially methylated positions (-0.25 ≤ ∆β ≥ 0.25; adjusted p-value < 0.05), Hyper – 
hypermethylated, Hypo – hypomethylated, NA – not analyzed 
 
 When we performed the gene ontology analysis, immune response and apoptosis pathways 
were associated with the 215 hypermethylated CpGs common for all IDH1/2mut samples. 
Among the apoptosis-related genes, granzyme B (GZMB), a key protein for apoptosis 
induction (Chiusolo et al., 2017), was found. Another interesting gene found in the gene 
ontology analysis was CHFR (checkpoint with forkhead‐associated and RING finger 
domains), tumor suppressor gene that serves as a mitotic checkpoint and was recently 
described as a marker of poor prognosis when hypermethylated or downregulated  
(Gao et al., 2016; Zhou et al., 2018). 
 
4.1.2 DNA hydroxymethylation profiles 
The difference between measured BS and oxBS β-values corresponds  
to the hydroxymethylation level of each CpG from the array. We applied the champ.DMP 
function to find statistically significant differences (ΔβBS-oxBS with adjusted p-value < 0.05) 




computation is described in chapter 3.1.3). For the subsequent analyses, we selected 536,617 
probes for which at least one sample passed this threshold (had ΔβBS-oxBS > 0.03335304).  
In the hierarchical clustering analysis, dendrogram is shown in Figure 5, three clusters 
of specific groups emerged: controls, IDH2mut patients and DNMT3Amut patients. The last 
group of samples clustered together with healthy controls and comprised mostly of IHD1mut 
and DNMT3A&IDH1mut samples.   
 
Figure 5 Hierarchical clustering of hydroxymethylation profiles of AML samples (n = 24) and healthy 
controls’ samples (n = 4) represented by ΔβBS-oxBS values of 536,617 probes. Probes with  
ΔβBS-oxBS < 0.03335304 were taken as not hydroxymethylated and assigned a value of 0.0001.   
 
Next, we set a threshold of ΔβBS-oxBS ≥ 0.2 for the selection of CpGs with biologically 
relevant DNA hydroxymethylation. In Table 11, we provide the numbers of detected 
hydroxymethylated positions (hmCpGs) in each group of samples.  The numbers of hmCpGs 
were much lower when compared with the numbers of differentially methylated sites 
(Table 10). The lowest number of hmCpGs was found in the group of DNMT3Amut patients 
and the highest number among IDH2mut samples. Significantly more hydroxymethylated 
positions were detected in IDH2mut samples than in IDH1mut samples, a similar phenomenon 
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hmCpGs – hydroxymethylated CpGs (∆βBS-oxBS ≥ 0.2, adjusted p-value < 0.05), Hyper-hmCpGs – 
hyperhydroxymethylated CpGs when compared to controls, NA – not analyzed 
 
 In the gene ontology analysis, a well-known protooncogene MYB was found  
to be hydroxymethylated and also upregulated (according to the results from the expression 
analysis, chapter 4.1.5) in IDH2mut samples, see Figure 6. Another gene, RNF2016 (ring 
finger protein 216), was found as hydroxymethylated in all samples, except the DNMT3Amut 
group. This gene encodes a protein with fundamental role in cellular homeostasis. 
Upregulation of RNF2016 was shown to be associated with progression of colorectal cancer 
(Wang et al., 2016). 
 
 
Figure 6 MYB expression and hydroxymethylation levels in all samples’ groups. Expression levels 
were calculated as log2 normalized expression data from HumanHT-12 v4 Expression BeadChip 
(Illumina). Hydroxymethylatin data are represented by ΔβBS-oxBS, measured with Infinium 




4.1.3 Validation of DNA methylation and hydroxymethylation data 
We validated the methylation and hydroxymethylation levels measured via Infinium 
MethylationEPIC BeadChip with pyrosequencing. For the validation, we selected two 
methylated loci cg00771752 and cg00338702 (associated with GZMB and CHFR genes, 
respectively), and two hydroxymethylated positions cg23073132 and cg05617317 (associated 
with MYB and RNF2016). 
 The methylation levels were successfully validated in all samples (n = 28), with  
Pearson correlation coefficients R = 0.91 (p-value < 1.87e-5) for GZMB and R = 0.72  
(p-value < 3,52e-7) for CHFR locus. However, we were not able to fully reproduce 
the hydroxymethylation data by pyrosequencing. For nine samples, we performed two 
pyrosequencing analyses, one with BS and one with oxBS converted DNA. Subsequently, we 
computed the difference ΔβBS-oxBS but the values were significantly smaller (3.11 ± 3.82 for 
RNF216 and 3.85 ± 3.21 for MYB) than those detected with arrays (20.15 ± 17.52 for RNF216 
and 9.79 ± 11.2 for MYB). Nevertheless, the correlation between original and validation data 
was quite good with R = 0.82 (p-value=0.002) for RNF2016 and R = 0.70 (p-value= 0.024) 
for MYB. 
 
4.1.3.1 DNA hydroxymethylation assessment with mass spectrometry 
To confirm the assumption from previous two chapters, that DNA hydroxymethylation levels 
in peripheral blood samples are considerably lower than the levels of DNA methylation, 
we analyzed an independent cohort of AML samples at diagnosis (n = 40) and two healthy 
donors’ samples with LC-MS/MS. There was a profound difference between 




Figure 7 Levels of 5-deoxyhydroxymethylcytosine (5hmdC) and 5-deoxymethylcytosine (5mdC) 
in 40 AML patients and 2 healthy donors’ samples measured with LC-MS/MS. Levels are expressed 
as percentage from total cytosine bases. *** p-value < 0.001. 
 
4.1.4 Influence of co-mutations (other than DNMT3A and IDH1/2) on DNA methylation 
and hydroxymethylation profiles 
Mutations in NPM1 were the most often co-occurring mutations found in 15 AML samples 
(62.5 %) and it seems that the presence of NPM1mut influenced the methylation profiles 
of investigated patients. DNMT3Amut samples with mutated NPM1 (DNMT3Amut_1,3,4,6) 
and wild-type NPM1 (DNMT3Amut_2,5,7,8) had a tendency to cluster together. Also, only one 
sample out of the IDH1/2mut groups (IDH1mut_4) did not bear NPM1mut and clustered away 
from the rest of IDH1/2mut samples (Figure 4). 
 The presence of FLT3-ITD (in 10 out of 24 AML) had no obvious effect on DNA 
methylation profiles of the investigated samples. 
 There were two DNMT3Amut patients (DNMT3Amut_5,8) with co-occurring TET2 
mutations. These samples did not display any similarity with the DNA methylation profiles 
of DNMT3A&IDH1/2mut samples and clustered within the rest of DNMT3Amut samples 
(Figure 4). In the hydroxymethylation analysis, these two samples clustered together 
(Figure 5). 
 
4.1.5 Overall expression profiles 
After the initial data processing, we acquired 45,607 probes with which we performed 
differential gene expression analysis, results are summarized in Table 12. We compared each 
group of patients with healthy donors’ samples. The highest numbers of deregulated genes 
were detected among DNMT3Amut and IDH2mut patients. On the contrary, the group with 




most of the differentially expressed genes were linked to DNA binding, transcription, 
splicing, and translation processes. 
To compare the overall gene expression profiles of investigated samples, we performed 
a hierarchical clustering analysis with probes that had detection p-value < 0.05 (n = 10,067), 
resulting dendrogram is shown in Figure 8. The cluster did not reproduce the results obtained 
from either DNA methylation or hydroxymethylation analyses (Figures 4 and 5). Only 
the group of healthy donors (controls) formed a united cluster. 
 
Table 12 Summary of differential gene expression analysis between healthy donors and groups 
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IDH2 mut 730 
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Figure 8 Hierarchical clustering analysis of gene expression data measured with HumanHT-12 
v4 Expression BeadChip (Illumina). Investigated samples, AML (n = 24) and healthy controls (n = 4), 
are represented by 10,067 probes (with detection p-value < 0.05). Two technical replicates were 
analyzed with two different arrays (DNMT3Amut1-1/2; DNMT3Amut4-1/2). 
 
4.1.6 CHFR methylation levels as a potential prognostic biomarker 
When we performed the gene ontology analysis of aberrantly methylated CpGs, a tumor 
suppressor CHFR was detected among the differentially methylated sites in all IDH1/2mut 
samples (chapter 4.1.1). Therefore, we measured the DNA methylation (at cg00338702) 
and CHFR expression in a statistically significant number of patients (n = 104) to see if there 
is a connection.  
Only 4 % of investigated AML samples exhibited downregulated expression 
(values < average – 2·SD, standard deviation). These samples also showed a significantly 
higher methylation in associated locus (average 92.8 ± 6.6 %) in comparison with the rest 
of the samples (19.2 ± 15.0 %, p-value < 0.0001). Due to the low number of patients with 
hypermethylation and downregulated CHFR expression, we were not able to analyze 
the prognostic significance of this aberration.  
 
4.1.7 GZMB methylation levels as a potential prognostic biomarker 
Similar to CHFR, aberrant methylation of apoptosis-related gene GZMB was also detected 




approximately 40 kbp upstream of the gene and covers two adjacent CpGs. We examined 
the site via pyrosequencing in 104 AML patients and 10 healthy donors. Based on the DNA 
methylation levels detected in the cohort of healthy donors, we set an upper methylation 
threshold of 45 %. Subsequently, we divided the AML patients into three groups: 
unmethylated (UM) with methylation level < 45 % at both CpGs (n = 40); intermediately 
methylated (IM) with one CpG > 45 % and one CpG < 45 % methylated (n = 15); 
and hypermethylated (HM) with both CpGs > 45 % methylated (n = 49).  
 When we investigated the gene expression of GZMB in these groups, we found only 
a weak correlation with methylation levels for UM (R = 0.3, p-value = 0.12)  
and HM (R = -0.4, p-value = 0.02) patients. However, we discovered a significant difference 
in survival between these groups with GZMB hypermethylation being a marker of inferior 
prognosis (see Figure 9).    
 
 
Figure 9 Kaplan-Meier curves for overall and event-free survival of AML patients divided 
by methylation status of GZMB-associated region. 
 
We confirmed the prognostic implication of aberrant GZMB methylation in a Cox 
multivariate analysis, where it remained significant for overall survival of patients, together 
with age, presence of FLT3-ITD, and transplantation in the first remission (Table 13). GZMB 
hypermethylation was not among the prognostically significant covariates for event-free 
survival, where only ELN classification (Döhner et al., 2017), FLT3-ITD, and transplantation 









Table 13 Multivariate Cox regression analysis for overall and event-free survival of AML patients. 
Overall survival 
Variable  HR 95% CI p-value 
GZMB methylation 1.446 1.027-2.036 0.035 * 
Prognostic group according to ELN  1.612 0.952-2.729 0.076 ns 
Age at diagnosis 1.036 1.008-1.065 0.012 * 
Leukocytes at diagnosis 1.000 0.995-1.005 0.933 ns 
Percentage of blasts in peripheral blood 0.993 0.982-1.003 0.169 ns 
FLT3-ITD  3.257 1.381-7.679 0.007 ** 
NPM1 mutation 0.652 0.317-1.339 0.244 ns 
Transplantation in the 1st CR 0.378 0.191-0.748 0.005 ** 
Event-free survival 
Variable  HR 95% CI p-value 
GZMB methylation 1.202 0.891-1.622 0.229 ns 
Prognostic group according to ELN  2.465 1.501-4.048 0.0001 *** 
Age at diagnosis 1.013 0.991-1.036 0.246 ns 
Leukocytes at diagnosis 1.001 0.996-1.006 0.604 ns 
Percentage of blasts in peripheral blood 1.000 0.991-1.010 0.960 ns 
FLT3-ITD  2.696 1.273-5.711 0.01 * 
NPM1 mutation 0.737 0.385-1.411 0.356 ns 
Transplantation in the 1st CR 0.178 0.088-0.360 0.0001 *** 
HR- hazard ratio, CI – confidence interval, ELN – European LeukemiaNet classification  
(Döhner et al., 2017), CR – complete remission, ns – not significant   
 
 Because we did not find a reliable connection between GZMB methylation and expression, 
we tested whether the negative prognostic value could be explained by the presence 
of IDH1/2 mutations (the aberrant hypermethylation of GZMB gene was discovered 
in IDH1/2mut samples). But only 35 % of patients from the HM group had mutation in either 
IDH1 or IDH2 gene.  
We also tested whether the GZMB hypermethylation is linked only to the leukemic cell 
population and thus dependent on the percentage of blasts at diagnosis. We selected 
23 patients from the original cohort (n = 104) and measured the DNA methylation of GZMB 
associated region in sorted blast populations (CD34+/CD117+ cells). The methylation levels 
for both positions correlated well (R = 0.95 with p-value = 1.45e-11 and R = 0.91 with  
p-value = 5.33e-9) and samples belonged to the same UM/IM/HM category as if divided 





4.2 DNA methylation validation methods 
4.2.1 MSRE analysis 
With MSRE analysis, we were able to accurately measure the DNA methylation levels 
at methylated (M) and unmethylated (U) regions. The average values for all investigated 
samples (n = 10) were 95.3 ± 1.8 % and 2.3 ± 0.5 % for M and U regions, respectively. 
However, for the intermediately methylated (IM) region, we obtained lower methylation 
levels than expected, the average was 12.6 ± 2.2 %. Thus, we tried to shorten the digestion 
time in order to see if it will increase the methods’ accuracy for the IM region. We performed 
two additional experiments with 1.5-hour and 1-hour digestions (a 2-hour digestion was 
recommended in the original protocol). We measured four samples and there was only a slight 
change in the acquired methylation levels for IM region after shorter cleavage  
to 13.3 % (1.5-hour digestion) and 17.0 % (1-hour digestion), see Figure 10. The results 
for M and U regions remained unchanged.  
 
Figure 10 Methylation levels measured with MSRE analysis with various digestion times. Error bars 
represent the standard deviation for four samples. M – methylated region, IM – intermediately 
methylated region, U – unmethylated region. 
 
4.2.2 Pyrosequencing 
The most important step in pyrosequencing is the initial PCR where a strong amplicon must 
be obtained. We always checked the quality of amplicons on agarose gel electrophoresis, see 






Figure 11 Agarose gel electrophoresis of eight samples (marked 1-8 in the picture) after the initial 
PCR for pyrosequencing of methylated (M), intermediately methylated (IM) and unmethylated (U) 
loci. L - 100 bp DNA ladder, 300-500 bp bands are marked in the picture. 
 
 However, even after we acquired satisfactory amplicons, we did not achieve a sufficient 
signal during pyrosequencing. Thus, we decided to enhance the binding of the PCR product 
to the streptavidin beads by adding gradually 1, 2 and 3 µl of the beads per sample. Samples 
where 2 µl of streptavidin beads were added gained the strongest signal on pyrogram. 
To further increase the number of bound PCR amplicons, we prolonged the agitation step 
to 20 minutes. It was also essential to proceed immediately to the next step after the agitation, 
because the beads must be well resuspended in the tube in order to be efficiently taken  
up by the probes, used in the subsequent step. After these adjustments, the peak heights 
in resulting pyrograms varied from 50 to 200 units, which was satisfactory since at least 
40 units are required according to the manufacturer’s recommendations for proper 
measurements.  
 In our experiment, we measured the DNA methylation of four regions that included 
selected M, IM and U loci in ten samples. In the region around M locus, all other CpG sites 
(n = 3) were methylated, average methylation for the whole region was 95.4 ± 3.1 %. 
We obtained similar result for the region surrounding U locus, where all investigated CpGs 
(n = 3) were unmethylated with average methylation 7.4 ± 3.1 %. There were two CpGs in the 
intermediately methylated region. The average methylation level of the selected IM CpG was 
58.5 ± 7.3 %, however, the other CpG was rather unmethylated with average 18.4 ± 3.8 %, 






For the MS-HRM experiments, we designed two sets of primers for M and U regions. One 
primer pair did not have any CpG in in their sequence and the other pair had one or two CpGs 
in its 5’-end (called Wojdacz primers, see Table 9). For the IM region, we only had primers 
without CpGs because of the lack of CG dinucleotides in the area (see Figure 3). 
  From measured MS-HRM data, we computed calibration curves for each primer set 
as described by Tse et al. (2007). In Table 14, a summary of calculated methylation levels for 
each region together with coefficients of determination (R2) for the peak-height based 
calibration curves is provided. We also computed the methylation levels from AUC-based 
calibration curves, see Table 15. In both cases, the R2 coefficients were somewhat lower for 
M region and, on the contrary, slightly better for U region when Wojdacz primers were used. 
 
Table 14 Coefficients of determination and counted methylation levels for peak height-based  
MS-HRM calibration 
Region name Primer set R2 
Average methylation [%] 
(n = 10) 
± SD 
M M HRM 0.95 93.61 5.28 
M M HRM Wojdacz 0.80 85.49 5.13 
IM IM HRM 0.97 29.20 4.71 
U U HRM 0.87 2.69 1.04 
U U HRM Wojdacz 0.94 0.57 0.81 
M - methylated, IM – intermediately methylated, U – unmethylated, R2 – coefficient of determination, 
SD – standard deviation 
 
Table 15 Coefficients of determination and counted methylation levels for AUC-based MS-HRM 
calibration 
Region name Primer set R2 
Average methylation [%] 
(n = 10) 
± SD 
M M HRM 0.96 95.43 5.85 
M M HRM Wojdacz 0.85 148.58 8.68 
IM IM HRM 0.93 16.73 3.72 
U U HRM 0.85 1.95 0.69 
U U HRM Wojdacz 0.95 4.88 7.82 
M - methylated, IM – intermediately methylated, U – unmethylated, R2 – coefficient of determination, 
SD – standard deviation 
 
 With Wojdacz primers, lower methylation levels were obtained for both M and U regions 
when using the peak-height calibration and higher methylation levels when employing 
the AUC-based calibration. Furthermore, the methylation of M region measured with 
Wojdacz primers is disproportionately high when using the AUC-based calibration. 




calibration approaches. The methylation measured for IM region was more accurate with 
the peak-height based calibration.  
 
4.2.4 Quantitative MS-PCR 
To perform the qMSP experiments, we designed two sets of primers for each region, 
methylated (Met) and unmethylated (Unm). In all investigated samples (n = 10), the M region 
was amplified only by Met primers, the U region only by Unm primers, and IM region 
by both sets of primers. At the same time, the DNA standards were always amplified only 
with the corresponding primer set, see Figure 12. 
  
 
Figure 12 Specificity test of primers designed for qMSP experiments. Methylated DNA standard 
(Mstd), unmethylated DNA standard (Ustd), and one sample were amplified. Each region  
(M-methylated, IM – intermediately methylated, U - unmethylated) was amplified with primers 
specific for methylated DNA sequence (Met) and unmethylated DNA sequence (Unm). Agarose gel 
electrophoresis was performed with 100 bp DNA ladder (L), sizes 100 - 300 bp are marked. Red 
arrows point to visible amplicons. 
 
 We used a quantitative approach to evaluate the methylation levels of investigated 
samples. For these purposes, we used the HRM primers as methylation-unspecific primers. 
In Table 16, a summary of Ct values and amplification efficiencies for each primer set 
are provided. We were not able to properly measure the efficiency for IM Unm primers due 
to a high deviation between duplicates. The amplification of the first dilution for this primer 
pair started always after the 34th cycle, so we assume that the efficiency was quite low. Thus, 
despite the great coefficient of determination for the calibration curve (R2 > 0.99), the results 
were not entirely reliable. Therefore, we chose a different approach to count the primers’ 
efficiency based on standards’ Ct values and an assumption that HRM primers have  




𝑀𝑆𝑃, we computed 




efficiencies assessed with the classical approach (Pfaffl, 2007), see Table 16. For the IM Unm 
primers, the counted efficiency was used in the subsequent analysis. 
 




Average Ct of samples (n=10) Ct of standards Amplification efficiency 







M Met 23.18 0.52 22.88 0.27 24.01 22.7 96.47 94.57 83 
IM Met 34.54 1.23 
24.33 0.35 
29.23 24.51 81.13 83.85 
94.78 
IM Unm 32.21 0.5 31.99 25.15 125.8 78.63 
U Unm 37.36 0.8 23.04 0.2 37.95 23.4 65.93 61.66 90.52 
M - methylated, IM – intermediately methylated, U – unmethylated, Met – primers for methylated 
DNA sequence, Unm – primers for unmethylated DNA sequence, MSP – methylation specific 
primers, HRM –methylation independent primers, SD – standard deviation 
 
 Data measured with the quantitative PCR were analyzed with three approaches, reviewed 
by Husseiny et al. (2012). Demethylation index and ΔΔCt method provided similar results. 
The relative expression ratio gave highly variable results with extreme standard deviations. 
Results for all three methods are shown in Table 17.   
 
Table 17 Summary of qMSP methylation results calculated using three different approaches 
Region and 
used primer set 
Demethylation index ΔΔCt Relative expression ratio 
Average (n=10) ± SD Average (n=10) ± SD Average (n=10) ± SD 
M Met 2.02 0.60 2.09 0.66 204.46 256.01 
IM Met 0.05 0.03 0.03 0.02 1.92E-09 3.63E-09 
IM Unm 0.51 0.10 0.50 0.12 0.02 0.02 
U Unm 1.03 0.30 1.30 0.66 8.77 13.27 
M - methylated, IM – intermediately methylated, U – unmethylated, Met – primers for methylated 
DNA sequence, Unm – primers for unmethylated DNA sequence, SD – standard deviation 
 
 The M region was highly amplified by the Met primers, the amplification was seemingly 
double in comparison with HRM primers (indicated by demethylation index/ΔΔCt ~ 2). 
The fact, that amplification efficiency of Met primers was higher than HRM primers may 
explain this discrepancy. We also tried to repeat the experiment with five samples  
and the ΔΔCt was 1.5 ± 0.3 for the M region and Met primers, so another reason  
for the inconsistency may be simply the method’s inaccuracy. The results for U region were 
close to 1, meaning a comparable amplification by HRM and U Unm primers. Regarding 
the IM region, the IM Unm primers amplified about half of the molecules in comparison with 




amplification of the region by IM Met primers. The discrepancy in the computation may 
be caused by the great difference between Ct for methylated DNA standard (29.23) and 
samples (34.54) resulting in a low ratio of molecules amplified by IM Met primers. This was 
probably due to the higher affinity of IM Met primers to methylated DNA standard 
in comparison with samples, where the IM region is rather unmethylated with one CpG 
~ 58 % methylated and the other ~ 18 % methylated (as measured by pyrosequencing, chapter 
4.2.2). 
 
4.2.5 Overall comparison of investigated methods 
We compared the methylation results acquired by each method, see Figure 13. All methods 
correlated well with R2 > 0.92 and p-value of regression analysis < 1.2e-17, except the qMSP 
results that were spoiled by very high standard deviations. Furthermore, we evaluated 
the investigated methods with regard to financial requirements (Table 18) and a few other 
perspectives (Table 19).  
 
 
Figure 13 Average DNA methylation of ten samples measured with four different methods. Error bars 
represent the standard deviation. MSRE data were measured after 2-hour digestion. MS-HRM data 
were acquired using HRM M, HRM IM and HRM U Wojdacz primers. qMSP data were calculated 
using ΔΔCt approach and multiplied by 100 to gain percentage. For the M locus, all values were 
higher than 100 % so we set the mean to 100 % to make the figure more comprehensible.  
For the IM and U loci in qMSP, we calculated the methylation percentage as 1-(Unm ΔΔCt). 
The qMSP SDs were calculated from the original values multiplied by 100. M – methylated 




Table 18 Summary of costs for each method 
Method 
Total cost of 
analysis [$] 
Number of samples measured 
Number of standards 
measured 




MSRE analysis 576 
10 for each locus1, Test and 
Reference reaction, duplicates 
2 for each locus1, duplicates 144 4 
pyrosequencing 1623 10 for each locus1 2 for each locus1 36 4.5 
MS-HRM 85 10 for each locus1, duplicates 6 for each locus1, duplicates 96 0.9 
qMSP 196 10 for each primer set1, duplicates 
2 for each primer set2, 
duplicates 
216 0.9 
1Number of loci = 3 
2Number of MSP/HRM primer sets for each locus = 3 
3price of the pyrosequencing instrument ca 45 000 $ 
 
 










Time consumption Price 
MSRE analysis - * * * * *** 
Pyrosequencing + *** * * *** ** 
MS-HRM - *** ** */**(if needed) * * 
qMSP - ** *** *** ** ** 






 Pyrosequencing has most advantages when assessing DNA methylation of a single locus 
thanks to its base resolution. The primer design and results’ interpretation are also very 
straightforward with provided software. Optimization is required only for the initial PCR step 
but is not always necessary. The only disadvantage is the high price of the pyrosequencing 
instrument. The price per measured sample is higher too because the method comprises 
of three steps: PCR, gel electrophoresis, and sequencing. 
 When the pyrosequencing is financially unaffordable, MS-HRM seems to be the second-
best choice. Primer design is feasible for most regions, in our case we designed primers 
for CpG rich (M and U regions) as well as CpG poor (IM region) DNA sequences without 
problems. Thorough optimization of primer sequences and annealing temperatures  
is not necessary. The method itself is very simple, time and cost effective. Approximate 
methylation levels can be derived right from the melting curves. Exact quantification is a bit 
challenging without a specific chargeable software. However, it is feasible with a free online 
software and Microsoft Excel, as we showed in our analysis. 
   MSRE analysis is a quick and simple method with easy data assessment. The main 
advantage is that it does not require BS conversion and thus less DNA amount is needed 
and also the primer design is easier. The downside of this method is the higher price 
per measurement. 
  The last evaluated method, qMSP, was the most challenging one. The primer design was 
very difficult and nearly impossible for the CpG poor IM region. Finding a suitable annealing 
temperature at which both Met and Unm primers were specific only for the appropriate 
methylated or unmethylated allele of the region but at the same time amplified 
the corresponding DNA standard was very exacting. The performance of the measurement 
is also a bit demanding because it requires the amplification of a chosen region by at least one 
MSP primer set and one methylation unspecific primer set. The exact quantification  
of the methylation levels was not easy, too.  
 
4.3 DNA methylation sequencing panel  
4.3.1 Acquired sequencing data and their comparison with source literature 
Two independent groups of patients, test (n = 128) and validation (n = 50) cohorts, were 
sequenced. For each sample, the bisulfite conversion ratio was > 99 % and more than  




and could be used in further analyses. We obtained the methylation levels of 48,128 CpGs 
for the test cohort and 56,246 CpGs for the validation cohort.  
 Our sequencing panel was largely based on previously published studies (from years 
2011 - 2019) that evaluated prognostic significance of certain DNA methylation changes. 
We wanted to validate the reported effect of DNA methylation on patients’ survival with 
the data acquired for the test cohort. We selected regions that corresponded to the original 
publications and tried to use the same thresholds for DNA methylation levels. In cases where 
it was not possible due to a larger difference between published and our DNA methylation 
levels, we set the threshold as median or average methylation for all AML patients (whatever 
was closer to the original study). This was mainly a case when authors used qMSP for DNA 
methylation assessment. In our comparison, we were able to confirm the prognostic 
significance of DNA methylation in six regions out of nineteen investigated, a summary  
of the results is presented in Table 20.  
 The regions where we were able to confirm the predictive effect of DNA methylation were 
published in five studies. In three of them, authors measured the DNA methylation 
with microarrays (Deneberg et al., 2011; Božić et al., 2015; Qu et al., 2017), NGS was used 
in one publication (Marcucci et al., 2014) and the last one utilized bisulfite sequencing  
(Lin et al., 2011). One study investigated the methylation of only one locus  
(Božić et al., 2015) and in two studies only one (Lin et al., 2011) or two (Qu et al., 2017) 
small regions were examined. Two studies based their prognostication on a summarizing 
methylation score computed from a number of regions, mostly CGIs (Deneberg et al., 2011; 




Table 20 Validation of prognostic significance of previously published DNA methylation changes. 










Deneberg et al. (2011) 
HumanMethylation27 
BeadChip 
BHMT, CHST13, COL21A1, CST11, 
ESM1, ETNK2, GAL3ST3, KCNA1, 
KCNA6, KCNK4, MEGF10, 
MGC39715, NEUROG1, OXGR1, 
SLC4A11, SNCAIP, TCF15, TF 
30 % (AML average 
methylation of all 
genes) 
0.025 0.032 * 
Lin et al. (2011)  
Bisulfite sequencing, 
quantitative MassArray 
CEBPA promoter  5 % (AML2 median) 0.002 0.001 ** 
Hájková et al. (2012) MethyLight 
CDKN2B, ESR1, MYOD1, CALCA, 
SOCS1, CDH1 
cumulative methylation 
value3 < 7 
0.475 0.433 ns 
SOCS1 promoter 0.2 % (AML median) 0.472 0.614 ns 




VTRNA2-1 promoter 10 %, 38 % 0.871 0.892 ns 
Hájková et al. (2014) NGS, pyrosequencing PBX3 (TAF1 binding site) 20 % (average AML) 0.3194 0.1224 ns 
Jost et al. (2014) 
TCGA data, pyrosequencing 
(validation) 
1 CpG in DNMT3A promoter5  0 % 0.999 0.815 ns 
Marcucci et al. (2014) 
NGS: MethylCap enriched by 
MBD2, validation by RRBS 
and MassArray 
CD34, RHOC, SCRN1, F2RL1, 
FAM92A1, MIR155HG, VWA8 
low methylation  
(> 4 out of 7 genes have 
lower methylation than 
average in healthy 
controls) 
0.004 0.004 ** 
Božić et al. (2015) 
TCGA data, pyrosequencing 
(validation) 



















Zhou et al. (2016) 
qMSP, validation by bisulfite 
sequencing 
DLX4 20 % (AML average) 0.128 0.049 ns 
Guo et al. (2017) qMSP 
SFRP1 promoter 15 % (AML average) 0.830 0.920 ns 
SFRP2 promoter 15 % (AML average) 0.236 0.196 ns 
SFRP1, SFRP2 14,7 % (AML average) 0.186 0.175 ns 
Kelly et al. (2017) 
DREAM, pyrosequencing, 
validation on TCGA data 
NPM2, SCGB3A1, CDKN2B, 
OSCP1 
20 % (AML average 
methylation of all 
genes) 
0.230 0.217 ns 
Li et al. (2017) qMSP, Bisulfite sequencing NKD2 promoter 5 % (AML median) 0.131 0.082 ns 
Liu et al. (2017) qMSP RASSF1 promoter 1 % 0.342 0.196 ns 
Qu et al. (2017) 
CHARMcox, pyrosequencing 
(validation) 
UZTS2 40 % (AML median) 0.090 0.062 . 
NR6A1 15 % (AML median) 0.015 0.009 * 
UTZS2, NR6A1 
methylation < median 
methylation level in 
both genes 
0.031 0.017 * 
Zhou et al. (2017) qMSP GPX3 2 % (AML average) 0.227 0.100 ns 
Šestáková et al. (2019) 
MethylationEPIC BeadChip, 
pyrosequencing (validation) 
2 CpGs in GZMB associated IGR 
45 % at both/one/none 
of the two CpGs 
0.781 0.897 ns 
1 p-value for both logrank and Wilcoxon tests < 0.1 (.); <0.05 (*); <0.01 (**)  
2 Excluded patients with favorable cytogenetic profile, NPM1mut a CEBPAmut  
3 Cumulative methylation value = (1·number of genes with methylation < 15 %) + (2·number of genes with methylation 15-50 %) + (3·number of genes with 
methylation > 50 %); range 4-16 for our data  
4 Data for cumulative incidence of relapse 
5 Data for 2 surrounding CpGs, the particular one was not sequenced 
MassArray - Mass spectrometry analysis of cleaved fragments of chosen regions amplified by PCR, TCGA data - data from The Cancer Genome Atlas 
Research Network 2013 AML study (Ley et al., 2013), DREAM - Digital Restriction Enzyme Analysis of Methylation, qMSP - quantitative methylation-
specific polymerase chain reaction, CHARMcox - Comprehensive High-throughput Array-based Relative Methylation Analysis combined with Cox 





4.3.2 MethScore  
We developed a complex approach for prognostic evaluation of all loci targeted by our 
sequencing panel. First, we estimated the effect of DNA methylation level of each detected 
CpG on OS of patients from the test cohort using univariate Cox regression. We subsequently 
selected only those CpGs significant in the analysis (with p < 0.05) and got a set  
of 1,961 CpGs. Positions and average methylation levels of these CpGs are shown 
in Figures 14 and 15.  
 
 
Figure 14 Positions of CpGs (n = 1,961), methylation levels of which are significantly associated with 
the overall survival of patients in the test cohort and which were used for MethScore computation. 
 
 
Figure 15 Mean methylation levels of CpGs (n = 1,961), methylation of which is significantly 
associated with the overall survival of patients in the test cohort, counted for the group of healthy 
donors’ samples (controls), test cohort, and validation cohort of AML patients. The lines represent 




In 864 CpGs from this selection, lower methylation was prognostically favorable.  
In the rest of the CpGs (n = 1,097) lower methylation indicated poorer survival. A total  
of 141 genes were annotated to these CpGs and these genes were mainly associated with 
DNA binding, regulation of RNA metabolism and transcription, and embryonic development. 
In Table 21, genes associated with CpGs most significant for patients’ OS are shown. 
 
Table 21 Genes annotated to most significant CpGs. 












EZH2 promoter 0.00013 
HOTTIP - lncRNA associated with HOXA cluster, AC012531.2 - lncRNA associated with HOXC 
cluster 
 
Using the methylation levels and Cox regression coefficients of these 1,961 CpGs, 
we computed the MethScore (exact calculation is described in chapter 3.3.5) for each patient 
in the test cohort. MethScore was ranging from 72 to 1,565 with median 808 and average 814. 
To get an overview of acquired MethScore values, we computed the z-score and compared 
it with the overall average methylation and number of mutations of each patient, 
see Figure 16. It seems that higher MethScore slightly correlates with lower average 
methylation and higher number of mutations. We also estimated the MethScore of healthy 
donors’ samples where the maximum value was 1,071 and minimum 462, median was 765, 






Figure 16 Z-score values computed from MethScore together with the average methylation 
and number of mutations for each patient from the test cohort (n = 128). 
  
We subsequently divided the patients according to the median MethScore and compared 
the OS and EFS of the two groups. Patients with lower MethScore (n = 64) had markedly 
longer survival than patients with higher MethScore (n = 64, logrank test for OS: p < 2e-16; 
for EFS: p < 2e-12), see Figure 17. 
 
 
Figure 17 Kaplan-Meier curves with p-values of two-sided logrank test comparing both OS and EFS 
of patients with higher and lower MethScore in the test cohort (n = 128). 
 
Next, we computed the MethScore for samples from the validation cohort to confirm 
its predictive ability for patients’ survival. We used the same set of 1,961 CpGs and the same 
procedure (chapter 3.3.5). To see if there is any major difference in the methylation levels 
measured for the test and validation cohort, we compared the average methylation for each 




values for the validation cohort was 244 – 1,413 with median 669, and mean 705. 
We computed the z-score and plotted it together with average methylation and number 
of mutations for each patient, the same way we did for the test cohort, see Figure 18. Patients 
were then divided according to the median MethScore and Kaplan-Meier curves were plotted 
(Figure 19). There was again a significant difference in both OS and EFS between patients 
with lower (n = 25) and higher (n = 25) MethScore.   
 
 
Figure 18 Z-score values computed from MethScore together with the average methylation 
and number of mutations for each patient from the validation cohort (n = 50). 
 
 
Figure 19 Kaplan-Meier curves with p-values of two-sided logrank test comparing OS and EFS 
of patients with higher and lower MethScore in the validation cohort (n = 50). 
 
 We further examined the prognostic relevance of MethScore in multivariate analyses. 
The results for both cohorts are summarized in Tables 22 and 23 for OS and EFS, 
respectively. MethScore together with transplantation in the first remission and age were 




significant for OS only in the test cohort. On the contrary, the presence of NPM1 mutation 
and cytogenetic classification were predictive for OS only for the validation cohorts’ samples. 
MethScore together with the transplantation remained the most significant covariates also 
for EFS prediction. In the validation cohort, cytogenetic classification remained also highly 
significant and, in addition, mutations in NPM1 came out as predictive. In the test cohort, 
FLT3-ITD together with mutations in DNMT3A and NPM1 gained significance for EFS 
prediction. The hazard ratio of DNMT3A mutation would suggest a better outcome 
for patients with DNMT3Amut which contradicts the current knowledge that classifies 
mutations in DNMT3A as an adverse prognostic factor (see chapter 1.2.2.1). However, it was 
shown that the outcome of DNMT3Amut patients is strongly dependent on other co-mutations, 
especially NPM1mut and FLT3-ITD (Gale et al., 2015). In the test cohort, 67 % of patients 
with EFS shorter than 2 years (n = 74) had NPM1mut and 42 % had FLT3-ITD, compared 
to patients with longer EFS (n = 54) where 60 % had NPM1mut but only 27 % possessed 
FLT3-ITD. In Figures 20 and 21, full mutational backgrounds of investigated patients from 
both cohorts are shown.  
 
Table 22 Summary of results from Cox multivariate regression analysis for overall survival 
Overall Survival  Test cohort, n=128  Validation cohort, n=50 
Covariates  HR (95 % CI) p-value  HR (95 % CI) p-value 
Age  1.05 (1.01-1.09) 0.006  1.05 (1.001-1.09) 0.045 
Leukocyte count  1.01 (1.00-1.02) 0.027  0.99 (0.982-1.00) 0.105 
Cytogenetics1  1.08 (0.45-2.60) 0.856  5.70 (1.307-24.87) 0.021 
Transplantation in 1st CR  0.30 (0.13-0.69) 0.005  0.16 (0.046-0.58) 0.005 
FLT3-ITD  2.34 (1.14-4.82) 0.021  2.01 (0.373-10.84) 0.417 
DNMT3A mutation  0.53 (0.23-1.21) 0.134  3.36 (0.774-14.62) 0.106 
IDH1/2 mutation  2.05 (0.97-4.32) 0.06  1.68 (0.440-6.41) 0.448 
TET2 mutation  1.97 (0.72-5.37) 0.185  0.20 (0.020-2.06) 0.177 
ASXL1 mutation  0.36 (0.11-1.22) 0.101  0.41 (0.085-1.97) 0.266 
TP53 mutation  1.53 (0.52-4.54) 0.44  0.96 (0.122-7.59) 0.970 
NPM1 mutation  0.46 (0.21-1.80) 0.053  0.21 (0.056-0.80) 0.022 
CEBPA mutation  0.60 (0.20-1.80) 0.367  3.00 (0.326-27.54) 0.332 
RUNX1 mutation  0.77 (0.23-2.61) 0.68  0.37 (0.029-4.68) 0.442 
MethScore  1.01 (1.00-1.01) <0.001  1.00 (1.002-1.01) 0.002 
HR - hazard ratio, CI - confidence interval, CR - complete remission 










Table 23 Summary of result from Cox multivariate regression analysis for event-free survival. 
Event-free Survival  Test cohort, n=128  Validation cohort, n=50 
Covariates  HR (95 % CI) p-value  HR (95 % CI) p-value 
Age  1.01 (0.98-1.03) 0.589  1.02 (0.979-1.06) 0.390 
Leukocyte count  1.00 (0.99-1.01) 0.832  0.99 (0.985-1.00) 0.267 
Cytogenetics1  1.63 (0.77-3.46) 0.204  5.49 (1.519-19.85) 0.009 
Transplantation in 1st CR  0.21 (0.10-0.42) <0.001  0.07 (0.021-0.26) <0.001 
FLT3-ITD  2.78 (1.44-5.34) 0.002  1.40 (0.322-6.08) 0.654 
DNMT3A mutation  0.34 (0.17-0.70) 0.003  2.45 (0.682-8.78) 0.170 
IDH1/2 mutation  1.55 (0.82-2.93) 0.176  2.71 (0.697-10.57) 0.150 
TET2 mutation  0.95 (0.39-2.31) 0.912  0.30 (0.046-1.94) 0.207 
ASXL1 mutation  0.93 (0.36-2.41) 0.876  0.35 (0.078-1.55) 0.165 
TP53 mutation  1.47 (0.52-4.16) 0.466  4.13 (0.53-32.23) 0.176 
NPM1 mutation  0.49 (0.25-0.96) 0.038  0.27 (0.078-0.92) 0.036 
CEBPA mutation  1.09 (0.43-2.77) 0.851  3.28 (0.375-28.69) 0.283 
RUNX1 mutation  0.65 (0.25-1.72) 0.384  1.16 (0.109-12.33) 0.903 
MethScore  1.00 (1.00-1.01) <0.001  1.00 (1.001-1.01) 0.003 
HR - hazard ratio, CI - confidence interval, CR - complete remission 
1 revised classification by Grimwade et al. (2010) 
 
 
Figure 20 The mutational background of patients from the validation cohort investigated by NGS 





Figure 21 The mutational background of patients from the test cohort, NGS data were acquired in collaborative study by Folta et al. (2019), some  
of the patients were investigated in the Institute of Hematology and Blood Transfusion for FLT3-ITD and mutations in NPM1, CEBPA, DNMT3A, IDH1/2 





Additionally, in Table 24 we provide further comparison of patients with lower and higher 
MethScore for both cohorts. As expected, the most significant differences were in the survival 
time and number of deaths. Furthermore, in the test cohort, the two groups differed  
in the representation of AML subtypes. There was significantly more M2 type AML  
in the low MethScore group and more M4 AML in the high MethScore group. The majority 
of patients with favorable cytogenetics were in the lower MethScore group and, opposingly, 
most of the patients with adverse cytogenetic changes were those with higher MethScore. 
The groups also differed in the number of transplanted patients and patients that reached 
complete remission that were more represented in the lower MethScore group. Nearly all 
patients with mutated TP53 and majority of patients with mutations in TET2 were those with 
higher MethScore. Patients with lower MethScore were also significantly younger, had lower 
levels of leukocytes at diagnosis, and also fewer gene mutations when compared with higher 
MethScore group. In the validation cohort, the groups varied less. There was a significant 
difference in the representation of male and female patients. Furthermore, nearly all patients 
with FLT3-ITD were in the higher MethScore group and patients from this group had also 





Table 24 Comparison of patients with lower (< median) and higher (> median) MethScore. 
  Test cohort (n=128)  Validation cohort (n=50) 
    
Lower MethScore            
(n = 64) 
Higher MethScore                
(n = 64) 
p-value  
Lower MethScore              
(n = 25) 
Higher MethScore              
(n = 25) 
p-value 
FAB classification 
M1 18 13 
0.028 
 6 1 
0.451 
M2 19 7  4 6 
M3 0 0  0 0 
M4 10 20  4 6 
M5 6 11  1 2 
M6 4 2  2 0 
M7 0 1  0 0 
AML RAEB 7 10  8 9 
Cytogenetics          
(Grimwade 2010) 
Favorable 8 1 
0.001 
 2 1 
1 Intermediate  47 40  19 19 
Adverse 8 22  4 5 
Sex Male / Female 34 / 30 34 / 30 1  16 / 9 8 / 17 0.046 
Transplantation in 1st CR 
Yes / No 
36 / 28 21 / 43 0.012  12 / 13 6 / 19 0.140 
Relapse 20 / 44 22 / 42 0.851  10 / 15 13 / 12 0.571 
CR after 1st induction 46 / 18 24 / 40 0.0003  17 / 8 17 / 8 1 
FLT3-ITD 
Positive / Negative / 
NA 
13 / 50 / 1 19 / 45 / 0 0.307  2 / 23 11 / 14 0.008 
DNMT3A mutation 17 / 41 / 6 23 / 32 / 9 0.175  3 / 22 7 / 18 0.289 
IDH1/2 mutation 12 / 46 / 6 14 / 41 / 9 0.656  4 / 21 3 / 22 1 
TET2 mutation 2 / 51 / 11 9 / 40 / 15 0.024  1 / 24 3 / 22 0.609 
ASXL1 mutation 4 / 49 / 11 5 / 44 / 15 0.735  1 / 24 4 / 21 0.349 
NRAS mutation 6 / 47 / 11 11 / 38 / 15 0.184  7 / 18 6 / 19 1 
TP53 mutation 1 / 53 / 10 11 / 45 / 8 0.004  2 / 23 1 / 24 1 
NPM1 mutation 19 / 43 / 2 24 / 37 / 3 0.348  9 / 16 12 / 13 0.567 
CEBPA mutation 4 / 59 / 1 4 / 55 / 5 1  1 / 24 2 / 23 1 








  Test cohort (n=128)   Validation cohort (n=50)  
 
 
Lower MethScore            
(n = 64) 
Higher MethScore                
(n = 64) 
p-value  
Lower MethScore              
(n = 25) 
Higher MethScore              
(n = 25) 
p-value 
Number of mutations 
Average ± SD / 
Median 
1.6 ± 1.3 / 1 2.3 ± 1.7 / 2.5 0.021  1.6 ± 1.0 / 1 2.5 ± 1.6 / 2 0.034 
Age 46.4 ± 13.7 / 49.1 54.2 ± 10.4 / 57.85 0.001  57.7 ± 13.9 / 62 53.4 ± 13.7 / 57 0.180 
Leukocytes 59 ± 38.6 / 53 74.1 ± 39.8 / 78 0.032  46.3 ± 61.0 / 19.9 51.9 ± 60.0 / 25.9 0.318 
Blasts PB 30.7 ± 31.18 / 17.4 34.1 ± 35.4 / 19 0.770  33.0 ± 32.3 / 18 37.3 ± 30.1 / 27 0.869 
Blasts BM 52.7 ± 26.2 / 53.6 54.9 ± 28.8 / 52.8 0.601  49.7 ± 23.9 / 45 53.6 ± 22.1 / 54.9 0.542 
OS [months] 52.1 ± 20.1 / 51.9 17.8 ± 19.5 / 9.7 < 0.0001  40.4 ± 26.2 / 51.8 26.3 ± 22.6 / 14.4 0.061 
EFS [months] 40.7 ± 25.2 / 45.0 11.2 ± 18.4 / 2.3 < 0.0001  34.3 ± 28.2 / 37.7 17.5 ± 22.8 / 7.4 0.029 
Death 
Event / Censored 
14 / 50 56 / 8 < 0.0001  10 / 15 19 / 6 0.021 
Death/Relapse 25 / 39 57 / 7 < 0.0001  12 / 13 20 / 5 0.038 





4.3.2.1 MethScore in patients from intermediate risk group 
We wanted to evaluate the prognostic capability of MethScore for AML patients 
from intermediate risk group because especially they would benefit from a better prognostic 
stratification. To get statistically more significant results, we combined patients from 
both cohorts and selected those with intermediate cytogenetic risk (according  
to Grimwade et al., 2010). We further divided the patients into four groups: patients with 
intermediate cytogenetics  (IR, n = 112; 74 from the test cohort, 38 from the validation 
cohort); patients with intermediate cytogenetics and FLT3-ITD (IRFLT3+, n = 37; 25 from 
the test cohort, 12 from the validation cohort); patients with intermediate cytogenetics 
and wild-type NPM1 (IRNPM1-, n = 60; 40 from the test cohort, 20 from the validation cohort); 
and patients with intermediate cytogenetics, FLT3-ITD and NPM1mut (IRFLT3+NPM1+, n = 23; 
13 from the test cohort, 10 from the validation cohort). In each group, patients with lower 
and higher MethScore, as estimated by median values in the previous analysis, were 
compared.  
 It is evident from the Kaplan-Meier curves shown in Figures 22 and 23 that MethScore 
reliably stratified patients with better and worse survival. We further validated the prognostic 
ability of MethScore in multivariate analyses. Because of the small number of patients,  
it was not possible to perform the multivariate analysis for the IRFLT3+NPM1+ group. Results  
for the other groups of patients are summarized in Tables 25 and 26. MethScore was the most 
significant variable for both OS and EFS together with the transplantation in the first 
remission. In the group of IR patients, other significant covariates were number of leukocytes 
at diagnosis and mutations in NPM1 which were significant for both OS and EFS. FLT3-ITD 
came out as significant only for EFS. In the IRNPM1- group, age, leukocytes, and mutations 
in IDH1/2 were predictive of patients’ EFS. Mutations in TET2 and ASXL1 together with age 
were among significant covariates for EFS in IRFLT3+ group. The hazard ratio incorrectly 
suggests that ASXL1mut is a favorable marker for patients’ outcome, which it is not (see 
chapter 1.2.2.1). However, only three patients in the IRFLT3+ had ASXL1 mutations,  
so the prognostic effect could not be appropriately evaluated. Also, the hazard ratio of age, 
which was a significant variable for EFS in IRFLT3+ and IRNPM1-, suggest an opposite effect 
than expected. However, this may be caused by the fact that IR patients were mostly younger 
(47 ± 14 years in IRFLT3+, 52 ± 13 in IRNPM1-) and thus the consideration of age may  















Table 25 Results from multivariate Cox regression analysis of overall survival of patients from intermediate risk groups 
Overall Survival Intermediate cytogenetics 
(n=112)  
Intermediate cytogenetics, 
FLT3-ITD (n=37)  
Intermediate cytogenetics, 
NPM1wt (n=50) 
Covariates HR (95 % CI) p-value  HR (95 % CI) p-value  HR (95 % CI) p-value 
Age 1.012 (0.979-1.05) 0.48  0.951 (0.895-1.01) 0.105  0.952 (0.899-1.01) 0.086 
Leukocyte count 0.991 (0.984-1.00) 0.012  0.989 (0.976-1.00) 0.118  0.991 (0.982-1.00) 0.065 
Transplantation in 1st CR 0.097 (0.034-0.28) <0.001  0.046 (0.008-0.27) <0.001  0.069 (0.014-0.35) 0.001 
FLT3-ITD 2.167 (0.973-4.82) 0.058  - -  0.686 (0.159-2.96) 0.614 
DNMT3A mutation 0.974 (0.440-2.16) 0.949  0.516 (0.099-2.70) 0.433  0.913 (0.247-3.37) 0.892 
IDH1/2 mutation 0.813 (0.374-1.77) 0.602  2.044 (0.448-9.34) 0.356  1.336 (0.459-3.89) 0.595 
TET2 mutation 0.617 (0.188-2.03) 0.426  0.265 (0.040-1.75) 0.168  0.365 (0.070-1.92) 0.234 
ASXL1 mutation 0.369 (0.087-1.56) 0.174  0.043 (0.001-1.48) 0.081  0.243 (0.005-12.97) 0.485 
TP53 mutation 0.571 (0.04-8.09) 0.678  - -  0.903 (0.043-19.17) 0.948 
NPM1 mutation 0.327 (0.153-0.70) 0.004  0.619 (0.178-2.15) 0.451  - - 
CEBPA mutation 1.611 (0.325-7.99) 0.559  - -  0.894 (0.116-6.92) 0.914 
RUNX1 mutation 0.349 (0.066-1.86) 0.217  0.548 (0.019-16.14) 0.727  0.357 (0.009-13.87) 0.581 
MethScore 1.005 (1.003-1.01) < 0.001  1.008 (1.004-1.01) <0.001  1.007 (1.004-1.01) <0.001 
HR - hazard ratio, CI - confidence interval, CR - complete remission 















Table 26 Results from multivariate Cox regression analysis of event-free survival of patients from intermediate risk groups 
Event-free Survival Intermediate cytogenetics 
(n=112)  
Intermediate cytogenetics, 
FLT3-ITD (n=37)  
Intermediate cytogenetics, 
NPM1wt (n=50) 
Covariates HR (95 % CI) p-value  HR (95 % CI) p-value  HR (95 % CI) p-value 
Age 0.99 (0.964-1.02) 0.422  0.927 (0.879-0.98) 0.005  0.929 (0.887-0.97) 0.001 
Leukocyte count 0.99 (0.986-1.00) 0.018  0.989 (0.977-1.00) 0.102  0.990 (0.982-1.00) 0.027 
Transplantation in 1st CR 0.11 (0.046-0.25) <0.001  0.056 (0.012-0.27) <0.001  0.046 (0.012-0.18) <0.001 
FLT3-ITD 3.12 (1.538-6.33) 0.002  - -  1.600 (0.529-4.84) 0.406 
DNMT3A mutation 0.63 (0.303-1.32) 0.223  0.226 (0.046-1.11) 0.067  0.593 (0.190-1.85) 0.369 
IDH1/2 mutation 1.08 (0.555-2.11) 0.818  0.927 (0.304-2.83) 0.894  2.764 (1.068-7.16) 0.036 
TET2 mutation 0.51 (0.185-1.41) 0.195  0.113 (0.020-0.64) 0.013  0.370 (0.090-1.52) 0.168 
ASXL1 mutation 0.56 (0.200-1.55) 0.263  0.097 (0.012-0.79) 0.029  1.478 (0.134-16.32) 0.75 
TP53 mutation 2.22 (0.187-26.43) 0.527  - -  12.783 (0.655-249.63) 0.093 
NPM1 mutation 0.35 (0.175-0.71) 0.003  0.748 (0.243-2.3) 0.613  - - 
CEBPA mutation 2.79 (0.730-10.66) 0.134  - -  0.979 (0.156-6.15) 0.982 
RUNX1 mutation 0.57 (0.175-1.88) 0.358  0.407 (0.071-2.31) 0.310  0.281 (0.033-2.36) 0.242 
MethScore 1.00 (1.003-1.01) <0.001  1.007 (1.003-1.01) <0.001  1.005 (1.003-1.01) <0.001 
HR - hazard ratio, CI - confidence interval, CR - complete remission 






4.3.3 HOX genes  
In the set of 1,961 CpGs that were used for the MethScore computation, 637 CpGs (32.5 %) 
were associated with HOX genes. Most CpGs belonged to the HOXA gene cluster (n = 294) 
and here, CpGs for which lower methylation values indicated better patients’ outcome 
prevailed (76 %). HOXB associated CpGs were also highly represented (n = 149) and there 
was nearly an equal number of CpGs with prognostically positive lower (51 %) and higher 
(49 %) methylation values. The rest of the significant CpGs were assigned to HOXC (n = 33) 
and HOXD (n = 161) gene clusters and majority of these CpGs (73 % and 80 %, respectively) 
were those for which hypermethylation was favorable for patients’ outcome.  
To better understand the observed DNA methylation changes in case of HOXA and HOXB 
genes, we plotted the average methylation values of healthy donors and AML samples divided 
according to their survival, see Figure 24. We revealed a distinct regulatory region in both 









Figure 24 Average methylation levels of CpGs within HOXA/B clusters that were found as significant 
for patients’ OS. Values for healthy donors (n = 11), AML patients with OS < 2 years (n = 54), 
and AML patients with OS > 2 years (n = 74) are shown. The lower half of each image was taken from 
UCSC Genome Browser, assembly GRCh38/hg19 (Kent et al., 2002) A HOXA gene cluster B HOXB 








5.1 DNA methylation and hydroxymethylation changes in AML patients with 
mutations in DNMT3A, IDH1/2 or their combinations 
In this project, we wanted to evaluate the DNA methylation, hydroxymethylation 
and expression landscape of patients with distinct mutational background. We focused 
on patients with mutations in DNMT3A and IDH1/2 or their combinations, because  
these genetic aberrations have an opposing effect on DNA methylation  
(Russler-Germain et al., 2014; Fong et al., 2014) and especially the epigenetic landscape 
of patients with both genes concurrently mutated may be interesting.  
We investigated the overall methylation and hydroxymethylation profiles via EPIC arrays 
(Illumina) that target nearly 850 thousand CpGs throughout the genome. The results showed 
a profound hypomethylation of DNA in DNMT3Amut patients and a prevailing DNA 
hypermethylation in IDH1/2mut patients, which is in accordance with previous studies 
(Figueroa et al., 2010; Hájková et al., 2012). It is noticeable, that there was a significant 
difference in number of DMPs between IDH1mut and IDH2mut patients. This somewhat 
disagrees with a study that described highly similar DNA methylation profiles for IDH1 
and IDH2 mutated patients (Figueroa et al., 2010). However, in a more recent paper, 
the theory that the biological background of those two mutations is distinct was published 
in case of gliomas (Wang et al., 2016). Patients with mutations in both genes 
(DNMT3A&IDH1/2mut) had markedly fewer differentially methylated sites and the numbers 
of hyper- and hypomethylated DMPs were more balanced than in patients with only one gene 
mutated. DNMT3A&IDH1/2mut patients thus exhibited a mixed DNA methylation profile that 
reflected the antagonistic influence of the two mutated genes. The same conclusions were 
presented in a recent study, where authors further reported that most CpGs hypermethylated 
in IDH2mut patients and hypomethylated in DNMT3Amut patients were unchanged 
in DNMT3A&IDH1mut patients and samples with both genes mutated had a specific set 
of hypo- and hypermethylated CpGs (Glass et al., 2017).  
Regarding the DNA hydroxymethylation, we detected a significantly lower number 
of hydroxymethylated sites in all samples’ groups when compared with aberrantly methylated 
CpGs. The lowest number of 5-hmCs was detected among DNMT3Amut patients. This may 
be explained by the substantial DNA hypomethylation in those samples, causing a relative 




(Ko et al., 2015). Surprisingly, the highest level of hydroxymethylation was observed 
in IDH2mut patients. This is a rather unexpected observation when we consider that  
it is the product of mutated IDH1/2 enzyme that inhibits the TET2-mediated DNA 
hydroxymethylation (Grimwade et al., 2016). However, IDH2mut patients had the highest 
number of hypermethylated CpGs that could be oxidized via TET2 so it is possible 
that despite the decreased activity of the enzyme, there was still the biggest opportunity 
for hydroxymethylation to occur. Nevertheless, we are not able to drive a clear assumption 
regarding the DNA hydroxymethylation patterns, due to the generally low numbers  
of 5-hmCs detected in our blood samples. This also caused difficulties during the validation 
of array data, where we were unable to properly measure the 5-hmC levels with 
pyrosequencing. To confirm our observations regarding the low levels of DNA 
hydroxymethylation, we performed an additional experiment where we measured the total 
amount of methylated and hydroxymethylated cytosines in blood samples via mass 
spectrometry. Our results agreed with a study comparing DNA hydroxymethylation 
in samples from brain and blood tissue, where authors acquired the same low levels  
of 5-hmC and 5-mC for a blood sample (0.04 % and ~ 4 %, respectively) as we did  
(Stewart et al., 2015). 
 Next, we focused on the influence of other mutations on the overall DNA hydroxy-
/methylation patterns. We noticed an effect of NPM1 mutations in the clustering analysis 
of DNA methylation data which is in line with previously described observations of NPM1mut 
influencing the hypermethylation phenotype in AML patients (Figueroa et al., 2010).  
We did not detect any impact of TET2 mutations on DNA methylation. The reason why 
samples with DNMT3Amut and TET2mut did not resemble DNMT3A&IDH1/2mut samples may 
lie in the different degree of TET2 inhibition via 2-hydroxyglutarate compared to a direct 
mutation of the enzyme. Nevertheless, we observed an apparent influence of TET2mut  
on the DNA hydroxymethylation pattern.  
 Our results further showed that the overall expression profiles of investigated samples 
do not copy the layout of either DNA methylation or hydroxymethylation patterns. Therefore, 
we could assume that not all DNA hydroxy-/methylation alterations are translated into 
changes in gene expression. Similar findings were published by Spencer et al. (2017), where 
the authors did not find any clear trends when comparing the gene expression and DNA 
methylation in associated gene promoters, gene bodies or other regulatory elements in AML 
patients with DNMT3Amut. This is further supported by a recent study showing the great 




(Spainhour et al., 2019). Nevertheless, we did observe a slight connection because the most 
differentially expressed genes were detected in DNMT3Amut and IDH2mut samples that also 
possessed the highest number of DMPs. On the contrary, least deregulated gene expression 
was observed among DNMT3A&IDH2mut samples, methylation profiles of which were 
the ones most similar to healthy donors. 
 
5.1.1 Prognostically significant DNA methylation changes 
We investigated the prognostic significance of discovered aberrant DNA methylation in two 
regions. The first site was associated with tumor suppressor CHFR. The effect of differential 
methylation and expression of CHFR on patients’ outcome was discussed in two recent 
papers (Gao et al., 2016; Zhou et al., 2018). In one publication, hypermethylation of the 
CHFR promoter region was described as a frequent event (observed in 24 % of samples) 
associated with an adverse outcome of AML patients (Gao et al., 2016). We did not confirm 
this observation with our data as we detected higher methylation levels only in a small 
fraction of patients (4 %). Furthermore, we found out that the region studied by Gao et al. 
(2016) actually belonged to a promoter of another gene, ZNF605, located nearly 70 kbp 
upstream from the CHFR promoter.  Thus, the results are not comparable with our data. In the 
second study, authors claimed that DNA methylation in CHFR promoter (a site adjacent  
to our investigated region) is a rare event and is not connected with downregulation of CHFR 
expression, which is a negative prognostic factor for AML patients (Zhou et al., 2018). This 
is in accordance with our findings regarding the DNA hypermethylation; however, we also 
observed a strong connection with CHFR downregulation. The prognostic effect of the DNA 
hypermethylation and the corresponding decrease in gene expression could not be evaluated 
in our case due to the small number of affected patients. 
 The second investigated region belonged to an enhancer of GZMB gene encoding 
granzyme B, a protein indispensable for the immune response of natural killer (NK) cells 
and T-cells (Cao et al., 2007). We discovered a negative prognostic effect of DNA 
hypermethylation in the area that was independent of blast percentage and IDH1/2 mutations. 
However, we did not find a clear association between the increased methylation and 
expression of GZMB. One explanation may be that the enhancer located 40 kbp upstream 
from GZMB gene is associated with another gene. GZMB is located on chromosome 17 and 
tightly linked with GZMH (granzyme H) and CTSG (cathepsin G) genes located in the close 
proximity (Sedelies et al., 2004). The GeneHancer, a database of human enhancers and their 




Nevertheless, a gene ontology tool GREAT linked our region only to granzyme B. It is also 
possible that GZMB transcription is affected, however, we are not able to detect  
it in the whole blood mRNA samples since active expression of GZMB occurs only  
in NK-cells and cytotoxic T-cells (Susanto et al., 2012). The disruption of the immune 
response mechanism would explain the inferior outcome of GZMB hypermethylated patients. 
 
5.2 DNA methylation validation methods 
In order to choose the best method for DNA methylation validation, needed in our first 
project, we decided to compare four most common methods used for these purposes: analysis 
with methylation dependent or independent restriction enzymes (MSRE), pyrosequencing, 
methylation-specific high-resolution melting analysis (MS-HRM), and methylation-specific 
quantitative PCR (qMSP).  
 MSRE analysis proved to be the fastest and easiest method. However, it provided accurate 
measurements only for either highly methylated or unmethylated sites. MSRE cleavage was 
not suitable for proper assessment of intermediately methylated regions for which 
we obtained underestimated values. We found out that shorter cleavage time (one hour instead 
of two) did not improve this disability, however, it made the analysis even faster without 
spoiling the results for hyper- or unmethylated sites. One more disadvantage of this method is 
that it is suitable only for CpGs placed inside a specific restriction sequence  
and at least two restriction sites must be present in the studied DNA region (Itoi et al., 2007). 
Thus, it is impossible to establish the methylation level of a single CpG. 
 The only method with base-pair resolution was pyrosequencing. This advantage 
is somehow counterweighted with the ability to study only short (100 - 150 bp) DNA regions 
(Delaney et al., 2015). This limitation is caused by the methodology itself because with every 
dispensation cycle the volume of the reaction increases and the background signal rises 
(Tost & Gut, 2007). We confirmed this in our experiments with an observation of decreasing 
quality of the signal after 45th dispensation cycle in the resulting pyrograms which 
corresponded to ~ 100 bp sequence. Another benefit of pyrosequencing is the use of bisulfite 
conversion control that enables to check for complete BS conversion (Tost & Gut, 2007). 
We always included at least three BS controls in every pyrosequencing assay. Altogether, 
we confirmed the benefits of pyrosequencing published by Reed et al. (2010). According 
to this paper, pyrosequencing may replace the bisulfite sequencing (via cloning) which is still 
considered a golden standard for DNA methylation analysis (Reed et al., 2010;  




 MS-HRM analysis was easy to perform and accurate in DNA methylation assessment. 
The biggest advantage of MS-HRM over pyrosequencing is the low price of the method.  
It is also recommended for this approach to keep the amplicon small in order to reduce 
the complexity of resulting melting profiles (Hansen et al., 2008). However, the shorter PCR 
product is used, the higher the sensitivity but lower the resolution of the method becomes. 
The methylation profiles of longer sequences are more distinguishable  
(Wojdacz & Dobrovic, 2007). In our experiments, we were also addressing the question 
whether to include a CpG site into the primers’ sequence or not. The study group  
of T.K. Wojdacz repeatedly showed that CpGs present in the 5’-end area of primers 
compensate a PCR bias towards unmethylated DNA sequence by favoring the amplification 
of methylated sequence, resulting in an increased sensitivity of the method  
(Wojdacz & Hansen, 2006; Wojdacz et al., 2008; Wojdacz et al., 2009). In our experiments, 
we compared the results from MS-HRM acquired with primers designed either with 
or without CpGs in their sequence. The Wojdacz modification resulted in more accurate 
calibration curves for the unmethylated region for both AUC-based and peak height-based 
approaches. However, it had an exactly opposite effect on calibration curves for methylated 
region, where the accuracy dropped. Moreover, in the AUC-based assessment the Wojdacz 
modification resulted in a disproportionately high methylation value for the methylated 
region. Thus, it seems that introducing CpGs inside primers’ sequences is not 
so straightforwardly beneficial and it apparently requires and additional thorough 
optimization of annealing temperature and PCR conditions.    
 The last evaluated method was qMSP. This method, similarly to MSRE analysis, seemed 
to be more suitable for highly methylated or unmethylated regions but not accurate enough 
for measurement of intermediate DNA methylation. The overall precision of the method was 
also low and the introduction and optimization was very demanding. We do not consider this 
method to be suitable for proper measurement of DNA methylation. Unfortunately, it is still 
a quite popular method among researchers used in many studies (Zhou et al., 2016;  
Guo et al., 2017; Zhou et al., 2017; Li et al., 2017).  
 In the overall comparison, pyrosequencing proved to be the best method, not demanding 
and precise with high resolution, with the only disadvantage being the high price  
of the instrument. MS-HRM provided comparably accurate results as pyrosequencing and 
is affordable and easily performed. MSRE analysis was the fastest and simplest approach but 




drawbacks may better serve only as a method for decision whether the region is or is not 
methylated rather than for an assessment of an exact DNA methylation level. 
 
5.3 DNA methylation sequencing panel  
5.3.1 Comparison of our sequencing data with source literature 
We based our custom DNA methylation panel on twenty previously published studies that 
described specific DNA methylation changes with an impact on patient’s outcome. With our 
data, we tried to validate the prognostic significance reported in sixteen of them. We were 
unable to reproduce and validate the results of four studies that developed a specific approach 
for the evaluation of DNA methylation changes. Figueroa et al. (2010) used a novel 
methylation classifier based on principal component analysis. However, we were not able 
to get the SuperPC tool (Bair et al., 2006) to work to repeat their analysis. This approach was 
further developed by Wertheim et al. (2015) and Luskin et al. (2016). Using random forest 
method, the authors computed a value called M-score. We did not perform the calculation 
of M-score due to its methodological complexity. And finally, Li et al. (2016) evaluated 
the shift of DNA methylation in the genome rather than the actual methylation levels. 
Nevertheless, we tried to reproduce the results for the rest of the studies as faithfully 
and meaningfully as possible.  
We were able to confirm the reported prognostic significance in case of only five 
publications. One possible explanation is the difference in methodologies used for the DNA 
methylation assessment. As discussed in the previous chapter, qMSP may not be a very 
accurate method. Nevertheless, it was used in six publications (when we include MethyLight 
as a qMSP method) and we did not validate the results from any of them. Apart from 
the methodical issues, a lack of a validation cohort of samples may be another reason for the 
validation failure. From the sixteen studies evaluated, only seven verified their results  
on an independent set of patients. From these seven, we confirmed the results of four 
publications (Božić et al., 2015; Deneberg et al., 2011; Qu et al., 2017; Marcucci et al., 2014) 
and failed to find the same prognostic meaning as published in three of them 
(Kelly et al., 2017; Jost et al., 2014; Hájková et al., 2014). In case of Jost et al. (2014), we did 
not investigate the exact same locus because the particular CpG was not available in our data 
which can be the reason we did not confirm the reported prognostic ability of the aberrant 
DNA methylation. Sadly, we did not verify the results from our own previous studies. 




was used. In case of Hájková et al. (2014) and Šestáková et al. (2019), the reasons may  
be an insufficiently large test cohort, only 79 AML patients, or the lack of an independent 
validation cohort, respectively.  
 There is no association between the studies and the regions for which we successfully 
validated the reported prognostic effect. Therefore, we provide only a summary of authors’ 
discoveries. Božić et al. (2015) found a hypermethylation in C1R gene linked to poor 
prognosis of AML patients. C1R encodes a subcomponent of a complement protein involved 
in the innate immune system (GeneCards, 2020). The authors reported only a moderate 
correlation with gene expression and assigned the aberrant DNA methylation to global 
chromosomal changes (Božić et al., 2015). Qu et al. (2017) discovered that lower methylation 
at two CpG island shores, one of a transcription regulator LZTS2 and second of a nuclear 
receptor NR6A1 (GeneCards, 2020), is associated with inferior outcome in AML. Next study 
described that an increased methylation in distal promoter of CEBPA is associated with lower 
expression of the gene and better survival of AML patients (Lin et al., 2011). Lin et al. (2011) 
stressed in their work that this implies to patients without CEBPA mutations, thus, proving 
that the methylation level at that particular region is an independent prognostic marker able 
to further refine the AML prognosis. Marcucci et al. (2014) correlated differentially 
methylated promoters and gene expression levels and identified a set of seven genes where 
higher methylation and downregulated transcription were associated with better survival 
of AML patients. Two of the genes, encoding molecular marker CD34 and miRNA 
MIR155HG, were previously associated with aggressive AML (Raspadori et al., 1997; 
Marcucci et al., 2013). Four other genes from the set have been linked to and adverse 
phenotype of various other tumors (Marcucci et al., 2014) but otherwise represent 
a heterogenous group of genes associated with G-protein signaling (RHOC, F2RL1), 
exocytosis of mastocytes (SCRN1), and embryogenesis (FAM92A1) (GeneCards, 2020). 
The last gene from the seven-gene set was a poorly characterized ATPase VWA8  
(GeneCards, 2020). Deneberg et al. (2017) also based their analysis on promoter methylation 
levels coupled with gene expression. The authors described eighteen genes where promoter 
hypermethylation was associated with better survival of AML patients. The only thing these 
genes have in common is that they are regulated by polycomb group proteins  
(Deneberg et al., 2011). Otherwise it is a heterogenous group of proteins comprising 
potassium channels (KCNA1/4/6), various enzymes (BHMT, CHTS13, ETNK2, GAL3ST3), 
proteins involved in intra- and extracellular trafficking (MGC39715, SLC4A11, TF), proteins 




involved in apoptosis (MEGF10), and others with various functions (COL21A1, CTS11, 
ESM1, OXGR1) (GeneCards, 2020).   
 In general, the low number of regions for which we confirmed the prognostic impact with 
our NGS-based approach is not surprising. It rather highlights the importance of such 
validation studies and a need for a consistent and easy-to-reproduce approach to assess 
the impact of various changes in DNA methylation on AML prognosis. 
 
5.3.2 MethScore as a new surrogate marker for AML 
In this work, we introduced MethScore, a simply computed value that coherently evaluates 
the prognostic impact of various changes in DNA methylation. Our computation was inspired 
by the work of Marcucci et al. (2014). They used a similar method to count a summarizing 
score of differential gene expression.  
 The first step in MethScore assessment was to find CpGs with methylation levels 
associated with patients’ survival. We identified a set of almost two thousand loci. In nearly 
half of them, lower methylation was linked to a better survival and, opposingly, to a worse 
outcome in the remaining CpGs. This is in accordance with the related literature where half 
of the studies reported adverse outcome of AML patients with hypermethylation and the other 
half with hypomethylation at specific regions. In the average methylation levels comparison 
of these selected CpGs, we did not see any striking difference in DNA methylation between 
the healthy donors’ samples and the two AML cohorts. This is not unexpected given 
the dichotomous nature of the prognostically significant epigenetic changes. This similarity 
in global methylation levels was also reflected in the MethScore of healthy donors that was 
comparable with the average MethScore of AML patients.  
 From the figures showing MethScore values together with average methylation 
and number of mutations of individual patients, it seemed that higher MethScore slightly 
correlates with an increased number of mutations and lower overall methylation. The higher 
mutational burden may represent a progressing genome instability that is also characterized 
by substantial DNA methylation changes (Cai & Levine, 2019). The lower average 
methylation in patients with higher MethScore and thus adverse outcome may reflect 
the previously published discoveries that increased methylation at specific loci may serve  
as a break preventing AML progression (Spencer et al., 2016) and thus higher DNA 
methylation is prognostically more favorable (Kroeger et al., 2007; Hájková et al., 2012). 
 In the Kaplan-Meier analyses of the test cohort, MethScore had a striking significance 




Cox analysis. In the multivariate analyses, hazard ratios of mutations in DNMT3A, ASXL1, 
and RUNX1 were opposite to what was expected, pointing to a favorable prognosis of patients 
with the particular mutation. In case of DNMT3Amut, it may be caused by the co-mutational 
background of the patients. As already mentioned in the results section, a study 
by Gale et al. (2015) highlighted the effect of NPM1 and FLT3 co-mutations on the prognosis 
of patients with mutated DNMT3A. However, regarding ASXL1 and RUNX1 mutations,  
we do not have any satisfactory explanation. We evaluated the effect of those mutations 
separately in univariate analyses and there the hazard ratio pointed to the mutations having 
correctly an adverse effect on patients’ survival. We also checked the proportionality 
assumption for each multivariate model to make sure of its accuracy. Thus, the discrepancy 
was probably caused only by the limited number of patients with these mutations, nine in both 
cases, that could not be properly statistically evaluated in the all-embracing regression model.  
 We further verified the predictive ability of MethScore on an independent validation 
cohort. The difference in Kaplan-Meier curves of patients with higher and lower MethScore 
was somewhat lower than in the test cohort, nevertheless, still statistically significant. This 
was again confirmed in multivariate Cox regression analyses. The difference between the two 
AML cohorts may be explained partially by the lower number of samples in the validation 
cohort. Moreover, there was a difference between the mutational backgrounds of each cohort 
mainly in the numbers of NRAS, IDH2, and IDH1 mutations. Even though the total 
percentage of patients with IDH1/2 mutations was similar in both cohorts (19 and 14 %), 
there was markedly fewer IDH2mut patients in the validation cohort. This may have influenced 
the epigenetic landscape of the samples in accordance with the theory of diverse biological 
nature of the two mutations (Wang et al., 2016) discussed in our first project and could 
introduce a bias into MethScore values. 
 In the comparison of patients with higher and lower MethScore, there was a significant 
difference in some of the aspects commonly used for the risk stratification of AML. It was 
age, cytogenetics, and TP53 mutation in the test cohort and FLT3-ITD in the validation 
cohort. There were also more transplanted patients in the group with lower MethScore 
and thus better survival. This would imply that MethScore is just another surrogate marker 
further confirming the outcome of patients as already established with the traditional markers. 
Therefore, we focused only on patients with intermediate risk, that would benefit most from 
a better stratification (Döhner et al., 2017). Patients were again perfectly stratified 




was again confirmed with multivariate analyses. This assured us of the validity and clinical 
applicability of MethScore.  
 
5.3.3 The role of DNA methylation changes associated with HOX genes 
The indispensable role of homeobox genes in hematopoiesis control is well-known and their 
impaired expression and aberrant DNA methylation have been implicated as a prognostic 
marker in AML (Deneberg et al., 2011; Hájková et al., 2012; Jost et al., 2014). Therefore, 
when designing our DNA methylation panel, we included sequences covering all HOX genes. 
 Most of the CpGs from the set of loci with methylation significantly affecting the patient’s 
survival were associated with HOXA and HOXB gene clusters. These genes are predominantly 
expressed in myeloid and erythroid cells (Alharbi et al., 2012) and their upregulated 
expression is a negative prognostic marker in AML (Drabkin et al., 2002; Chen et al., 2019; 
Nagy et al., 2019). Spencer et al. (2015) also showed that the overexpression of HOXA 
and HOXB genes is connected with their hypomethylation. Similar observation was reported 
by Jung et al. (2015) who described overexpression and hypomethylation of HOXA genes 
as a key feature of leukemia stem cells signature connected with worse survival of AML 
patients. Within HOXA CpGs significantly associated with survival, those with lower 
methylation related to better outcome prevailed which would seem contradictory  
to the literature. However, a closer look at the methylation levels of AML patients with 
comparison to healthy donors revealed a distinct region hypomethylated in patients with short 
survival. This region overlaps with a 38 kbp region reported as regulatory for HOXA genes 
(Spencer et al., 2015). Similarly, we noted a hypomethylation in worse surviving patients 
in regulatory region of HOXB cluster overlapping a ~ 50 bp HOXB control region also 
described by Spencer et al. (2015). 
 HOXC genes are typically expressed in lymphoid cells (Alharbi et al., 2012) and thus  
it is not too surprising that such a small number of CpGs significant for AML patient’s 
survival was associated with this gene cluster. Interestingly, HOXD genes, which 
are not expressed during hematopoiesis (Alharbi et al., 2012), were quite highly represented. 
Aberrant methylation of HOXD genes in AML has been reported (Jelinek et al., 2008; 
Hájková et al., 2012). Unfortunately, the authors did not mention any implications 
for patients’ prognosis. Generally, we can presume that the detected favorable 
hypermethylation of these genes indicates their silencing based on the consistently reported 
inverse correlation between expression and methylation of HOX genes (Strathdee et al., 2007; 




The regulation processes of HOX gene clusters are very complex, requiring tight 
cooperation between DNA methylation and histone modifications. Also, two other homeobox 
genes, PBX and MEIS, are known cofactors recruited by HOX genes for specific DNA 
binding (Moens & Selleri, 2006). In our set of CpGs with methylation significant for patients’ 
outcome, we also had loci linked to PBX3 (n = 16), MEIS1 (n = 4) and MEIS1-AS (n = 44), 
which may further affect the HOX-related processes in AML progression. Moreover, 
the mutational background of patients can also influence the HOX gene expression, especially 
the MLL translocations and NPM1 mutations (He et al., 2011; Alharbi et al., 2012). 
Therefore, without more thorough research we are not able to properly estimate the real 
biological role of DNA methylation changes associated with HOX genes in AML 
pathogenesis. But still, our data showed distinct regions within HOX gene clusters that may 






Our results showed that distinct mutational backgrounds of AML patients based on mutations 
in DNMT3A and IDH1/2 are characterized by specific DNA methylation 
and hydroxymethylation profiles. We observed a mixed DNA hydroxy-/methylation profile 
in patients with concurrent mutations in both DNMT3A and IHD1/2 genes. Detected 
epigenetic alterations were not entirely reflected by changes in the gene expression. 
Furthermore, there was a considerable difference in numbers and sites with aberrant DNA 
hydroxy-/methylation and also in differentially expressed genes between IHD1mut 
and IDH2mut patients which supports the theory that these mutations represent distinct 
biological entities. 
 We observed in the array data and confirmed with the mass spectrometry analysis 
that levels of DNA hydroxymethylation in blood samples are very low in comparison with 
DNA methylation. Thus, we assume that the role of DNA hydroxymethylation in AML 
pathogenesis is not as important as that of DNA methylation. 
 We detected a hypermethylation in an upstream enhancer linked to GZMB gene, encoding 
a mediator of apoptosis, that was associated with an inferior survival of AML patients. 
Unfortunately, we were not able to determine the biological mechanism behind this altered 
DNA methylation. 
 We compared four standard approaches for validation of DNA methylation in order to find 
the most appropriate method that would be suitable for a common laboratory practice. 
Pyrosequencing together with MS-HRM were rated the best in terms of overall feasibility 
and results’ consistency across different methylation levels. The base resolution 
of pyrosequencing represented the main advantage over the other approaches. MSRE analysis 
proved to be the fastest method but not suitable for precise evaluation of intermediately 
methylated regions. qMSP approach was the most demanding and did not provide satisfactory 
results. 
 We introduced a DNA methylation sequencing panel targeting sites with aberrant DNA 
methylation that were described as prognostically significant for AML patients in twenty 
publications. With our data, we were able to successfully validate the reported significance 
for patient’s survival in five of those studies. We did not verify the prognostic relevance 
of more regions probably due to the different methodologies used for the assessment of DNA 
methylation levels and their significance or an insufficient number of tested samples, in some 




the importance of independent validation studies that are essential for the translation of DNA 
methylation changes into clinical decision making. 
 For a comprehensive evaluation of all investigated DNA methylation changes, 
we developed a summarizing value and called it MethScore. MethScore stratified with high 
accuracy patients with better and worse survival and its prognostic significance was 
confirmed in multivariate analyses. We validated the ability of MethScore to separate patients 
with longer and shorter survival on an independent cohort of AML patients. Furthermore, 
we showed that MethScore is able to reliably distinguish also patients within the intermediate 
risk group that may mostly benefit from a better stratification. 
 From our data, it is apparent that aberrant methylation of HOX genes affects the outcome 
of AML patients. We discovered DNA hypomethylation in regulatory regions of HOXA and 
HOXB clusters in patients with short survival. We also observed a hypermethylation of HOXC 
and HOXD genes favorable for patients’ outcome. However, the regulation processes of HOX 









7 LIST OF ABBREVIATIONS 
5-hmC 5-hydroxymethylcytosine 
5-mC 5-methylcytosine 
ABL1 Abelson Tyrosine-Protein Kinase 1 
AC012531.2  lncRNA associated with HOXC cluster 
AKT AKT Serine/Threonine Kinase 
AML Acute myeloid leukemia 
APL Acute promyelocytic leukemia 
ASXL1/2 Additional Sex Combs Like 1/2, Transcriptional Regulator 
ATO Arsenic trioxide 
ATRA All-trans retinoic acid 
AUC Area under the curve 
BCR Breakpoint Cluster Region Protein 
BM Bone marrow 
bp Base pairs 
BS Bisulfite 
C1R complement component 1 subcomponent R 
CALCA Calcitonin Related Polypeptide Alpha 
CBF Core binding factor 
CBF-AML Core binding factor acute myeloid leukemia 
CBFB Core-Binding Factor Subunit Beta 
CBL Cbl Proto-Oncogene 
CD34 Hematopoietic Progenitor Cell Antigen CD34 
CDH1 Cadherin 1 
CDKN2B Cyclin Dependent Kinase Inhibitor 2B 
CEBPA CCAAT/enhancer-binding protein alpha 
CEBPAdm CEBPA double mutant 
CGI CpG islands 
CI Confidence interval 
CIMP CGI methylator phenotype 
CN-AML Cytogenetically normal acute myeloid leukemia 
CpG CG dinucleotide 
CR Complete remission 
Ct Threshold cycle  
DEK DEK Proto-Oncogene 
DLX4 Distal-Less Homeobox 4 
DMP Differentially methylated position 
DMR Differentially methylated region 
DNMT DNA methyltransferase 
ELN European Leukemia Net 
ESR1 Estrogen Receptor 1 
EZH2 Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit 




FAB French-American-British AML classification 
FAM92A1 Family With Sequence Similarity 92 Member A1 
FDA U.S. Food and Drug Administration 
FLT3 FMS-like tyrosine kinase 3 
FLT3-ITD FLT3 kinase with internal tandem duplications 
FLT3-TKD FLT3 kinase with mutated tyrosine kinase domain 
GATA2 GATA Binding Protein 2 
GPX3 Glutathione Peroxidase 3 
GZMB Granzyme B 
HELP HpaII tiny fragment enrichment by ligation-mediated PCR 
HMAs Hypomethylating agents 
hmCpGs Hydroxymethylated positions 
HOTTIP lncRNA associated with HOXA cluster 
HOX Homeobox 
HR Hazard ratio 
HRM High resolution melting 
HSC Hematopoietic stem cells 
CHFR Checkpoint With Forkhead And Ring Finger Domains 
IDH1/2 Isocitrate dehydrogenase 
IM Intermediately methylated locus/region 
IR Patients from intermediate cytogenetics risk group 
IRFLT3+ Patients with intermediate cytogenetics and FLT3-ITD 
IRFLT3+NPM1+ Patients with intermediate cytogenetics and FLT3-ITD and NPM1mut 
IRNPM1- Patients with intermediate cytogenetics and no mutation in NPM1 gene 
KIT KIT Proto-Oncogene, Receptor Tyrosine Kinase 
KMT2A (MLL) Lysine Methyltransferase 2A 
LC Liquid chromatography 
lncRNA Long non-coding RNA 
LZTS2 Leucine Zipper Tumor Suppressor 2 
M Methylated locus/region 
MBD 5-methylcytosine binding protein 
MBP Methyl-CpG binding proteins 
MDS Myelodysplastic syndrome 
MECOM MDS1 And EVI1 Complex Locus 
MeDIP Methylated DNA immunoprecipitation 
MEIS Myeloid Ecotropic Viral Integration Site 1 Homolog 
MEK Mitogen-Activated Protein Kinase Kinase 1 
MELP Microsphere HpaII tiny fragment enrichment by ligation-mediated PCR 
MIR155HG MIR155 Host Gene 
miRNA Micro RNA 
MLL Lysine Methyltransferase 2A 
MNC Mononuclear cells 




mRNA Messenger RNA 
MS MethScore 
MS/MS Tandem mass spectrometry 
MS-HRM Methylation specific high-resolution melting analysis 
MSP Met Methylated methylation-specific primers 
MSP Unm Unmethylated methylation-specific primers  
MS-PCR Methylation specific PCR 
MSRE Methylation-specific restriction enzyme 
MYB MYB Proto-Oncogene, Transcription Factor 
MYH11  Myosin Heavy Chain 11 
MYOD1 Myogenic Differentiation 1 
NA Not analyzed 
NF1 Neurofibromin 1 
NGS Next-Generation Sequencing 
NK cells Natural killer cells 
NKD2 NKD Inhibitor Of WNT Signaling Pathway 2 
NPM1 Nucleophosmin 
NPM2 Nucleophosmin/Nucleoplasmin 2 
NR6A1 Nuclear Receptor Subfamily 6 Group A Member 1 
NRAS Neuroblastoma RAS Viral (V-Ras) Proto-Oncogene, GTPase 
NUP214 Nucleoporin 214 
OS Overall survival 
OSCP1 Organic Solute Carrier Partner 1 
PB Peripheral blood 
PBX Pre-B-Cell Leukemia Homeobox 
PcG Polycomb group proteins 
PCR Polymerase chain reaction 
PI3K Phosphoinositide 3-kinase 
PML PML Nuclear Body Scaffold 
PTPN11 Protein Tyrosine Phosphatase Non-Receptor Type 11 
PU.1 (SPI1) Spi-1 Proto-Oncogene 
qMSP Quantitative methylation-specific PCR 
RAD21 RAD21 Cohesin Complex Component 
RAF Raf-1 Proto-Oncogene, Serine/Threonine Kinase 
RARA Retinoic Acid Receptor Alpha 
RASSF1A Ras Association Domain Family Member 1 
RHOC Ras Homolog Family Member C 
RNF216 Ring Finger Protein 216 
RRBS Reduced representation bisulfite sequencing 
RUNX1 Runt-Related Transcription Factor 1 
RUNX1T1 RUNX1 Partner Transcriptional Co-Repressor 1 
SCGB3A1 Secretoglobin Family 3A Member 1 
SCRN1 Secernin 1 




SF3B1 Splicing Factor 3b Subunit 1 
SFRP1/2 Secreted Frizzled Related Protein 1/2 
siRNA Small interfering RNA 
SMC1A Structural Maintenance Of Chromosomes 1A 
SOCS1/2 Suppressor Of Cytokine Signaling 1/2 
SRSF2 Serine And Arginine Rich Splicing Factor 2 
STAG Stromal Antigen 
TAF1 TATA-Box Binding Protein Associated Factor 1 
Tann Annealing temperature 
TCGA The cancer genome atlas 
TET2 ten-eleven translocation oncogene family member 2 
Tm Melting temperature 
TP53 Tumor Protein P53 
U Unmethylated locus/region 
U2AF1 U2 Small Nuclear RNA Auxiliary Factor 1 
VAF Variant allele frequency 
VTRNA2-1 Vault RNA 2-1 
VWA8 Von Willebrand Factor A Domain Containing 8 
WES Whole exome sequencing 
WGS Whole genome sequencing 
WHO World Health Organization 
WT1 Wilms Tumor 1, Transcription Factor 
xMELP 
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1 Male HM 69,0 77,1 I/A 55,4 328,8 64 + - No 
2 Female IM 33,5 62,4 I 53,5 108,1 62 + + No 
3 Female HM 74,8 76,3 I 20,1 15,6 42 - - Yes 
4 Female HM 61,1 55,5 I 52,2 59,3 83 + + No 
5 Male IM 44,1 69,1 I 39,4 82,3 65 + + No 
6 Female HM 59,9 70,8 I 54,1 95,2 64 + + No 
7 Male HM 52,3 56,2 I 47,4 53,2 75 + + Yes 
8 Female HM 69,1 61,8 F 37,2 144,5 55 + - No 
9 Female HM 63,5 65,0 I/A 60,7 7,9 19 - - No 
10 Female IM 39,6 50,0 I 49,4 15,3 37 + + No 
11 Female HM 52,1 52,0 A 63,9 23,9 56 NT - No 
12 Male HM 69,4 71,2 A 64,4 16,4 63 - - No 
13 Female HM 79,7 80,5 A 41,8 50,1 73 - - No 
14 Female UM 33,9 36,8 I/A 56,6 0,2 20 - - Yes 
15 Female UM 32,1 42,5 I 57,7 17,5 12 + + No 
16 Male HM 80,8 84,1 F 58,8 161,4 9 - - No 
17 Female UM 27,7 28,2 I 53,4 68,9 58 + - No 
18 Female UM 16,0 23,4 I 19,2 43,2 63 - - No 
19 Male UM 10,6 16,1 F 31,6 8,4 51 - - No 




21 Female IM 39,7 76,5 I 50,9 70,4 80 + + No 
22 Female HM 47,1 67,6 I 52,6 37,5 40 - - No 
23 Female HM 69,8 76,5 F 66,0 6,7 16 - + No 
24 Male HM 84,3 94,0 I 45,6 115,3 97 + - Yes 
25 Male UM 21,9 35,0 I 65,4 6,1 60 - - No 
26 Female HM 64,6 81,3 I 50,3 79,7 73 + + No 
27 Male HM 50,4 55,6 I 65,0 8,0 29 - - No 
28 Male HM 80,3 91,2 I 37,1 185,1 95 + - No 
29 Female UM 14,7 22,4 I 49,8 88,5 84 - - No 
30 Female IM 61,5 43,8 F 22,3 54,7 43 - - Yes 
31 Female HM 72,6 78,9 F 43,9 9,2 74 - + No 
32 Male UM 9,9 16,1 I 36,0 13,0 94 - - No 
33 Female HM 83,1 89,5 I 36,2 49,9 99 - - No 
34 Female IM 51,2 23,6 I 39,8 45,6 82 - - Yes 
35 Female HM 74,1 80,0 I 62,4 4,4 71 - - No 
36 Female HM 48,7 57,5 I 30,6 27,7 35 + - No 
37 Female HM 65,3 78,4 I 40,3 16,9 42 + + No 
38 Male UM 41,5 37,9 I 34,9 3,5 28 - - No 
39 Male IM 40,7 47,9 F 55,4 3,3 32 - + No 
40 Female HM 63,7 57,9 I 62,5 32,5 29 - - No 
41 Female HM 85,5 86,1 I/A 61,9 121,0 90 + + No 
42 Male HM 67,8 73,0 A 33,2 5,7 54 - - Yes 
43 Male UM 21,3 23,2 F 43,7 54,7 1 - + No 
44 Male UM 6,6 10,2 F 32,1 10,3 74 - - No 
45 Female HM 66,3 78,2 I 67,4 2,7 65 - - No 
46 Female UM 37,5 24,3 I 57,5 50,1 67 - + Yes 
47 Female HM 80,1 85,9 F 60,8 67,0 82 - + Yes 
48 Male UM 20,9 30,6 I 33,0 49,8 94 - - Yes 
49 Female UM 44,8 42,6 I 44,5 78,0 30 + + Yes 




51 Male IM 43,6 46,6 I 51,1 21,7 1 + + Yes 
52 Male UM 9,7 11,0 F 64,5 120,3 27 - + No 
53 Female HM 60,6 53,6 I/A 62,2 8,4 17 - - No 
54 Male HM 83,4 88,9 I/A 24,0 148,5 89 + + Yes 
55 Male IM 37,2 47,5 F 35,7 4,9 32 + - No 
56 Female UM 10,0 13,0 I 39,9 7,3 38 - - No 
57 Male UM 7,0 10,0 A 25,4 37,2 85 + - Yes 
58 Female UM 22,6 23,0 I 40,7 29,4 10 + + Yes 
59 Male UM 11,3 15,2 A 59,2 2,9 43 - - Yes 
60 Female HM 81,9 87,0 F 46,6 30,2 92 - + Yes 
61 Male UM 20,9 14,1 F 65,8 3,9 29 - - No 
62 Female HM 49,0 53,7 I 54,2 3,6 20 - - Yes 
63 Male UM 38,3 32,3 F 29,2 4,7 58 - - Yes 
64 Female UM 22,2 20,1 I 32,7 1,7 1 - - Yes 
65 Female HM 47,4 64,7 F 46,4 18,3 53 - + No 
66 Female HM 70,8 74,6 I 21,0 33,8 44 + - Yes 
67 Female IM 48,5 39,2 I 64,3 2,5 6 - - No 
68 Female UM 42,5 34,1 I 56,3 2,0 1 - - Yes 
69 Male UM 39,3 36,8 I/A 44,5 3,6 1 + - No 
70 Male HM 47,4 48,2 I 54,2 120,8 16 - - No 
71 Male HM 67,7 72,5 I 52,6 6,3 57 - - No 
72 Female IM 52,6 42,1 F 44,6 75,4 29 - - No 
73 Male UM 39,0 41,6 F 57,3 65,0 5 - + No 
74 Female UM 5,8 6,9 A 62,1 123,3 32 + - Yes 
75 Male UM 11,4 8,9 F 20,6 2,20 17 - - No 
76 Male IM 46,1 42,2 I 59,6 2,0 9 - - No 
77 Female HM 66,1 68,8 F 33,1 29,8 73 - + No 
78 Female HM 72,3 79,9 I/A 60,2 140,4 84 + + No 
79 Male HM 53,7 57,3 I/A 58,1 31,6 60 - - No 




81 Male UM 22,3 31,8 A 48,5 2,1 3 - - Yes 
82 Female UM 20,3 21,1 A 26,2 1,3 10 - - Yes 
83 Male UM 13,5 11,6 A 61,7 107,7 85 - - No 
84 Female UM 32,2 21,6 A 60,5 1,4 1 - - No 
85 Male HM 79,4 84,6 I 38,5 10,0 91 - - Yes 
86 Male HM 79,7 86,5 I 63,4 25,6 92 - - No 
87 Female HM 54,0 60,2 I 57,2 271,4 92 + - Yes 
88 Male UM 14,2 6,7 F 55,3 11,3 73 - - No 
89 Male HM 69,1 76,6 I 62,7 8,1 52 - - No 
90 Male IM 40,7 46,4 I 61,4 2,9 5 + - No 
91 Male UM 27,5 23,2 I 63,4 1,5 2 - - No 
92 Male IM 57,8 29,5 A 56,4 8,0 86 - - Yes 
93 Male UM 40,8 43,7 I 56,1 1,2 0 - - Yes 
94 Male UM 8,2 10,4 F 33,5 28,7 72 - - No 
95 Male HM 63,8 52,9 A 58,5 1,3 8 - - Yes 
96 Female UM 41,0 34,0 I 47,9 2,7 1 - - No 
97 Male HM 70,0 73,5 I 61,9 2,1 66 - - Yes 
98 Male IM 47,9 39,0 A 55,4 1,6 14 - - No 
99 Female UM 15,9 17,7 I 21,0 4,1 11 + - Yes 
100 Male HM 63,9 47,0 F 40,9 55,2 89 - + Yes 
101 Male UM 25,0 26,0 I 30,0 6,6 85 + - Yes 
102 Male UM 23,4 24,5 I 59,9 1,2 20 - - No 
103 Female HM 86,9 91,5 I 65,8 154,4 99 - - Yes 
104 Female HM 54,6 53,6 A 38,5 10,0 0 - NT No 











































































































































































































































































































A1 57 M 4 44 0.0 17.8 2 1 6.9 0 1 3 0 1 0 0 0 0 0 1 0 0 48.6 0 43.3 0 669.6 low 
A2 64 F 2 64 6.3 15.0 2 0 0.0 1 0 0 0 0 0 NA NA NA 0 0 0 NA 35.7 1 34.0 1 1013.7 high 
A3 56 F 8 55 15.4 38.0 2 0 0.0 0 1 4 1 1 1 0 0 0 0 1 0 0 83.2 0 82.0 0 606.7 low 
A4 58 M 8 81 2.0 24.2 2 0 0.0 0 0 1 0 0 0 0 0 0 0 0 0 0 8.0 1 4.0 1 1370.6 high 
A5 33 F 5 23 0.5 67.0 2 1 5.8 0 1 1 0 0 0 1 0 0 0 0 0 0 8.2 1 7.3 1 1180.9 high 
A6 45 M 5 83 100.0 0.0 2 0 0.0 1 1 1 1 0 0 0 0 0 0 0 0 0 9.9 1 2.2 1 993.2 high 
A7 36 M 8 52 23.0 20.8 2 0 0.0 0 1 4 1 1 0 0 0 0 0 1 0 0 75.1 0 74.2 0 126.1 low 
A8 40 M 8 9 0.0 30.8 3 0 0.0 0 1 1 0 0 0 0 0 0 1 0 0 0 30.3 1 1.5 1 1203.9 high 
A9 49 M 8 58 2.5 24.0 3 1 1.6 1 0 3 0 1 0 1 0 0 0 0 0 0 26.5 1 22.7 1 1002.4 high 
A10 58 M 4 39 11.0 36.0 2 0 0.0 1 1 4 0 1 1 0 0 1 0 1 0 0 11.5 1 8.6 1 1114.6 high 
A11 62 M 5 136 14.5 39.2 2 0 0.0 0 1 3 0 1 0 0 0 0 0 1 0 0 25.0 1 24.0 1 1088.1 high 
A12 63 F 5 132 0.0 77.0 2 0 0.0 0 NA 3 0 0 0 0 1 0 0 0 0 0 1.1 1 0.0 1 1411.0 high 
A13 53 F 4 1 63.5 78.8 2 0 0.0 0 0 3 1 1 0 1 0 0 0 0 0 0 1.3 1 0.0 1 1365.8 high 
A14 52 F 1 92 98.0 96.4 2 0 0.0 1 0 4 1 0 0 0 1 0 0 1 0 1 12.1 1 0.0 1 1191.7 high 
A15 36 M 5 11 15.2 93.2 3 0 0.0 0 0 0 0 0 0 NA NA NA 0 0 0 NA 0.7 1 0.0 1 859.2 high 
A16 52 M 1 7 3.4 68.2 2 1 5.3 0 0 1 0 1 0 0 0 0 0 0 0 0 59.5 0 57.2 0 542.2 low 
A17 56 M 6 59 0.0 1.2 2 0 0.0 0 0 0 0 0 0 NA NA NA NA 0 0 NA 3.9 1 0.3 1 1427.6 high 
A18 58 M 6 25 1.4 9.8 2 1 3.9 0 1 0 0 0 0 NA NA NA NA 0 0 NA 60.1 0 58.7 0 658.7 low 




A20 42 F 2 12 4.0 49.0 3 1 4.4 0 0 0 0 NA NA NA NA NA NA 0 0 NA 51.6 0 49.7 0 667.1 low 
A21 57 M 2 49 64.5 67.4 2 1 6.0 0 0 1 0 1 0 0 0 0 0 0 0 0 49.2 0 47.5 0 572.3 low 
A22 65 F 6 6 2.5 5.4 2 1 5.1 0 1 1 0 NA NA NA NA NA 0 0 0 NA 48.6 0 47.5 0 582.7 low 
A23 30 F 4 51 27.5 72.4 2 1 5.5 1 1 4 0 1 0 0 1 1 0 1 0 0 65.9 0 16.3 1 638.9 low 
A24 27 M 1 18 2.0 22.0 3 1 5.9 0 0 0 0 0 0 0 0 0 0 0 0 0 44.4 0 42.2 0 723.3 low 
A25 61 F 7 24 0.0 67.2 3 0 0.0 0 1 3 0 1 0 0 0 0 1 0 1 0 8.5 1 6.4 1 1225.4 high 
A26 53 M 2 NA 27.0 73.0 2 1 0.3 0 0 1 0 1 NA NA NA NA NA NA NA NA 4.0 1 0.0 1 1353.9 high 
A27 62 M 8 96 9.9 23.4 3 1 5.3 1 0 0 0 0 0 0 0 0 0 0 0 0 10.6 1 5.7 1 1144.3 high 
A28 55 F 8 94 3.2 NA NA 1 3.9 1 0 0 0 NA NA NA NA NA 0 NA NA NA 8.3 1 0.0 1 1125.1 high 
A29 48 F 5 87 12.0 59.6 2 1 5.1 1 1 4 1 1 0 0 0 1 0 1 0 0 9.9 1 7.4 1 1016.7 high 
A30 62 M 8 8 0.5 17.8 2 1 3.9 0 1 0 0 0 0 NA NA NA NA 0 0 NA 36.9 0 34.2 0 496.0 low 
A31 61 M 4 29 9.5 26.8 2 0 0.0 0 0 3 1 0 0 0 1 0 0 0 0 1 6.7 1 0.0 1 1478.6 high 
A32 51 F 4 119 43.0 47.4 2 1 6.6 1 1 3 1 1 0 0 0 0 0 1 0 0 55.8 0 20.4 1 1088.6 high 
A33 43 M 4 88 40.6 46.4 2 1 16.7 0 1 2 0 0 1 NA NA NA NA 1 NA NA 63.5 0 46.8 0 939.6 high 
A34 46 F 2 53 46.0 46.0 2 0 0.0 1 1 2 0 1 0 0 0 0 0 1 0 0 86.4 0 60.3 1 739.9 low 
A35 62 M 5 115 0.5 48.6 3 0 0.0 1 1 4 0 1 0 0 0 1 0 1 0 0 3.8 1 2.5 1 950.4 high 
A36 34 F 4 126 5.0 21.6 2 0 0.0 1 1 3 0 1 0 0 0 0 0 1 0 0 21.7 1 8.7 1 1255.4 high 
A37 64 M 4 133 77.0 80.6 2 0 0.0 0 0 4 1 1 1 0 0 0 0 1 0 0 1.8 1 0.0 1 1385.6 high 
A38 58 M 1 85 60.4 92.8 2 0 0.0 0 0 2 0 1 1 0 0 0 0 0 0 0 4.1 1 0.0 1 1563.1 high 
A39 48 F 5 106 4.5 53.2 2 1 7.5 1 1 2 0 1 0 0 0 0 0 1 0 0 43.9 0 22.9 1 613.4 low 
A40 38 F 8 15 8.8 23.6 2 0 0.0 1 1 0 0 NA NA NA NA NA NA NA 0 NA 40.6 0 31.8 1 597.1 low 
A41 62 F 2 17 19.1 52.8 3 1 4.6 0 1 1 0 0 0 NA NA NA NA 0 0 NA 9.2 1 8.1 1 1126.5 high 
A42 43 F 4 135 9.5 35.0 2 1 4.8 0 0 2 1 NA NA NA NA NA NA 1 0 NA 38.0 0 35.8 0 887.6 high 
A43 22 F 5 95 0.9 93.2 3 0 0.0 1 1 0 0 NA NA NA NA NA NA 0 0 NA 5.9 1 0.5 1 1261.9 high 
A44 57 F 5 77 92.0 92.0 2 1 5.0 0 0 3 1 1 0 0 0 0 0 0 0 0 68.7 0 66.1 0 1088.0 high 
A45 26 F 1 14 9.5 81.8 3 1 6.0 0 0 2 0 1 1 0 0 0 0 0 0 0 73.4 0 72.1 0 535.7 low 
A46 59 M 6 13 8.3 12.6 3 1 5.1 0 0 0 0 NA NA NA NA NA 0 0 NA NA 67.5 0 64.3 0 999.8 high 
A47 57 F 5 68 36.0 95.8 2 1 5.4 0 1 0 0 0 0 0 0 0 0 0 0 0 16.3 1 14.9 1 775.9 low 
A48 27 M 4 76 2.0 19.6 2 1 3.5 0 1 1 0 NA NA NA NA NA NA 0 0 NA 3.9 1 3.0 1 758.7 low 




A50 54 M 4 34 19.0 19.4 2 0 0.0 1 1 0 0 NA NA NA NA NA NA 0 0 NA 9.6 1 4.2 1 1134.2 high 
A51 61 F 2 16 0.5 70.2 3 0 0.0 0 0 1 0 0 0 0 0 0 1 0 0 0 16.2 1 0.0 1 1168.7 high 
A52 60 F 8 50 25.0 NA 2 1 2.3 0 1 5 1 1 0 0 0 1 0 1 0 0 10.7 1 9.5 1 903.6 high 
A53 61 M 2 67 5.0 22.6 2 0 0.0 0 0 4 1 1 1 0 0 0 0 0 0 0 4.3 1 0.0 1 1062.1 high 
A54 63 M 1 20 1.9 68.8 2 0 0.0 1 1 2 0 0 1 0 0 0 0 0 0 0 48.4 1 8.4 1 768.8 low 
A55 58 M 8 57 2.9 26.6 3 0 0.0 0 0 1 0 0 0 0 0 0 1 0 0 0 19.1 1 0.0 1 852.8 high 
A56 34 M 2 78 72.0 44.8 1 0 0.0 1 1 0 0 0 0 0 0 0 0 0 0 0 32.1 1 1.3 1 908.2 high 
A57 21 F 1 93 11.0 53.6 2 1 5.3 0 1 1 1 0 0 0 0 0 0 0 0 0 64.9 0 63.8 0 385.9 low 
A58 41 M 1 108 89.0 85.2 2 1 4.1 0 0 3 0 0 0 1 0 1 0 1 0 0 63.7 0 61.6 0 857.9 high 
A59 30 M 2 112 84.5 45.0 2 1 4.5 1 1 2 1 0 1 0 0 0 0 0 0 0 62.8 0 13.1 1 549.4 low 
A60 60 M 1 10 20.0 69.8 2 0 0.0 1 1 3 0 1 1 0 0 0 0 0 0 0 51.8 1 11.1 1 569.7 low 
A61 39 F 4 134 0.0 20.2 3 0 0.0 0 0 1 0 0 0 0 0 0 1 0 0 0 2.1 1 0.0 1 1231.2 high 
A62 53 F 4 110 62.0 46.4 2 0 0.0 0 1 4 0 1 1 0 0 1 0 1 0 0 16.9 1 15.8 1 1060.7 high 
A63 69 F 1 37 96.0 93.2 2 0 0.0 0 0 4 1 0 0 1 0 0 0 1 0 0 4.2 1 0.0 1 1327.0 high 
A64 60 M 1 35 94.0 96.4 2 1 3.9 1 0 6 1 1 1 1 0 0 0 1 1 0 22.8 1 16.8 1 1125.2 high 
A65 60 M 2 103 64.0 69.8 2 0 0.0 0 0 3 0 0 1 0 0 0 0 1 0 0 0.9 1 0.0 1 1227.2 high 
A66 51 F 5 5 2.9 88.8 NA 1 3.4 1 1 1 0 0 0 0 0 0 0 0 0 0 37.4 1 27.7 1 610.9 low 
A67 61 F 1 97 86.0 79.6 2 0 0.0 1 1 3 0 1 1 0 0 0 0 0 1 0 24.1 1 6.3 1 745.8 low 
A68 62 M 1 19 3.0 49.2 2 1 4.4 0 0 0 0 0 0 0 0 0 0 0 0 0 52.0 0 49.8 0 245.8 low 
A69 62 F 4 98 1.5 21.0 3 1 6.2 1 0 1 0 NA NA NA NA NA 1 0 0 NA 12.5 1 7.1 1 852.3 high 
A70 59 F 4 99 73.5 71.8 3 0 0.0 0 0 3 0 0 0 1 1 1 0 0 0 0 6.1 1 0.0 1 1415.4 high 
A71 28 M 1 122 0.0 69.6 2 1 6.8 0 1 2 1 0 0 0 0 0 0 0 0 0 61.7 0 60.6 0 326.8 low 
A72 67 M 4 120 13.0 24.4 3 0 0.0 0 0 3 0 0 0 0 0 0 1 0 0 0 0.8 1 0.0 1 1185.9 high 
A73 39 F 4 69 7.5 25.4 3 1 3.4 1 1 2 0 0 0 0 0 0 0 0 1 0 61.0 0 5.3 1 717.4 low 
A74 62 M 5 4 0.5 82.2 2 0 0.0 0 1 0 0 0 0 0 0 0 0 0 0 0 3.5 1 2.6 1 993.6 high 
A75 63 M 8 28 19.0 NA 3 0 0.0 0 0 1 0 NA NA NA NA NA 1 NA NA NA 5.3 1 0.0 1 1187.5 high 
A76 43 M 4 101 20.5 42.0 3 0 0.0 1 0 3 0 0 0 0 0 0 0 0 1 1 26.4 1 1.8 1 1187.3 high 
A77 61 F 1 3 0.0 80.8 2 1 3.5 0 1 3 1 0 1 0 0 0 0 1 0 0 49.0 0 48.1 0 98.4 low 
A78 58 M 1 71 NA 94.0 2 1 7.0 0 0 3 0 0 0 1 0 1 0 1 0 0 52.6 0 51.0 0 817.2 high 




A80 28 F 4 121 14.5 35.2 2 0 0.0 0 0 4 1 1 0 1 0 0 0 1 0 0 3.2 1 0.0 1 1289.3 high 
A81 38 F 1 91 84.0 90.6 1 1 5.2 1 1 1 0 0 0 0 0 0 0 0 0 0 42.3 0 1.1 1 588.5 low 
A82 65 F 5 117 22.5 88.0 2 0 0.0 0 1 4 0 1 0 1 0 0 0 1 0 0 41.1 0 39.5 0 656.0 low 
A83 58 M 2 32 12.5 41.6 2 1 4.9 0 0 1 0 1 0 NA NA NA NA 0 0 NA 36.6 1 34.4 1 642.9 low 
A84 57 M 5 118 4.5 34.2 2 0 0.0 0 1 2 0 0 0 0 0 0 0 1 0 0 75.8 0 74.9 0 504.0 low 
A85 63 F 1 116 98.5 97.8 2 0 0.0 0 0 4 1 0 1 0 0 0 0 0 0 1 0.8 1 0.0 1 1303.9 high 
A86 52 M 8 40 7.0 24.8 2 0 0.0 0 0 1 0 0 0 0 0 0 0 0 0 1 43.1 0 39.8 0 424.1 low 
A87 21 F 2 86 43.0 51.0 2 1 5.4 1 0 2 1 0 0 0 0 0 0 0 0 0 82.9 0 1.4 1 611.7 low 
A88 63 M 1 104 67.0 60.8 2 0 0.0 0 0 2 0 0 0 0 1 1 0 0 0 0 7.6 1 0.0 1 1368.5 high 
A89 37 M 4 79 36.0 55.4 1 1 17.9 0 1 2 1 0 0 0 0 0 0 0 0 0 79.6 0 78.5 0 396.5 low 
A90 62 F 4 36 32.0 69.0 3 1 4.8 0 1 2 1 0 0 0 0 0 0 1 0 0 10.2 1 9.3 1 824.1 high 
A91 53 M 2 111 57.0 54.6 2 0 0.0 1 1 4 1 0 1 0 0 1 0 0 0 0 41.4 1 6.8 1 538.5 low 
A92 31 M 2 75 17.4 26.0 1 0 0.0 0 1 0 0 0 0 0 0 0 0 0 0 0 76.4 0 75.0 0 281.6 low 
A93 60 M 4 26 8.6 48.6 2 0 0.0 1 1 1 0 0 0 0 0 0 0 0 0 0 19.7 1 3.0 1 434.0 low 
A94 33 F 2 80 73.0 69.2 2 0 0.0 0 1 2 0 0 0 0 0 1 0 1 0 0 35.8 0 34.8 0 503.2 low 
A95 42 M 8 61 1.0 20.2 3 0 0.0 1 NA 1 0 NA NA NA NA NA 0 0 0 NA 75.4 1 65.3 1 857.7 high 
A96 58 M 2 33 55.0 75.0 2 0 0.0 1 1 3 0 0 1 0 0 0 0 1 0 1 76.3 0 38.0 1 428.5 low 
A97 54 M 8 123 1.0 21.6 2 1 6.8 0 1 1 0 0 0 0 0 0 0 0 0 0 66.5 0 65.3 0 409.9 low 
A98 55 M 2 30 73.0 53.8 1 0 0.0 1 1 0 0 0 0 0 0 0 0 0 0 0 8.3 1 3.0 1 800.7 low 
A99 63 M 2 130 52.0 31.6 2 0 0.0 0 0 1 0 0 0 1 0 0 0 0 0 0 60.6 0 57.8 0 278.7 low 
A100 39 M 2 27 91.0 64.6 2 1 4.5 0 0 1 0 1 0 0 0 0 0 0 0 0 74.5 0 73.1 0 326.9 low 
A101 56 M 1 124 86.0 95.0 3 1 3.3 1 1 4 0 1 1 0 0 0 1 0 0 1 10.0 1 8.2 1 1022.4 high 
A102 62 M 1 60 65.6 79.4 2 1 4.1 0 0 2 0 0 1 0 0 0 0 0 1 0 65.9 0 64.5 0 289.5 low 
A103 63 M 1 74 92.0 68.4 2 0 0.0 0 0 2 0 0 0 0 0 0 1 0 1 0 9.4 1 0.0 1 993.3 high 
A104 36 F 6 22 10.0 4.8 2 0 0.0 0 1 1 0 0 0 NA NA NA NA 1 0 NA 60.5 0 59.4 0 288.6 low 
A105 55 F 2 109 75.0 74.4 2 1 6.7 0 1 2 1 0 0 0 0 0 0 1 0 0 58.9 0 58.0 0 661.6 low 
A106 24 F 1 48 89.5 93.6 2 1 4.6 0 1 4 1 0 1 0 1 0 0 1 0 0 46.7 0 45.8 0 744.2 low 
A107 37 M 1 114 83.0 90.2 3 0 0.0 1 0 1 0 0 0 0 0 1 0 0 0 0 15.7 1 12.4 1 596.4 low 
A108 39 M 4 72 61.6 61.6 2 1 5.6 0 1 2 1 0 0 0 0 0 0 0 0 1 53.6 0 52.5 0 429.0 low 




A110 50 M 1 62 53.4 94.0 3 1 4.9 0 0 3 0 0 0 0 0 0 0 1 0 1 48.7 0 46.4 0 307.3 low 
A111 52 F 1 82 75.1 75.2 2 0 0.0 0 1 3 0 1 1 0 0 0 0 1 0 0 47.4 0 46.5 0 841.7 high 
A112 61 F 4 70 49.0 47.2 3 1 4.4 1 0 2 0 0 0 0 0 1 1 0 0 0 7.4 1 4.3 1 1151.4 high 
A113 66 F 1 45 98.5 92.6 2 1 6.6 0 0 1 0 0 1 0 0 0 0 0 0 0 58.8 0 56.4 0 566.3 low 
A114 28 F 1 102 0.0 88.0 2 0 0.0 1 1 1 0 0 0 0 0 0 0 0 1 0 62.1 0 16.9 1 345.6 low 
A115 55 F 4 100 25.5 32.2 2 0 0.0 1 1 7 0 1 1 0 0 1 0 1 0 0 35.3 1 18.2 1 927.2 high 
A116 37 F 4 65 1.4 31.4 3 0 0.0 0 0 0 0 NA NA NA NA NA NA 0 0 NA 2.4 1 0.0 1 716.9 low 
A117 56 F 4 128 46.0 56.8 2 0 0.0 0 0 2 1 0 0 0 0 0 0 0 0 0 4.4 1 0.0 1 1127.9 high 
A118 45 F 4 127 29.0 37.8 1 0 0.0 0 1 2 0 0 0 0 1 1 0 0 0 0 80.0 0 78.9 0 484.1 low 
A119 35 F 4 46 44.0 58.2 1 1 21.4 0 1 1 0 0 0 0 0 0 0 0 0 0 47.0 0 45.7 0 180.5 low 
A120 21 M 1 56 17.0 59.6 1 0 0.0 0 1 1 0 0 0 0 1 0 0 0 0 0 78.0 0 76.6 0 72.1 low 
A121 37 F 2 131 60.0 67.6 2 0 0.0 0 1 5 0 1 0 0 0 1 0 1 0 0 40.8 0 39.9 0 574.9 low 
A122 64 F 2 NA NA NA 2 0 0.0 0 0 0 NA NA NA NA NA NA NA NA NA NA 42.5 1 0.0 1 685.9 low 
A123 61 M 1 73 89.5 95.6 2 1 3.9 0 1 6 1 1 1 0 0 0 0 1 0 0 12.6 1 11.6 1 1031.8 high 
A124 41 M 2 84 23.2 23.2 1 1 26.7 0 1 0 0 0 0 0 0 0 0 0 0 0 45.6 0 44.2 0 400.8 low 
A125 60 F 1 41 83.5 81.2 2 0 0.0 0 0 4 1 1 1 0 0 0 0 1 0 0 5.3 1 0.0 1 1184.5 high 
A126 56 M 6 11 0.0 32.0 2 1 5.1 0 1 1 0 0 0 0 0 0 0 0 0 0 70.0 0 69.0 0 220.6 low 
A127 55 M 2 21 13.6 30.6 3 0 0.0 1 0 2 0 0 0 0 0 0 1 0 0 0 14.3 1 4.1 1 745.6 low 
A128 61 M 8 2 2.6 40.2 3 0 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 31.7 1 0.0 1 923.3 high 




























































































































   












































































































































































B48 66 F M8 75.5 2 55.8 2 0 0 0 0 3 1 0 0 0 1 1 0 0 0 0 2.1 1 0.0 1 1413.9 high 
B07 33  M M4 14.7 7 51.2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2.6 1 0.0 1 897.1 high 
B03 75 F M1 1.64 8 29.8 3 0 0 0 0 2 0 0 0 0 0 0 1 0 0 0 3.4 1 0.0 1 606.9 low 
B41 46 F M8 25.9 50 36.4 2 0 0 0 0 3 1 1 0 0 0 0 0 1 0 0 3.8 1 0.0 1 967.2 high 
B43 69  M M8 12.1 27 20.4 2 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 3.9 1 0.0 1 552.3 low 
B32 70  M M4 22.6 27 50.4 2 0 0 1 1 5 0 1 1 0 0 0 0 1 0 0 4.9 1 0.7 1 593.2 low 
B44 58 F M2 9.36 42.5 61.8 2 0 0 1 1 4 0 1 0 1 0 0 0 1 1 0 6.1 1 4.2 1 1088.7 high 
B17 47  M M2 14.4 84.5 65.8 3 0 0 0 0 2 0 0 0 0 0 0 0 0 1 0 6.9 1 0.0 1 745.9 high 
B25 73 F M8 0.69 15.5 46 2 0 0 1 0 2 0 1 1 0 0 0 0 0 0 0 7.0 1 3.0 1 629.6 low 
B11 57 F M4 106 52 69.6 2 0 0 0 0 2 1 1 0 0 0 0 0 0 0 0 7.0 1 0.0 1 708.3 high 
B37 67 F M8 23.1 17 24.4 2 0 0 1 1 4 1 1 0 0 0 0 0 1 0 0 8.5 1 4.1 1 974.9 high 
B24 65  M M6 36.7 29.5 35.8 3 1 3.6 1 0 1 0 0 0 0 0 0 1 0 0 0 8.9 1 5.4 1 669.9 low 
B35 53  M M5 29 9.5 82.6 2 0 0 1 1 3 1 1 0 0 0 0 0 1 0 0 10.0 1 4.6 1 1007.2 high 
B30 67  M M8 7.84 10.5 20 2 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 10.2 1 5.6 1 421.1 low 
B06 32  M M1 58.4 91.5 82.2 3 1 4.0 1 0 1 0 0 0 0 0 1 0 0 0 0 10.7 1 6.4 1 666.2 low 
B12 56 F M2 9.06 11 41.4 3 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 11.3 1 0.0 1 675.3 high 
B02 59 F M4 41 27 59 2 0 0 1 1 5 1 1 0 0 0 1 0 1 0 0 12.1 1 8.7 1 745.3 high 
B01 63  M M4 7.99 15.5 27.8 2 0 0 1 1 1 0 0 0 0 0 1 0 0 0 0 12.6 1 6.5 1 667.0 low 
B40 66 F M4 19.4 24.5 25 3 1 3.9 1 0 1 0 0 0 0 1 0 0 0 0 0 14.1 1 7.8 1 814.7 high 
B29 45 F M8 1.82 1.5 57.2 2 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 14.3 1 8.1 1 700.4 high 




B10 40 F M2 54.7 77.5 54 2 0 0 1 1 1 0 0 0 0 0 1 0 0 0 0 14.6 1 7.1 1 1003.7 high 
B45 47  M M4 83.4 19.5 39.8 2 1 7.6 1 1 2 1 0 0 0 0 0 0 1 0 0 17.2 1 8.5 1 721.9 high 
B14 68  M M8 12.7 7 28.2 2 0 0 1 1 2 0 0 0 1 0 0 0 1 0 0 21.7 0 7.9 1 507.8 low 
B38 54 F M8 105 7.5 34.4 2 0 0 1 1 1 0 0 0 0 0 1 0 0 0 0 29.3 1 7.5 1 631.0 low 
B09 43  M M2 39.6 53.5 74.8 2 1 3.9 1 0 1 0 0 0 0 0 0 0 0 0 0 31.8 1 24.9 1 390.1 low 
B46 65  M M8 2.47 1.5 25 2 0 0 1 1 2 0 0 0 0 1 0 0 0 0 0 33.0 1 16.8 1 699.3 high 
B39 59 F M2 182 85 63.4 2 0 0 1 1 3 0 0 1 0 0 0 0 1 0 0 33.2 1 7.4 1 895.1 high 
B50 24 F M8 64.5 65 28.8 3 0 0 1 1 4 1 0 1 0 0 1 0 1 0 0 33.8 1 5.8 1 670.0 high 
B20 25  M M4 96.1 35.5 27.8 2 1 4.6 0 1 1 0 0 0 0 0 0 0 1 0 0 38.7 0 37.7 0 438.8 low 
B04 70  M M2 30.3 68.5 90 2 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 48.4 1 46.9 1 725.0 high 
B49 50  M M2 1.28 11.5 45 3 1 5.1 0 0 2 0 0 0 0 0 1 0 0 0 0 51.8 0 48.9 0 244.4 low 
B47 60 F M8 1.93 6 25 2 1 4.1 0 0 1 0 0 0 0 0 0 0 0 0 0 54.5 0 52.7 0 770.3 high 
B42 54 F M8 218 57.5 NA 2 1 3.6 0 1 3 1 1 0 0 0 0 0 1 0 0 55.8 0 54.5 0 1194.7 high 
B36 62  M M1 110 97 82 2 1 4.9 0 1 0 0 0 0 0 0 0 0 0 0 0 58.4 0 57.2 0 505.4 low 
B33 60 F M2 19.9 18 30.4 1 0 0 0 1 2 0 1 0 0 0 0 0 0 0 0 59.4 0 58.2 0 422.6 low 
B26 70 F M1 147 84.5 91.11 2 0 0 0 1 3 1 0 0 1 0 0 0 1 0 0 61.1 0 59.9 0 946.8 high 
B31 62  M M6 1.24 6 74 2 0 0 0 1 1 0 0 0 0 1 0 0 0 0 0 61.5 0 59.9 0 506.6 low 
B22 64 F M1  3.95 69 89.4 2 1 4.4 0 1 5 1 0 1 1 0 0 0 1 0 0 62.2 0 61.2 0 825.4 high 
B08 67 F M2 1.35 0.5 25.2 2 0 0 0 1 2 0 0 0 0 0 1 0 1 0 0 62.9 0 61.9 0 629.4 low 
B28 54 F M1 133 94.5 91.8 2 1 4.8 0 1 3 1 0 1 0 0 0 0 1 0 0 63.1 0 61.9 0 605.3 low 
B18 47 F M8 0.81 28 50 2 1 5.6 0 0 1 0 0 0 0 0 0 0 0 0 1 63.7 0 61.8 0 508.6 low 
B27 47  M M1 218 92 86.4 2 1 4.7 0 1 3 0 0 0 0 0 1 0 0 1 0 63.8 0 62.6 0 426.5 low 
B23 28  M M5 16.1 49.5 77.4 3 1 4.6 0 1 1 0 0 0 0 0 0 0 0 0 0 64.7 0 63.5 0 731.9 high 
B21 31 F M4 3.93 16.5 40 1 0 0 1 1 2 0 0 0 0 0 1 0 0 0 0 64.9 0 10.2 1 768.5 high 
B19 72 F M4 44.9 17 37 1 0 0 0 1 1 0 0 0 0 0 1 0 0 0 0 65.2 0 64.2 0 465.9 low 
B15 64  M M5 185 21.5 72.2 2 1 5.6 0 1 2 1 0 0 0 0 0 0 1 0 0 65.9 0 64.8 0 661.9 low 
B16 59 F M1 2.17 8 71.4 2 1 6.5 0 1 2 0 0 1 0 0 0 0 1 0 0 67.6 0 66.3 0 399.6 low 
B13 66  M M8 34.9 87 73.4 2 0 0 1 1 2 0 0 0 0 0 0 0 1 0 0 69.0 0 11.1 1 655.9 low 
B05 29  M M8 2.53 15 26.4 2 1 3.2 0 1 0 0 0 0 0 0 0 0 0 0 0 74.4 0 73.3 0 637.5 low 




Supplementary Table 4 Genomic regions targeted by the methylation sequencing panel (according 
to Human GRCh37/hg19 assembly) 




chr1 208083683 208085683 CD34 2001 
Marcucci et al., 2014 
chr1 113249025 113251025 RHOC 2001 
chr7 30028425 30030425 SCRN1 2001 
chr5 76113832 76115832 F2RL1 2001 
chr8 94711772 94713772 FAM92A1 2001 
chr21 26933456 26935456 MIR155HG 2001 
chr13 42534221 42536221 VWA8 2001 
chr11 118763110 118763426 BLR1 (CXCR5) 316 
Figueroa et al., 2010; 
Wertheim et al., 2014; 
Luskin et al., 2016 
chr17 2208021 2208391 SMG6/SRR 370 
chr19 37958559 37958860 ZNF569 301 
chr20 814970 815202 FAM110A 232 
chr13 53028642 53029495 CKAP 853 
chr20 11898555 11898849 BTBD3 294 
chr3 129274773 129275235 PLXND1 462 
chr14 24867489 24867729 KIAA1305 240 
chr15 50838542 50839225 USP50 683 
chr6 34856156 34857019 ANKS1A 863 
chr20 11898849 11899205 BTBD3 356 
chr18 5293969 5294770 ZFP161 801 
chr2 158114266 158115184 GALNT5 918 
chr16 68345197 68345691 SLC7A6OS/PRMT7 494 
chr20 11899205 11899843 BTBD3 638 
chr20 32274469 32275009 E2F1 540 
chr14 106354882 106355276 FAM30A 394 
chrX 48795887 48797005 OUTD5 1118 
chr1 32739167 32739750 LCK 583 
chr12 6233715 6234255 VWF 540 
chr3 8542436 8543339 LMCD1 903 
chr14 100069833 100070055 CCDC85C 223 
Li et al., 2016 
chr3 239867 240082 CHL1 216 
chr9 23820756 23820974 ELAVL2 219 
chr7 143582381 143582625 FAM115A 245 
chr10 128995052 128995292 FAM196A 241 
chr7 1096275 1096523 GPR146 249 
chr6 110300208 110300421 GPR6 214 
chr20 62198506 62198740 HELZ2 235 
chr6 19837914 19838139 ID4 226 
chr6 19837413 19837624 ID4 212 
chr10 6104037 6104302 IL2RA 266 
chr2 42720178 42720398 KCNG3 221 




chr15 89921302 89921553 LOC254559 252 
chr15 89921743 89922005 LOC254559 263 
chr2 101437038 101437287 NPAS2 250 
chr5 140346432 140346663 PCDHAC2 232 
chr5 140346119 140346352 PCDHAC2 234 
chr5 138729890 138730214 PROB1 325 
chr17 11145296 11145505 SHISA6 210 
chr10 50818800 50819045 SLC18A3 246 
chr12 93967113 93967390 SOCS2 278 
chr1 231298882 231299100 TRIM67 219 
chr4 188916669 188916902 ZFP42 234 
chr12 7244833 7245222 CR1 390 Božić et al., 2015 
chr10 102760670 102761270 LZTS2 601 
Qu et al., 2017 
chr9 127531036 127532010 NR6A1 975 
chr2 11887332 11888329 LPIN1 998 
chr10 102756826 102762363 LZTS2 5538 
chr9 127531279 127534048 NR6A1 2770 
chr5 1008954 1009718 NKD2 765 Li et al., 2017 
chr17 48049597 48050018 DLX4 422 Zhou et al., 2016 
chr2 25499904 25500262 DNMT3A 359 Jost et al., 2014 
chr19 33794630 33794925 CEBPA 296 Lin et al., 2011 
chr5 78407502 78407733 BHMT 232 
Deneberg et al., 2011 
chr3 126243341 126243461 CHST13 121 
chr3 126242430 126242550 CHST13 121 
chr6 56112241 56112534 COL21A1 294 
chr20 23433299 23433553 CST11 255 
chr5 54281286 54281487 ESM1 202 
chr1 204121865 204121985 ETNK2 121 
chr1 204120529 204120649 ETNK2 121 
chr11 65816582 65816702 GAL3ST3 121 
chr12 5020142 5020262 KCNA1 121 
chr12 5020633 5020753 KCNA1 121 
chr12 4918109 4918229 KCNA6 121 
chr12 4918331 4918451 KCNA6 121 
chr11 64058818 64058938 KCNK4 121 
chr11 64057747 64057867 KCNK4 121 
chr5 126626447 126626769 MEGF10 323 
chr8 101661418 101661538 MGC39715 121 
chr8 101661993 101662113 MGC39715 121 
chr5 134871106 134871226 NEUROG1 121 
chr5 134871402 134871522 NEUROG1 121 
chr5 134871598 134871718 NEUROG1 121 
chr5 134870454 134870574 NEUROG1 121 
chr5 134870917 134871037 NEUROG1 121 




chr13 97646281 97646401 OXGR1 121 
chr13 97646751 97646871 OXGR1 121 
chr20 3218085 3218205 SLC4A11 121 
chr20 3218440 3218560 SLC4A11 121 
chr5 121647798 121647918 SNCAIP 121 
chr5 121647248 121647368 SNCAIP 121 
chr20 591340 591460 TCF15 121 
chr20 590183 590303 TCF15 121 
chr3 133465409 133465529 TF 121 
chr3 133465120 133465240 TF 121 
chr8 21881434 21883388 NPM2 1955 
Kelly et al., 2017 
chr5 180016802 180019096 SCGB3A1 2295 
chr9 22007977 22009873 CDKN2B 1897 
chr9 22004658 22006684 CDKN2B 2027 
chr1 36915167 36916986 OSCP1 1820 
chr11 14993444 14994500 CALCA 1057 
Hájková et al., 2012 
chr16 11348266 11350810 SOCS1 2545 
chr16 68770870 68772866 CDH1 1997 
chr11 17740807 17743777 MYOD1 2971 
chr6 152128341 152129813 ESR1 1473 
chr9 90112514 90114067 DAPK1 1554 
chr19 10380285 10381990 ICAM1 1706 
chr5 1293465 1295472 TERT 2008 
chr5 1282392 1283291 TERT 900 
chr22 33196800 33198315 TIMP3 1516 
chr5 138088422 138089841 CTNNA1 1420 
chr5 137799044 137802235 EGR1 3192 
chr11 47414710 47417876 PU1 enhancer 3167 
Curik et al., 2012 
chr11 47399455 47400777 PU1 promoter 1323 
chr5 135415044 135417216 VTRNA2-1 2173 Treppendahl et al., 2012 
chr3 50373957 50379097 RASSF1 5141 Liu et al., 2017 
chr8 41165479 41167704 SFRP1 2226 
Guo et al., 2017 
chr4 154709378 154714360 SFRP2 4983 
chr5 150395525 150403475 GPX3 7951 Zhou et al., 2017 
chr14 25142240 25143442 GZMB intergenic region 1203 Šestáková et al., 2019 
chr9 128509575 128511617 PBX3 2043 Hájková et al., 2014 
chr11 32440684 32476289 WT1 35606 
Genes typically 
associated with AML 
pathogenesis (HOX 
genes, WT1) and genes 
and regions investigated 
in our previous research 
chr12 133484657 133485928 CHFR enhancer 1272 
chr12 133463633 133464858 CHFR promoter 1226 
chr9 23820650 23822189 ELAVL2 1540 
chr17 56356348 56359520 MPO 3173 
chr20 6747931 6749579 BMP2 1649 
chr10 90750227 90751818 FAS 1592 




chr1 92952101 92952781 GFI1 681 
chr7 27169323 27171201 HOXA4 1879 
chr7 27172734 27177485 HOXA4-HOXA5 4752 
chr7 27178290 27181777 HOXA5 3488 
chr7 27182505 27186030 HOXA5 3526 
chr7 27154915 27166717 HOXA3 11803 
chr7 27186376 27192392 HOXA6 6017 
chr7 27193350 27196990 HOXA7 3641 
chr7 27197910 27201014 HOXA7 3105 
chr7 27203696 27209712 HOXA9 6017 
chr7 27212509 27220211 HOXA10 7703 
chr7 27223507 27233202 HOXA11 9696 
chr7 27238643 27261060 HOXA13 22418 
chr7 27139958 27153767 HOXA2-A3 13810 
chr7 27134068 27137303 HOXA1 3236 
chr17 46619215 46632388 HOXB2-B3 13174 
chr17 46604015 46608713 HOXB1 4699 
chr17 46640126 46643166 HOXB3 3041 
chr17 46651549 46660946 HOXB4 9398 
chr17 46669329 46675685 HOXB5 6357 
chr17 46679462 46683607 HOXB6 4146 
chr17 46684713 46698439 HOXB7-B8 13727 
chr17 46698623 46711520 HOXB9 12898 
chr17 46719166 46725338 HOXB enhancer 6173 
chr17 46795719 46806589 HOXB13 10871 
chr12 54444758 54448668 HOXC4 3911 
chr12 54440499 54441686 HOXC4 enhancer 1188 
chr12 54409989 54428840 HOXC5-C6 18852 
chr12 54399726 54403566 HOXC8 3841 
chr12 54387508 54394839 HOXC9 7332 
chr12 54378222 54380526 HOXC10 2305 
chr12 54366423 54369355 HOXC11 2933 
chr12 54343383 54349527 HOXC12 6145 
chr12 54332422 54333888 HOXC13 1467 
chr12 54319785 54322997 HOXC enhancer 3213 
chr2 177019560 177030824 HOXD3 11265 
chr2 177042088 177044146 HOXD-AS 2059 
chr2 177051619 177055302 HOXD1 3684 
chr2 177011979 177018152 HOXD4 6174 
chr2 176999849 177005805 HOXD-AS2 5957 
chr2 176992050 176996166 HOXD8 4117 
chr2 176985985 176988584 HOXD9 2600 




chr2 176961724 176972338 HOXD11-D12 10615 
chr2 176943637 176958583 HOXD13 14947 
chr2 176929340 176937139 HOXD enhancer 7800 
chr2 85810361 85813304 VAMP5 2944 
chr1 64058191 64060458 PGM1 2268 
chr19 55572760 55581129 RDH13 8370 
chr2 64066479 64070415 UGP2 3937 
chr10 17268605 17273715 VIM 5111 
chr12 66581289 66584587 IRAK3 3299 
chr15 40599247 40601307 PLCB2 promoter 2061 
chr15 40614106 40617359 PLCB2 enhancer 3254 
chr15 40583086 40583845 PLCB2 760 
chr6 32819966 32823082 PSMB9-TAP1 3117 
chr16 53467492 53471613 RBL2 4122 
chr10 73846564 73850018 SPOCK2 3455 
chr10 73855698 73859352 SPOCK2 enhancer 3655 
chr19 56163319 56168083 U2AF2 4765 
chr7 148578438 148583983 EZH2 5546 
chr7 148635825 148640261 EZH2 enhancer 4437 
chr12 56410763 56416635 IKZF4 5873 
chr8 22018546 22028232 BMP1 9687 
chr2 66652803 66673827 MEIS1 21025 
chr22 33196540 33200798 TIMP3 4259 
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